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In eukaryotes, DNA is wrapped around a group of proteins termed histones 
that are required to precisely control gene expression during development. The 
amino acids of both the globular domains and unstructured tails of these histones can 
be modified by chemical moieties, such as methylation, acetylation and 
ubiquitination. The ‘histone code’ hypothesis proposes that specific combinations of 
these and other histone modifications contain transcriptional information, which 
guides the cell machinery to activate or repress gene expression in individual cell 
types.  
Chromatin immunoprecipitation (ChIP) experiments using undifferentiated 
stem cell populations have identified the genomic co-localisation of histone 
modifications reported to have opposing effects on transcription, which is known as 
bivalency. The human α-globin promoter, a well-established model for the study of 
transcriptional regulation, is bivalent in embryonic stem (ES) cells and this bivalency 
is resolved once the ES cells terminally differentiate (i.e. only activating or 
repressing marks remain). In a humanised mouse model, the deletion of a bone fide 
enhancer within the human α-globin locus results in heterogeneous expression 
patterns in primary erythroid cells. Notably, this correlates with an unresolved 
bivalent state at this promoter in terminally differentiated cells.   
Using this mouse model it is not feasible to ascertain whether the 
transcriptional heterogeneity observed in the cells lacking an α-globin enhancer is 
reflective of epigenetic heterogeneity (i.e. a mixed population of cells) rather than 
co-localisation of bivalent histone modifications within the same cells. Furthermore, 
the functional contribution of bivalency to development has yet to be described. To 
address these difficulties, I aimed to generate a fluorescent reporter system for 
human α-globin to facilitate the separation of transcriptionally heterogeneous 
erythroid cells. This model will provide material for ChIP studies on transcriptionally 
active and inactive populations to determine whether the epigenetic bivalency is 
reflective of a mixed cell population or true bivalency. In addition, I aimed to 
produce epigenetic editing tools to target bivalent promoters, which in combination 
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with in vitro differentiation assays would provide an interesting framework to test the 
function of bivalency during development.  
In this study, I extensively tested gene-editing strategies for generating a 
fluorescent reporter knock-in in humanised mouse ES cells. I validated the suitability 
of humanised mouse ES cell lines for gene targeting studies and optimised a robust 
in vitro differentiation protocol for studying erythropoiesis. I utilised both 
recombineering and CRISPR/Cas9 gene editing tools in tandem with PiggyBac 
transposon technology, to knock-in the reporter gene. I made significant steps in 
gene targeting and successfully inserted the reporter downstream of the α-globin 
gene. I also generated a cloning system to express site-specific DNA-binding 
domains (TALEs) fused to epigenetic regulators with the aim to resolve bivalent 
histone modifications in vitro. From preliminary tests using these fusion proteins 
targeting Nrp1, a bivalent promoter in mES cells, I observed mild but significant 
changes in gene expression although histone modifications were unchanged. The 
various tools generated and tested in this study provide a solid foundation for future 





Mammals are made up of a large number of very different cell types that 
come together to form a complete organism. It is important to note that every cell in 
an individual organism has an identical copy of DNA. This DNA acts as a blueprint 
and contains information, encoded in units called genes, on how to generate every 
protein required in an organism. The proteins act as building blocks and particular 
sets of proteins are required to construct each different cell type. To ensure the 
correct set of proteins is available, each cell must turn ‘on’ (activate) the correct set 
of corresponding genes while also ensuring the rest of the genes remain switched 
‘off’ (repressed).  
The DNA is wrapped around a group of proteins, termed histones, which are 
involved in deciding what genes get activated or repressed in an individual cell. The 
activating or repressing action of histones involves different chemical modifications, 
often called epigenetic marks. A number of genes have been identified that appear to 
be marked by modifications associated with both gene activation and repression, a 
so-called ‘bivalent’ state. However, it is possible that in some cases of bivalency only 
the cells that do express a gene contain the modification associated with gene 
activation and vice versa.  
In testing this hypothesis I aimed to generate a new humanised mouse model 
which could facilitate the visualisation and separation of individual cells based on the 
expression of an important bivalent gene, human α-globin. Mutations that 
dysregulate α-globin cause α-thalassemia, a major blood disorder. In this study I 
successfully completed the initial steps in generating this model.  
There is not enough evidence to show if histone modifications instruct the 
cell to make decisions about gene activation or repression or if the modifications act 
more like an indexing system, preserving the information on whether a gene is 
activated or repressed. To test the precise function of these modifications I generated 
a system to construct a number of tools that could accumulate or remove individual 
histone modifications at particular genes. Interestingly, one of the tools was able to 
induce a mild activation of the target gene. The tools generated and tested in this 
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study provide a solid foundation for investigating the nature and function of histone 
modifications at human α-globin and other genes. The analysis of how gene 
expression is regulated will aid in the greater understanding of how both normal and 
diseased cell types develop.  
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Chapter One: Introduction 1 
Chapter 1 Introduction 
1.1 Epigenetics and transcriptional regulation 
Epigenetics traits are heritable phenotypes that are not derived from changes in 
DNA sequence (Berger et al., 2009). Prof. Conrad Waddington, a biologist and a 
philosopher who held the Directorship of the Institute of Genetics in the University of 
Edinburgh, coined this term in the 1940s (Slack, 2002). Waddington was the first to 
describe an “epigenetic landscape” in which each embryonic stem (ES) cell makes 
numerous decisions that can lead it down different developmental pathways. 
We now have a much clearer insight into the molecular causes of these 
epigenetic traits and developmental decisions. In a cell, DNA is wrapped around 
packaging proteins called nucleosomes in a structure termed “chromatin”. 
Nucleosomes are composed of four proteins called histones which form an octamer 
through the interaction of a tetramer of two copies of H3 and H4 with two dimers of 
H2A and H2B. Both the DNA and the histones can be chemically modified by 
methylation, while the histones can also be acetylated, phosphorylated and 
ubiquitinated. A set of enzymatic complexes are involved in the deposition of these 
chemical groups. These complexes include a “reader” domain that facilitates the 
correct localisation of the mark and a “writer” domain which catalyses the 
modification itself. Many “eraser” enzymes have also been identified that catalyse the 
removal of these modifications. Combinations of these modifications form a complex 
epigenetic code that is interpreted by the cell machinery. In synergy with both the 
general and cell-specific transcription factors (TFs), this code can influence the 
transcriptional activity of underlying genes. Many of these modifications are stably 
inherited by daughter cells after cell division. Accordingly, these DNA and histone 
modifications are often called epigenetic modifications. In this section, I will discuss 
the epigenetic mechanisms involved in the activation and repression of gene 
transcription, with a particular focus on histone methylation.   
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1.1.1 Epigenetics and gene activation 
Proteins associated with DNA (such as chemically modified histones), can be 
isolated by chromatin immunoprecipitation (ChIP) experiments. The genomic 
localisation of proteins can be interrogated by ChIP combined with qPCR (ChIP-
qPCR) or next generation sequencing (ChIP-seq). A number of chromatin 
modifications, such as the acetylation of a vast number of lysine residues on histone 
tails, have been correlated with gene activation (Wang et al., 2008). Histone 
acetylation reduces the positive charge of histones, therefore weakening the 
interactions between the histones and the negatively charged DNA (Bannister and 
Kouzarides, 2011). This relaxed structure is called “euchromatin” and allows 
transcriptional machinery to access the DNA more easily (Wang et al., 2008). Histone 
phosphorylation at a number of residues has also been linked to gene activation, as 
well as chromatin compaction during mitosis and meiosis (Rossetto et al., 2012). The 
methylation of certain histone amino acids has likewise been correlated with gene 
activation, for example, tri-methylation of lysine 4 on histone 3 (H3K4me3) and 
H3K36me3. H3K36me3 is catalysed by the histone methyltransferase SET2, and is 
highly enriched across the entire gene body in actively transcribed genes (Bannister et 
al., 2005; Krogan et al., 2003; Xiao et al., 2003). Below I will focus on H3K4me3, 
and discuss the evidence that suggests this mark may have a role in gene activation. 
 
1.1.1.1 H3K4me2/3 and gene activation 
One of the most intensively studied histone modifications is H3K4me3. 
H3K4me3 is enriched close to the transcriptional start site (TSS) of active promoters, 
which has long suggested it is involved in transcriptional activation (Bernstein et al., 
2005; Santos-Rosa et al., 2002). The breadth of H3K4me3 domains is positively 
correlated with consistency in gene transcription at a single cell level (Benayoun et 
al., 2014). The targeted writing of H3K4me3 at specific promoters using epigenetic 
editing tools (described in detail in section 1.5.2, pp. 40) has shown that an increase 
of localised H3K4me3 is sufficient to cause a mild increase in gene activation at 
tested gene promoters (Cano-Rodriguez et al., 2016). 
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SET domain containing proteins, including SET1 in yeast or SET1-like 
proteins in mammals (SET1A, SET1B, MLL1, MLL2, MLL3 and MLL4), catalyse 
the deposition of H3K4me2/3 (Herz et al., 2013; Shilatifard, 2012). H3K4me2 has 
also been associated with active gene transcription (Meissner et al., 2008). Most of 
these histone methyltransferase complexes contain zinc finger CxxC DNA binding 
domains which bind to unmethylated regions of DNA that are enriched for the CpG 
dinucleotide, termed CpG islands (Blackledge et al., 2013; Thomson et al., 2010). 
Vertebrate CpG islands are ~1 kb in length and are high in GC content. They are 
found in nearly all housekeeping genes and certain developmental regulators and 
tissue-specific genes (Deaton and Bird, 2011). Cfp1 is the CxxC containing 
component of the Set1d complex (Thomson et al., 2010). The binding specificity of 
Cfp1 to unmethylated CpG islands helps prevent ‘leakage’ of H3K4me3 to ectopic 
sites, but has not been proven necessary for histone methylation at target genes or 
critical for target gene expression regulation (Clouaire et al., 2012). Importantly, the 
deposition of H3K4me3 at artificial, promoterless CpG islands via Cfp1 is not 
sufficient to recruit the RNA polymerase II complex (PollII), suggesting that the 
recruitment of these two complexes occurs independently (Thomson et al., 2010). 
Cfp1 also contains PHD domains which recognise and bind to H3K4me1/2/3, 
promoting further deposition of the mark (Eberl et al., 2013). The MLL complexes 
appear to be important in methylating H3K4 at specific subsets of target sites, such 
as homeotic (Hox) genes and enhancers (Howe et al., 2017). 
A number of different studies have attempted to show a functional link 
between H3K4me3 and gene activation. Primarily, the TAF3 subunit of 
Transcription Factor II D (TFIID) binds to H3K4me3 through PHD finger 
interactions (Lauberth et al., 2013; Vermeulen et al., 2007). The recruitment of the 
TFIID in turn facilitates the assembly of the PollII preinitiation complex (Lauberth et 
al., 2013; Vermeulen et al., 2007). H3K4me3 also binds a number of other epigenetic 
effector proteins including the NURF chromatin remodelling complex and histone 
acetyl transferases, which act to facilitate chromatin accessibility and gene 
transcription (reviewed in Wozniak & Strahl 2014). Finally, H3K4me3 has also been 
implicated in the prevention of gene repression. JMJD2A, a H3K9me3 demethylase, 
binds to H3K4me3 through its double Tudor domains to remove this histone mark 
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that is associated with gene repression (Huang et al., 2006; Klose et al., 2006). The 
presence of the H3K4me3 also prevents the binding of the de novo DNA methylase 
Dnmt3a, thus preventing permanent repression via DNA methylation (Zhang et al., 
2010).  
It is clear from the evidence discussed above that H3K4me3 is positively 
correlated with gene expression (Benayoun et al., 2014; Bernstein et al., 2005; Cano-
Rodriguez et al., 2016; Santos-Rosa et al., 2002) and certain studies have even 
identified mechanistic links between H3K4me3 and the activation of gene 
transcription (Huang et al., 2006; Klose et al., 2006; Lauberth et al., 2013; Vermeulen 
et al., 2007; Wozniak and Strahl, 2014; Zhang et al., 2010). Despite this body of 
evidence, a number of studies have shown that the removal of the H3K4me3 
methyltransferase complex members, and a global reduction in H3K4me3, does not 
result in major changes in global gene expression levels (Clouaire et al., 2012; 
Hormanseder et al., 2017; Lenstra et al., 2011; Muramoto et al., 2010). Furthermore, 
genes marked with high levels of H3K4me3 (and no detectable marks associated with 
gene repression) are not always expressed (Vastenhouw et al., 2010). Instead of 
directly activating expression, H3K4me3 may instead be important in preserving the 
memory of transcriptional activation during cell division (Hormanseder et al., 2017; 
Howe et al., 2017; Muramoto et al., 2010). In agreement with this hypothesis, live 
cell imaging in Dictyostelium cells using the MS2 system for visualising transcription 
in real time (described in section 1.5.2.1, pp. 40) was performed on dividing cells 
(Muramoto et al., 2010). This study revealed that knocking out components of the 
Set1 complex in these cells led to a loss in H3K4me2/3 levels and a loss of the 
inheritance of transcriptional state (Muramoto et al., 2010). Similarly, H3K4me3 is 
involved in maintaining the transcriptional memory of donor cell identity in nuclear 
transfer experiments in Xenopus embryos (Hormanseder et al., 2017). A reduction of 
H3K4me3 levels in Xenopus embryos during nuclear transfer experiments reduced 
the levels of donor-cell specific gene transcription and improved the developmental 
capacity of nuclear transfer embryos (Hormanseder et al., 2017). A reduction of 
H3K4me3 enrichment can reduce transcriptional heterogeneity in a population and 
improve consistency in gene expression pathways (Howe et al., 2017).  
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Indeed, it is clear that H3K4me3 enrichment is associated with gene activity, 
although it does not appear to be causative in certain cases (Cano-Rodriguez et al., 
2016; Lauberth et al., 2013). H3K4me3 may more indirectly influence the 
maintenance of an active transcriptional state at the majority of genes (Hormanseder 
et al., 2017; Howe et al., 2017; Muramoto et al., 2010). In the following section I will 
discuss correlations between epigenetic marks and gene repression. 
 
1.1.2 Epigenetics and gene repression 
As previously described, histones that are not acetylated have a strong 
positive charge resulting in strong interactions with the negatively charged DNA 
molecules they are wrapped around. This leads to compaction of the chromatin into 
areas of “heterochromatin” in which the transcriptional machinery is unable to access 
the DNA, resulting in low expression of the genes located in these regions. Two types 
of heterochromatin are observed in cells (reviewed in Becker et al. 2016). 
Constitutive heterochromatin is stably formed in every cell type in an organism and 
can be found close to telomeres and centromeres. The histone methylation mark 
H3K9me2/3, deposited by members of the Suv39 family including SETDB1, GLP 
and G9A, and also PRDM2 is enriched in constitutive heterochromatin (and in 
patches of facultative heterochromatin).  H3K9me2/3 then recruits heterochromatin 
protein 1 (HP1), which causes chromatin compaction (Becker et al., 2016). 
Facultative heterochromatin is converted from euchromatin in certain cells, for 
example the inactivated X chromosome in female mammalian cells. The formation of 
facultative heterochromatin involves the deposition of several different histone marks 
which can include H3K27me3, H3K9me2 and the mono-ubiquitination of lysine 119 
on histone H2A (H2Aub) (Trojer and Reinberg, 2007).  
The methylation of 5-carbon on cytosine residues in CpG dinucleotides of 
DNA represses transcription (Maeder et al., 2013a; Stepper et al., 2016). Although 
DNA methylation has been well studied in vertebrates, many other model organisms 
such as Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces 
cereviceae lack DNA methylation (Deaton and Bird, 2011). DNA methylation is 
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observed in <20% CpG dinucleotides in mouse embryonic stem (mES) cells and 
changes dynamically during differentiation (Meissner et al., 2008). Importantly, the 
majority of CpG islands at housekeeping and other gene promoters are usually 
unmethylated i.e. the promoters are permissive for transcription (Deaton and Bird, 
2011; Meissner et al., 2008). DNA methylation is catalysed by DNA 
methyltransferases (DNMTs; “writer” enzymes), with DNMT1 maintaining DNA 
methylation through replication and DNMT3A/B catalysing de novo DNA 
methylation (Jackson et al., 2004). Interestingly, although the homozygous deletion 
of DNMT1 in human ES (hES) cells causes rapid cell death, hES cells carrying a 
homozygous deletion of DMNT3A or B are still viable and pluripotent with only a 
progressive mild reduction in DNA methylation levels over many passages (Liao et 
al., 2015). DNA methylation is believed to cause transcriptional repression via the 
inhibition of TF binding and the recruitment of chromatin remodelling complexes 
(Deaton and Bird, 2011). In the following sections, I will describe polycomb group 
proteins (PcGs) and discuss, how their deposited marks are associated with gene 
repression. I will focus in particular on polycomb repressive complex 2 (PRC2) and 
the histone modification H3K27me3. I will also briefly discuss some of the literature 
regarding how the PRC1 and 2 complexes are recruited to target genes.  
 
1.1.2.1 PRC1 and H2Aub 
PcGs were first identified in Drosophila melanogaster by mutant screens 
searching for upstream regulators of the Hox genes. Mutations in PcGs led to 
aberrant activation of these genes and gross body patterning defects which showed 
their importance in maintaining correct developmental patterning (Lewis, 1978). 
Since then, two families of PcG complexes have been identified that are involved in 
transcriptional silencing; PRC1 and PRC2 (Morey and Helin, 2010; Simon and 
Kingston, 2009). Both of these complex families have many components that can 
combine in multiple ways to form complexes that do not always functionally overlap 
(Morey and Helin, 2010; Simon and Kingston, 2009).  
Two components of PRC1 in humans, RING1B and BMI1, are required for 
the deposition of H2Aub (Cao et al. 2005). The H2Aub mark appears to be involved 
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in transcriptional repression via the inhibition of PolII elongation (Stock et al., 2007; 
Zhou et al., 2008). However, electron microscopy has shown that PRC1 components 
are capable of compacting nucleosomes associated with DNA, both in the presence 
and in the absence of histone tails in vitro (Francis et al., 2004). This evidence 
suggests that PRC1 mediates gene silencing through multiple pathways that do not 
only involve the H2Aub mark.  
 
1.1.2.2 PRC2 and H3K27me3 
The trimethylation of histone 3 at lysine 27 (H3K27me3) is deposited by 
PRC2. PRC2 complexes include EED (a “reader” enzyme), which binds to 
H3K27me3, and the histone methyltransferase EZH2 (a “writer” enzyme), which 
catalyses the H3K27me3 mark (Margueron et al., 2009). The importance of PRC2 in 
development is clear from early experiments where knocking out core PRC2 subunits 
genes Eed, Ezh2 and Suz12 proved to be embryonic lethal in mouse models (Faust et 
al., 1998; O’ Carroll et al., 2001; Pasini et al., 2004). H3K27me3 can be removed by 
the histone demethylases (“eraser” enzymes), UTX (KDM2A), UTY and JMJD3 
(KDM2B) (Agger et al., 2008; Walport et al., 2014).  
The mechanisms by which PRC2 complexes confer transcriptional silencing 
are somewhat unclear. It is known that EZH2 interacts with enzymatically active 
DNMTs in vitro (Viré et al., 2006). However, PRC2 generally binds to CpG island 
promoters that are unmethylated (Ku et al., 2008). Despite this, EZH2 bound 
promoters in ES cells can sometimes gain DNA methylation during differentiation, 
thus preventing future transcription from the locus (Cedar and Bergman, 2009; 
Meissner et al., 2008; Mohn et al., 2008). It has also been shown that the H3K27me3 
demethylase, JMJD3, is required for transcriptional elongation at genes enriched with 
this mark (Chen, et al. 2012; Estarás et al. 2013). This suggests that H3K27me3, like 
H2Aub, can prevent transcriptional elongation from occurring.  
It is important to note that the recruitment of PRC2, and the resulting 
deposition of H3K27me3, occurs only after transcription has been turned off or 
chromatin compaction has happened (Hosogane et al., 2013; Yuan et al., 2012). It has 
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also been shown that loss of H3K27me3 in adult mouse intestinal cells does not 
necessarily result in activation of gene expression, and vice versa (Jadhav et al., 
2016). This implies that the PRC2 mediated H3K27me3 mark is not required for gene 
repression (Hosogane et al., 2013; Jadhav et al., 2016; Yuan et al., 2012), although 
the evidence described above suggests it can play a direct role in gene silencing (Viré 
et al. 2006; Chen, et al. 2012; Estarás et al. 2013). A recent report in Drosophila 
melanogaster showed that local inheritance of the H3K27me3 mark, following 
excision of the closest polycomb repressive element (PRE), was sufficient for short-
term inheritance of Hox gene repression (Coleman and Struhl, 2017). This suggests 
that H3K27me3, like H3K4me3, may be more indirectly involved in the maintenance 
of a transcriptional state during cell division and differentiation.  
 
1.1.2.3 PcG recruitment 
PcG complexes are recruited to specific DNA sequences called PREs in 
Drosophila melanogaster (Kassis and Brown, 2013). The mechanism of recruitment 
of PcG proteins in mammals has been more difficult to elucidate. In certain biological 
contexts it seems that PRC2 can be recruited by binding to specific TFs, such as the 
REST and SNAIL TF families, in neuronal progenitor cells (Arnold et al., 2013). 
There is also evidence that shows certain long non-coding RNAs are able to recruit 
PRC2. For example, PRC2 binds to the long non-coding RNA Xist through the 
JARID2 subunit, to facilitate the transcriptional silencing of one X chromosome in 
female mammals (Brockdorff, 2013; da Rocha et al., 2014). However, it appears that 
mammalian PRC2 can bind irrelevant RNA sequences (such as bacterial RNA) with 
the same efficiency as specific verified target RNA (such as the Xist long non-coding 
RNA) (Davidovich et al., 2015). These specific examples of recruitment do not 
account for the majority of PRC2 binding.  
A prevailing theory proposes that PcG complexes, for the most part, ‘sample’ 
a large portion of genetic material in a sequence independent manner and then 
accumulate at ‘target’ sites, depending on the pre-existing chromatin and 
transcriptional context of that site (Klose et al., 2013). DNA methylation represses 
transcription and so it is thought that PcG recruitment is a method of preventing 
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transcription at genes that have escaped DNA methylation. Indeed, both PRC1 and 2 
complexes colocalise with unmethylated CpG islands (Ku et al., 2008). It has also 
been shown that the introduction of ectopic unmethylated CpG islands is sufficient to 
recruit both PRC1 and PRC2 machinery in a cell (Lynch et al., 2011; Mendenhall et 
al., 2010). The recruitment of PRC2 to target loci in mES cells is partially 
interdependent with JARID2 recruitment (Li et al., 2010). JARID2 interacts with and 
modulates the activity of PRC2 (Li et al., 2010, Son et al., 2013). Initial studies 
suggested that this recruitment was due to the DNA-binding or nucleosome-binding 
activity of JARID2 (Li et al., 2010, Pasini et al., 2010; Peng et al., 2009). More recent 
work has shown that the interaction of JARID2 with lncRNAs is also involved in 
regulating PRC2 recruitment (Kaneko et al., 2014, da Rocha et al., 2014). A subset of 
mammalian PRC1 complexes can be recruited to unmethylated CpG islands via one 
of its subunits; the H3K4/K36 demethylase KDM2B (Farcas et al., 2012; Wu et al., 
2013).  
Once a PcG complex has been recruited to a CpG island it samples the local 
chromatin environment. The presence of histone marks associated with active 
transcription, H3K4me3, H3K27ac and H3K36me2/3, are all inhibitory to PRC2 
enzymatic activity (Reynolds et al., 2012; Schmitges et al., 2011; Yuan et al., 2012). 
It is thought that PcG complexes identify correct target genes through uninhibited 
binding and then accumulate through positive feedback mechanisms (Klose et al., 
2013). Indeed, the colocalisation of PRC1 and PRC2 components at silenced genes 
suggests that both complexes are involved in transcriptional repression at a subset of 
genes (Bracken et al., 2006). A number of reports have shown that the PRC2 
mediated mark, H3K27me3, is required for PRC1 binding at certain loci (Cao et al., 
2002; Wang et al., 2004; Zhen et al., 2016). Conversely, other groups have shown 
that the PRC1 mediated mark, H2Aub, is required for PRC2 recruitment at certain 
genes (Blackledge et al. 2014; Cooper et al. 2014). It would appear that a number of 
different mechanisms are involved in the accumulation of PcGs at individual loci.  
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1.1.3 Epigenetics, development and disease  
Epigenetic mechanisms control many cellular decisions in stem cell biology, 
development, and disease. Global changes to the epigenetic landscape occur during 
early development. When an egg cell is fertilised and when primordial germ cells 
develop in the embryo, two large scale DNA demethylation and epigenetic 
reprogramming events occur, from which only certain heterochromatin and 
imprinted regions escape (Cantone and Fisher, 2013). As cells differentiate 
throughout development and adulthood, the epigenetic landscape continues to 
change, albeit at a more localised level. These dynamic changes can be observed by 
bisulphite sequencing (a method for determining the localisation of cytosine 
methylation) or ChIP-seq data sets from many different tissues, including pluripotent 
stem cells and lineage committed cells (Bernstein et al., 2010, 2012; Meissner et al., 
2008; Mikkelsen et al., 2007). Many genetic studies have shown that knocking out or 
knocking down members of the DNMT, SET1-like and PcG complexes can cause 
disruptions in ES cell gene expression, differentiation, or can even be embryonic 
lethal (Carroll et al., 2001; Faust et al., 1998; Jackson et al., 2004; Liao et al., 2015; 
Pasini et al., 2004; Shilatifard, 2012). This highlights the importance of epigenetics 
as a marker for, and an instructor of, appropriate development. Furthermore, 
dysregulation of these pathways has been shown to cause disease in a number of 
cases (reviewed in Brazel & Vernimmen 2016). In this section I will briefly discuss 
some of the major genetic mutations in epigenetic regulators associated with cancer.  
EZH2 is the most frequently mutated PRC2 component in cancer. Disruptions 
in H3K27me3 levels and localisation due to EZH2 mutations have been identified in 
many solid tumours and blood malignancies (Morin et al., 2010; Souroullas et al., 
2016). The DNA methyltransferase, DNMT3A, is also often catalytically inactivated 
by dominant-negative mutations in haematological malignancies (Ley et al., 2010; 
Yang et al., 2015). Indeed, the disruption of normal DNA methylation patterns in 
colorectal cancer cells has been correlated with a reduced expression of tumour 
suppressor genes and an overexpression of oncogenes (Irizarry et al., 2009). 
Disruption of epigenetic editing enzymes is commonly caused by chromosomal 
translocations, which can affect epigenetic regulators by creating novel fusion 
proteins with new functions. Chromosomal rearrangements involving the MLL gene 
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occur in over 70% of infant leukaemias, most of which cause a deletion of the 
catalytic H3K4 methlytransferase domain (Krivtsov and Armstrong, 2007). Despite 
the inactivation of the SET domain, the resulting fusion proteins cause 
overexpression of a number of different target genes, often via the recruitment of 
DOT1L, a H3K79 histone methyltransferase associated with transcriptional 
elongation (Bernt et al., 2011; Krivtsov et al., 2008). Mutations in the H3K27 
demethylases JMJD3 and UTX have also been associated with malignancies 
(Arcipowski et al., 2016; Ntziachristos et al., 2014). 
The contribution of epi-mutations to disease is less clear than that of genetic 
mutations in epigenetic regulators. It appears that specific DNA methylation and 
histone modification patterns can be used as biomarkers for diseases such as acute 
myeloid leukaemia (Figueroa et al., 2010), active ovarian cancer (Teschendorff et al., 
2009) and colorectal cancer (Akhtar-Zaidi et al., 2012). These disease specific 
patterns are thought to play a role in the downregulation of tumour suppressor genes 
and upregulation of oncogenes, and so represent therapeutic targets. Epigenome-wide 
association studies (EWAS) are being used to identify differentially methylated 
regions associated with disease. Epi-mutations associated with Wilms tumour and 
Lynch syndrome, two solid malignancies, have been identified (reviewed in Hitchins 
2015). The identification of epi-mutations is faced with fundamental challenges 
including intrinsic epigenetic variation between (and within) different cell types and 
developmental stages.  
Epigenetic regulation of development is of paramount importance, as 
demonstrated by the vast numbers of diseases that occur when epigenetic pathways 
are disturbed. To more clearly understand the pathological mechanisms involved in 
these diseases we must first completely understand the exact function of their 
associated epigenetic marks in normal conditions. As described in the above sections, 
despite years of research the exact function of two individual histone marks, 
H3K4me3 and H3K27me3, in controlling transcriptional regulation remains 
ambiguous. Furthermore, these two marks are not mutually exclusive and may 
provide the cell with a novel set of instructions, different from each individual mark. 
In the following section I will discuss in detail the colocalisation of these two marks, 
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termed “bivalency”, describing how it is identified, established, and evidence 
regarding its function.  
 
1.2 Epigenetic bivalency 
I have previously discussed two histone modifications, H3K4me3 and 
H3K27me3, and their association with transcriptional activation and repression, 
respectively. At first glance it would seem that the individual presence of these 
histone marks would lead to two opposing transcriptional states, and thus the marks 
would themselves be mutually exclusive. However, this does not appear to be the 
case at a large number of genomic loci. Colocalisation of these two marks was first 
reported in ES cells (Azuara et al., 2006; Bernstein et al., 2006; Ku et al., 2008; 
Mikkelsen et al., 2007). The colocalisation of these two marks is termed “bivalency” 
and forms an important theme of this thesis. Other groups have referred to bivalency 
as the colocalisation of H3K4me2/H3K27me3 (Minoux et al., 2017) or 
H3K4me3/H2Aub (Brookes et al., 2012). Here, I define bivalency as the 
colocalisation of H3K4me3/H3K27me3, unless otherwise stated. In this section I will 
first discuss the methods used to study bivalency, and the resulting information these 
different assays provide. I will then describe where and how bivalent domains are 
established in a cell and conclude with a discussion of the functions associated with 
bivalency.  
 
1.2.1 Methods used to study bivalency 
Bivalency can be identified by comparing two individual ChIP-qPCR or 
ChIP-seq data sets that use antibodies against H3K4me3 and H3K27me3 on 
chromatin preparations from the same population of cells. However, there is a chance 
that in an apparently homogenous cell population, for example a mES cell line, the 
occurrence of an epigenetically mixed population (Figure 1.1B) can lead to 
misinterpretation of data. Classic ChIP experiments require thousands to millions of 
cells (a classic ChIP protocol is used in this thesis and described in Chapter 2: 
Materials and Methods pp. 55). Even protocols optimized for cross-linked or native 
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ChIP using ultra-low cell numbers require at least 500-1,000 cells (Brind’Amour et 
al., 2015; Zheng et al., 2015). There is a significant risk that these cell populations 


















Figure 1.1 Different epigenetic landscapes can appear bivalent using classical 
ChIP protocols. A model of the possible epigenetic landscapes at a TSS that appears 
bivalent using classical ChIP protocols. The cells (blue ellipses) contain individual 
nucleosomes (purple circles) that carry the histone modifications H3K4me3 (green 
circles) or H3K27me3 (orange circles) on different histone tails.  
A. When H4K4me3/H3K27me3 colocalise on the same nucleosome, the promoter 
can be called truly bivalent. 
B. A promoter can be monovalently marked with either H3K4me3 or H3K27me3 in 
different cells. This is an epigenetically mixed population.  
C. Neighbouring nucleosomes can be monovalently marked with either H3K4me3 or 
H3K27me3 generating a heterogeneously marked promoter.  
D. Neighbouring nucleosomes can be monovalently marked with either H3K4me3 or 
H3K27me3, or be bivalently marked with both histone modifications, generating a 
heterogeneously marked promoter. 
mixture of different cell types. For example, whole tissue preparations (e.g. whole 
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mesodermal and ectodermal germ layers). Heterogeneity can also occur as a result of 
individual cells of the same cell type (e.g. ES cells) containing different histone 
modification at the same locus (Figure 1.1B). Moreover, this admixture of cells, 
containing either repressive or active chromatin marks at certain genes, may 
masquerade as true bivalent domains in ChIPs on large populations of cells (Figure 
1.1). 
A number of methods have been developed which can be used to elucidate 
whether the H3K4me3 and H3K27me3 marks are truly colocalised and not observed 
as a result of an epigenetically mixed or heterogeneous population. Sequential ChIP 
(re-ChIP) is a method whereby chromatin is immunoprecipitated with an antibody 
with high affinity towards one protein and then subjected to a second round of 
immunoprecipitation (IP) with an antibody that recognises a second protein (Hatzis 
and Talianidis, 2002). The aim is to recover only the chromatin that simultaneously 
carries both proteins. Re-ChIP studies using antibodies that identify H3K4me3 and 
H3K27me3 marks support the existence of bivalency at some loci (Bernstein et al., 
2006; De Gobbi et al., 2011; Ku et al., 2008; Mikkelsen et al., 2007). However, re-
ChIP studies are limited in their ability to identify loci with a low enrichment of 
either mark as the quantity of material is severely restricted due to repeated rounds of 
IP.  
Mass spectrometry analysis has been used on mononucleosomes that were 
immunoprecipitated with antibodies that recognise histone modifications to determine 
if these marks occur on the same nucleosome (Voigt et al., 2012). This study 
confirmed that H3K27me3 and H3K4me3 can colocalise to the same nucleosome and 
that these marks occupy opposite histone tails when found in a single nucleosome 
(Voigt et al., 2012). However, mass spectrometry analysis does not provide 
information regarding the genomic localisation of the bivalently marked nucleosome. 
It is therefore conceivable that although certain nucleosomes may be bivalently 
marked, some bivalency observed in classical ChIP studies may be due to 
epigenetically heterogeneous cell populations.  
In the last year, there have been a number of breakthroughs in the 
identification and mapping of bivalent marks on single molecules (Sadeh et al., 2016; 
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Shema et al., 2016; Weiner et al., 2016). Two groups used combinatorial indexed 
ChIP (co-ChIP-seq), a modified version of re-ChIP, to identify colocalisation of 
histone marks in cells from yeast and mice (Sadeh et al., 2016; Weiner et al., 2016). 
Co-ChIP-seq involves the ligation of barcoded adaptors during the first round of IP. 
This barcoding allows the samples from different IPs to be pooled before the second 
round of IP. This prevents the loss of information of which DNA fragments were 
immunoprecipitated with the first antibody, and prevents the loss of experimental 
material. Using this method, Weiner et al. (2016) identified >17,000 bivalent regions 
across the genome in mES cells. Another group recently developed single molecule 
imaging and sequencing to identify bivalent regions in mES cells (Shema et al., 
2016). In this study, chromatin fragments were ligated to fluorescent adaptors and 
captured on slides. These slides were then incubated with fluorescently labelled 
antibodies with high affinity for various histone modifications and the dynamic 
binding of these antibodies was recorded. Finally, proteins were removed from the 
DNA bound to the slide, and single molecule sequencing was performed to map the 
genomic localisation of the histone modifications. Shema et al. (2016) also used this 
method on individual histones isolated from mES cells and confirmed that the vast 
majority of putative bivalently marked nucleosomes carry only one of these marks 
(H3K4me3 or H3K27me3) on each histone tail (Voigt et al., 2012).  
These technical advancements have confirmed that individual nucleosomes 
can indeed carry both the H3K4me3 and H3K27me3 mark (Voigt et al., 2012) and 
have managed to map this bivalency to genomic loci in a number of cell types 
(Shema et al., 2016; Weiner et al., 2016). In the following section I will discuss the 
positioning of bivalent nucleosomes within a promoter and the types of cells and 
genes bivalency is observed in.  
 
1.2.2 Occurrence of bivalency 
Highly organised nucleosome positioning is observed during zebrafish 
embryogenesis in bivalent and H3K4me3 monovalent promoters, but not in 
H3K27me3 monovalent promoters (Zhang et al., 2014). Within bivalent promoters, 
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re-ChIP-seq analysis has shown that bivalent mono-nucleosomes tend to immediately 
flank the TSS (Sen et al., 2016). Sen et al. (2016) used classical ChIP-seq in the 
NCCIT human pluripotent germ cell tumour derived cell line, to show that broad 
domains of H3K27me3 (~4-8 kb) can overlap with narrower peaks of H3K4me3 (~1-
4 kb) slightly upstream of the TSS. However, the region of true bivalent 
mononucleosomes, as determined by re-ChIP-seq analysis, is even narrower (0.5-2 
kb) and tends to occur in the immediate vicinity of the TSS (Sen et al., 2016). This 
analysis revealed that although bivalent mononucleosomes tend to localise at the 
TSS, bivalent mononucleosomes can also occur throughout the promoter region, 
alongside monovalent mononucleosomes (Figure 1.1D; Sen et al. 2016). 
Bivalency was first identified in pluripotent ES cells from humans and mice 
(Azuara et al., 2006; Bernstein et al., 2006; Ku et al., 2008; Mikkelsen et al., 2007). 
Since then, many data sets have been produced using classical ChIP methods 
assessing individual marks in hES and mES cell populations. Two groups integrated 
and analysed 11 published datasets to determine a list of high confidence bivalent 
promoters (Court and Arnaud, 2017; Mantsoki et al., 2015). The previously 
described study by Weiner et al. (2016) identified >17,000 bivalent domains in hES 
cells in 1 kb sliding windows across the entire genome. Here, a set of ~4,300-5,000 
high confidence bivalent promoters, within 3-4 kb of an annotated TSS, were 
identified in hES cells (Court and Arnaud, 2017; Mantsoki et al., 2015). These high 
confidence bivalent promoters tend to be unmethylated CpG islands and tend to be 
associated with genes that have low expression in ES cells and tissue-specific 
expression patterns after differentiation (Court and Arnaud, 2017; Mantsoki et al., 
2015). Importantly, over 50% of bivalency is conserved between promoters from 
mES and hES cells, suggesting an important functional role of bivalency (Mantsoki 
et al., 2015).  
Bivalency is not restricted to pluripotent cells. A number of reports have 
identified bivalency at a large number of gene promoters in differentiated cells, for 
example lineage committed cell lines derived from mES cells (Mikkelsen et al., 
2007), primary human CD34+ cord blood cells (Lorzadeh et al., 2016), primary 
human CD4+ memory T cells (Kinkley et al., 2016) and adult mouse intestinal cells 
 
Chapter One: Introduction 17 
(Jadhav et al., 2016). These reports have often shown that a subset of bivalent 
domains overlap between ES cells and differentiated cells, but that certain bivalent 
domains are lost or new bivalent domains are formed. For example, Weiner et al. 
(2016) showed that of the 23,167 bivalent domains discovered in total in 5 different 
tissues, 5,786 change dynamically between mES cells and mouse adult brain, kidney, 
liver and lung tissues (from genome wide co-ChIP-seq analysis not restricted to 
promoter regions). Bivalency occurs in many different pluripotent and differentiated 
cell types and changes dynamically during differentiation. In the following section I 
will discuss how a bivalent state is formed at promoters.  
 
1.2.3 Establishment of bivalency 
A number of factors appear to be important in the establishment of bivalency. 
Firstly, an unmethylated CpG island is required to recruit members of the PcG and 
SET1 or SET1-like complexes that catalyse H3K27me3 and H3K4me3 (see section 
1.1.1, pp. 2 and section 1.1.2, pp. 5). Once these complexes have been recruited, no 
single complex can be allowed to outcompete the other and establish a monovalent 
domain. A balance between the two marks must be established by means of 
appropriate deposition and removal of the marks. Below, I will discuss the 
mechanisms involved in the establishment of bivalency.   
It has been well reported that bivalency predominately occurs in promoters 
containing unmethylated CpG islands (Court and Arnaud, 2017; Meissner et al., 
2008, Mantsoki et al., 2015). Indeed, it has recently been shown that DNA 
demethylation by the TET family is important for both the establishment and 
maintenance of bivalency (Kong et al., 2016). Overexpression of the DNA 
demethylase genes, TET1/2, in HEK293T cells caused DNA demethylation at a 
subset of hypermethylated CpG islands promoters and this was sufficient for the de 
novo establishment of bivalent domains (Kong et al., 2016). It has also been shown 
that demethylation of intragenic CpG (iCpG) islands (within the gene-body), is 
important in regulating the establishment of bivalent domains (Lee et al., 2017). 
Hypermethylation of iCpG islands is usually required for high activation of gene 
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expression but cell type specific methylation of iCpG islands can cause loss of 
bivalency at the associated gene promoter (Lee et al., 2017). 
It is possible that the deposition of H3K4me3 occurs before H3K27me3 at 
bivalent promoters. MLL2 is required to establish the H3K4me3 mark at bivalent 
promoters in mES cells (Denissov et al., 2014; Hu et al., 2013). While MLL1 is not 
required for the establishment of H3K4me3 at bivalent promoters (Denissov et al., 
2014), it is required to establish H3K4me2 at a subset of H3K27me3 marked CpG 
island promoters (Rickels et al., 2016). Dynamic changes have been observed in the 
presence of H3K4me3 at bivalent genes during the cell cycle and it has been shown 
that the MLL1/2 proteins are recruited to bivalent genes in a cell cycle dependent 
manner (Grandy et al., 2015).  
Once a H3K4me3 domain has been established at an unmethylated CpG 
island promoter, PRC2 mediated deposition of H3K27me3 is required to establish a 
bivalent domain. It had previously been shown that the presence of H3K4me3 can 
inhibit PRC2 methylation of H3 in nucleosomes (Schmitges et al., 2011). However, 
this inhibition of PRC2 does not extend to the ‘free’ unmarked H3 tail in 
asymmetrically H3K4me3 marked nucleosomes (Voigt et al., 2012). It has thus been 
proposed that when the K4me3 mark is removed from at least one H3 copy in a 
nucleosome by a histone demethylase, it can then be methylated by PRC2 resulting in 
bivalently marked domains (Voigt et al., 2013). Indeed, it has since been shown that 
the H3K4me2/3 demethylase, JARID1B (KDM5B), colocalises with the majority of 
bivalent genes in mES cells (Kidder et al., 2014). In the absence of Jarid1b, bivalent 
gene expression is delayed or reduced during differentiation of mES cells, suggesting 
that JARID1B is important in bivalent gene regulation (Kidder et al., 2013). Another 
H3K4me2/3 demethylase, KDM2A, is also recruited to bivalent promoters (Grandy et 
al., 2015), indicating that these histone demethylases may perform redundant 
functions at bivalent genes.  
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1.2.4 Functions of bivalency 
Once a bivalent domain has been established at a gene promoter, these genes 
are expressed at low or undetectable levels with a high degree of variation in 
expression between single cells (Bernstein et al., 2006, Court and Arnaud, 2017; 
Mantsoki et al., 2016, Mikkelsen et al., 2007). It has been proposed that bivalency 
poises developmental genes for timely activation or complete repression (Bernstein et 
al., 2006). It is thought that this activation or repression occurs following the 
resolution of bivalency, i.e. the conversion to a monovalent state. Bivalency 
resolution readily occurs during differentiation. Mouse adult brain tissues have lost 
bivalency at nearly 5,000 regions compared to ES cells (Weiner et al., 2016). To 
explore the function of bivalency during development, a number of studies have 
achieved the global depletion of one of the bivalent histone marks and analysed the 
resulting phenotypes. In this section I will discuss the results of these experiments and 
the various models of bivalency function.  
It has been proposed that the existence of the H3K4me3 mark on bivalent 
genes is important for their timely activation following differentiation. However, the 
loss of H3K4me3 from bivalently marked genes in mES cells does not appear to 
affect the expression of bivalent genes following differentiation, or the differentiation 
capacity of the cells (Denissov et al., 2014; Hu et al., 2013). Furthermore, the loss of 
the H3K4me2 mark at H3K4me2/H3K27me3 marked promoters only causes 
expression changes in <200 genes bound by MLL1 at the TSS (Rickels et al., 2016). 
These results do not suggest that the H3K4me2/3 mark at bivalent genes is important 
for their activation after differentiation.  
Another study focused on analysing gene expression changes after the 
depletion of the H3K27me3 mark on bivalent promoters (Jadhav et al., 2016). At a 
bivalent promoter, the loss of the H3K27me3 mark, and conversion to a monovalent 
H3K4me3 marked state, is proposed to mediate gene activation following 
differentiation. Indeed, it has been shown that the H3K27me3 demethylase, UTX, is 
required for activation of bivalent genes after the induction of mES cell 
differentiation (Dhar et al., 2016). Jadhav et al. (2016) inactivated PRC2 via an 
inducible Cre-mediated knockout of Eed in adult mouse intestinal cells, which led to 
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epithelial defects in the intestinal crypts. The knockout of Eed caused a loss of 
H3K27me3 and an increase in gene expression from genes that were specifically 
marked with H3K27me3 in the intestine. The increase in gene expression was directly 
proportional to the basal levels of H3K4me2/3 that were present at the promoter. This 
suggests that the tissue-specific localisation of H3K27me3 is important in 
maintaining repression of bivalent genes in these cells. Furthermore, the level of 
H3K4me2/3 at a bivalent promoter may be important in tuning gene expression levels 
following the removal of H3K27me3 (Jadhav et al., 2016).  
It is also possible that the recognition of bivalently marked chromatin by 
specific factors is developmentally important. Notably, a transcriptional regulator 
UTF1 is enriched at bivalent genes in mES cells and appears to compete with PRC2 
for binding sites, thus limiting PRC2 loading and H3K27me3 deposition (Jia et al., 
2012). Conversely, UTF1 also promotes the degradation of mRNAs transcribed from 
bivalent genes via the recruitment of the mRNA decapping enzyme DCP1A (Jia et 
al., 2012). A motif has been identified that is enriched in high confidence bivalent 
promoters suggesting that other modifiers of bivalent genes that bind to this sequence 
may yet be identified (Mantsoki et al., 2015).  
From these studies, a universal function of bivalency in transcriptional 
regulation during development is unclear. The classic model that bivalency is 
required for timely gene activation or complete repression following differentiation 
and resolution does not fit with the evidence presented to date. An alternative model 
suggests that MLL2 binding at bivalent genes prevents the binding of SET1C, which 
is only found at actively transcribing H3K4me3 marked promoters (Denissov et al., 
2014). Perhaps these genes are only activated once bound by SET1C. It seems that 
bivalency may be important at a tissue-specific level for the repression of genes. If 
this bivalency were resolved in these cells via H3K27me3 removal, the levels of 
H3K4me2/3 would determine the level of gene induction (Jadhav et al., 2016). The 
specific manipulation of these marks at particular bivalent genes and analysis of 
dynamic molecular changes during cell differentiation would help elucidate the role 
of bivalency in gene regulation. Another chromatin feature that is associated with 
regulating gene expression during development are long-distance regulatory elements 
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(referred to here as enhancers). In the following section I will discuss enhancers and 
focus on the models that describe their actions and functions.  
 
1.3 Enhancers 
A number of proximal and distal regulatory regions are involved in controlling 
gene transcription. Promoters are regions of DNA that are required for transcriptional 
activation at a gene TSS (Juven-Gershon and Kadonaga, 2010). Enhancers are DNA 
sequences that, when activated in a tissue-specific manner, can increase the 
probability their target gene is transcribed (Fiering et al., 2000). Enhancers can be 
located long distances of up to 1 Mb from their target promoters (Lettice et al., 
2003). In this section I will discuss how enhancers are identified and how they 
function to activate the transcription of a target gene.  
 
1.3.1 Identifying enhancers of transcription 
In 1981 the first enhancer was isolated, consisting of 72 bp repeats from 
Simian virus-40 (Banerji et al., 1981). This short regulatory region was found to 
increase the transcription of a β-globin gene when cloned into a reporter plasmid and 
transfected into HeLa cells (Banerji et al., 1981). The basic principles of enhancer 
validation studies have remained largely similar since that time. Predicted enhancers 
are often cloned into a reporter vector with a minimal promoter and introduced into 
cell lines or developing embryos. The enhancer activity can then be visualised and 
spatio-temporal regulation can be observed (Pennacchio et al., 2006). However, the 
temporally regulated activity of enhancers can sometimes make them difficult to 
validate, as they may not be active at the developmental stage they are tested. The site 
of random integration of the reporter construct may also reduce the apparent enhancer 
activity. Position effect variegation can cause up to 1,000 fold variation of enhancer 
activity based on the surrounding chromatin architecture, genomic context or 
transcriptional activity at the site of integration (Akhtar et al., 2013).  
Over a decade ago, enhancers began being identified by comparative 
genomics; non-coding regions undergoing evolutionary constraint were often found 
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to elicit enhancer activity when tested, but many false positives indicated that 
browsing DNA sequence alone would not be sufficient for enhancer identification 
(Pennacchio et al., 2013). Since then a number of studies have identified a unique 
combination of chromatin features that define enhancers. Unlike promoters, 
enhancers tend to be located in CpG poor regions in mammals (Andersson et al., 
2014a). Active enhancers are located in open chromatin regions that are depleted of 
nucleosomes and so, like other regulatory and coding regions, can be identified by 
hypersensitivity to the non-specific endonuclease DNaseI (Dorschner et al., 2004). A 
specific histone modification signature has also been associated with enhancers. An 
enrichment of H3K4me1 and depletion of H3K4me3 marks enhancer regions, while 
the inverse is indicative of a promoter region (Heintzman et al., 2007, 2009). The 
H3K27ac mark, deposited by the histone acetyltransferase and transcriptional 
coactivator p300, is enriched at both active enhancers and promoters (Creyghton et 
al., 2010; Visel et al., 2009). Bidirectional transcription of capped enhancer RNA 
(eRNA) also defines active enhancers (Andersson et al., 2014a, 2014b). Generally, 
enhancers can be defined as being within CpG poor, nucleosome depleted regions 
that are enriched with H3K4me1 and depleted of H3K4me3. Furthermore, active 
enhancers can be identified by the enrichment of H3K27ac, p300 and by the 
production of bidirectional capped transcripts. Multiple reporter assays have shown 
that these marks are very likely to identify functional enhancers when tested 
(Andersson et al., 2014a; Heintzman et al., 2007). Enhancers have also been 
identified that carry a combination of marks (H3K27ac and DNA methylation) 
associated with both active and inactive enhancers (Charlet et al., 2016).  
 
1.3.2 Functions of enhancers 
Once enhancers have been identified it is then important to understand how 
they function. In this section I will discuss the various models of how enhancers 
regulate gene activity and briefly describe the importance of TF binding to enhancers 
in mediating this activity.  
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1.3.2.1 A stochastic model for enhancer activity 
The vast majority of enhancers are only activate in particular tissues and at 
specific developmental time points (Arner et al., 2015; Nord et al., 2013). However, 
enhancer activation does not only occur in response to developmental cues. Challenge 
experiments have shown that some “latent” enhancers are only activated in terminally 
differentiated cells in response to an external stimulus (Ostuni et al., 2013). Recent 
data from the FANTOM Consortium has suggested that enhancers can rapidly 
become activated in response to a change in cell state, and that this activation occurs 
before changes in target gene transcription (Arner et al., 2015). Once enhancers have 
become activated they can regulate the expression of their target genes (Arner et al., 
2015).  
Two models of enhancer action have been proposed (reviewed in Fiering et al. 
2000). Originally, a “rheostatic” model proposed that enhancers increase the rate of 
transcription at a target gene. However, much evidence instead supports the second 
“stochastic” model which proposes that enhancers increase the probability of 
transcription occurring at a target gene (Bartman et al., 2016; Fukaya et al., 2016; De 
Gobbi et al., 2017). Individual enhancers can activate target gene expression (Banerji 
et al., 1981), or more complex clusters of enhancers such as “super enhancers” (Hay 
et al., 2016; Hnisz et al., 2013), originally termed “locus control regions” (Grosveld et 
al., 1987; Talbot et al., 1989), can work together to control the expression of a gene. 
In the following section I will discuss the various mechanisms that have been 
suggested to explain how enhancers regulate gene activation.  
 
1.3.2.2 Mechanisms controlling enhancer-mediated activation 
A large amount of studies, often using fluorescent in situ hybridization (FISH) 
visualization or 3C based technology, have shown that enhancers physically interact 
with their target promoters through the formation of a chromosomal loop (Amano et 
al., 2009; Dekker et al., 2002; Kieffer-Kwon et al., 2013). This physical interaction 
coincides with an increased concentration of factors required for transcriptional 
activation at the target promoter, including PolII (Vernimmen and Bickmore, 2015; 
Vernimmen et al., 2007, 2011). Of interest, the looping structure itself has been 
 
Chapter One: Introduction 24 
shown to be involved in the activation of target gene expression in the absence of TFs 
that are usually essential for transcription to occur (Deng et al., 2012). 
The binding of tissue-specific TFs to enhancers is integral in mediating 
spatiotemporal regulation of the target gene expression (Spitz and Furlong, 2012). 
Recently, a number of elegant experiments from the Levine lab (Princeton 
University, New Jersey) showed the fundamental importance of the order, 
orientation, spacing (together termed “syntax”) and sub-optimisation of TF binding 
sites in enhancers (Farley et al., 2015, 2016). Farley et al. (2015) randomly mutated 
TF binding sites and TF binding site syntax in enhancer sequences and generated 
reporter libraries with these mutations. These mutant libraries were then 
electroporated into Ciona intestinalis embryos and screened for changes in reporter 
activity relative to the unmutated enhancer (Farley et al., 2015). It was found that the 
combination of optimal TF binding sites and optimal syntax boosted reporter 
expression, but also abolished enhancer-mediated tissue-specific reporter activity 
(Farley et al., 2015, 2016). The presence of non-canonical TF binding sites and sub-
optimal syntax appears to be extremely important in conferring robust tissue-specific 
expression (Farley et al., 2015, 2016).  
It has also been shown that a small number of single-nucleotide 
polymorphisms (SNPs) in enhancers can result in dramatic morphological changes 
(Frankel et al., 2011; Lettice et al., 2003). SNPs in the Drosophila sechellia and 
Drosophila melanogaster enhancers are important in the tissue-specific expression of 
the target TF gene, shavenbaby, and result in dramatic morphological changes 
(Frankel et al., 2011). More recently it has also been shown that these SNPs formed a 
novel TF binding site for a potent repressor in the Drosophila sechellia enhancer that 
is important in limiting ectopic expression of shavenbaby (Preger-Ben Noon et al., 
2016). A study that identified active enhancers (H3K27ac+/H3K4me3-) and active 
promoters (H3K27ac+/H3K4me3+) and compared their underlying genomic 
sequences in liver tissue across 20 mammalian species showed that the enhancers are 
evolving rapidly, at approximately three times the rate of promoters (Villar et al., 
2015). It seems that the subtle changes in TF binding sites in enhancers can be 
extremely important in changing the spatiotemporal regulation of their target genes, 
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and that this may be an extremely important mechanism in evolution. In the 
following section I will discuss how enhancer SNPs, and also enhancer deletions, 
have been associated with a number of genetic diseases in humans.  
1.3.2.3 Enhancers and disease  
Point mutations (or SNPs) in enhancers have been shown to contribute to a 
number of diseases, indicating their importance in regulating gene transcription 
during development (reviewed in Brazel & Vernimmen 2016). As described in the 
above section, SNPs can affect enhancer activity by changing TF binding or syntax 
(Farley et al., 2015, 2016). A number of SNPs in enhancers have been identified that 
are associated with disease. For example, Hirschsprung disease, a multigenic, 
heritable disorder affecting the ganglion cells in the large intestine or gastrointestinal 
tract, is associated with SNPs in the enhancers of RET and SOX10 (Bondurand et al., 
2012; Emison et al., 2005; Lecerf et al., 2013). Point mutations in the enhancer of 
Sonic Hedgehog (SHH) have been shown to cause preaxial polydactyly (formation of 
extra digits) in humans (Lettice et al., 2008, 2003). A number of independent studies 
have identified distinct solid tumour risk associated SNPs in the 8q24 enhancer region 
(Ahmadiyeh et al., 2010). This enhancer region has a number of different target 
genes, including the oncogene MYC (Cai et al., 2016). Some of these enhancer SNPs 
have been shown to modify TF binding affinity. For example, a prostate cancer risk 
allele enhances interactions with the TF forkhead box protein A1 (FoxA1), while a 
renal cancer risk allele modulates binding of the hypoxia-inducible TFs (Grampp et 
al., 2016; Jia et al., 2009).  
The deletion of enhancers can also cause genetic diseases. For example, the 
deletion of the enhancers of globin genes has been shown to cause α- and β-
thalassaemia in certain patients via down regulation of their target genes 
(Vernimmen, 2014). The characterization of the molecular basis of β-thalassaemias 
in patients led to the identification of regulatory elements controlling the β-globin 
locus (Kioussis et al., 1983). The existence of an enhancer region for the α-globin 
cluster in humans was first identified due to a large 62 kb deletion upstream of the α-
globin cluster that caused α-thalassemia in a patient despite no mutations in their 
coding gene or promoter sequences (Hatton et al., 1990). Since then, a number of 
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causative deletions of varying size spanning the α-globin regulatory region have been 
identified from patients with α-thalassemia (reviewed in Higgs 2013). Many 
advances in our understanding of transcriptional regulation were made by studying 
the globin loci. In the following section I will describe the α-globin locus and focus 
on the role of enhancers in regulating α-globin transcription.  
  
1.4 Transcriptional regulation at the α-globin locus 
The α- and β-globin loci are two of the most well studied models of 
transcriptional regulation. In fact, a β-globin gene from rabbit was the first 
mammalian gene ever isolated with an intact promoter region (Maniatis et al., 1978). 
Haemoglobin is composed of α- and β- globin subunits and is expressed in the red 
blood cells of nearly all vertebrates and some invertebrates (McGrath and Palis, 
2008). Haemoglobin functions as an oxygen transporter, ensuring that oxygen is 
delivered from the lungs to all other tissues in the body through the circulatory 
system. Different forms of haemoglobin are produced at the embryonic, foetal and 
adult stages of development from different tissues and the ‘switching’ of expression 
between different globins has been studied extensively (reviewed in Dzierzak & 
Philipsen 2013). In adults, the haematopoietic stem cells that reside in the bone 
marrow can differentiate into common myeloid progenitor cells which give rise to the 
erythroid lineage (Higgs et al., 2008). Throughout erythropoiesis a cascade of TFs 
progressively accumulate at the globin promoters and associated enhancers during 
lineage restriction, culminating in the eventual maximal globin expression in 
intermediate erythroblasts (Ferreira et al., 2005; Higgs and Wood, 2008; Philipsen 
and Hardison, 2017). In this section, I will briefly describe the α-globin locus and 
discuss in detail a humanised mouse model used to study α-globin gene regulation.  
 
1.4.1 Organisation of the α-globin locus 
The α-globin locus is well conserved through vertebrate evolution. A region of 
conserved synteny has been identified across ~135 kb of the α-globin locus that spans 
~500 million years of evolution in 22 species (Hughes et al., 2005; Philipsen and 
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Hardison, 2017). In humans, the α-globin locus is located on Chromosome 16 and the 
five functional α-globin genes are arranged in the order shown in Figure 1.2  
 
 
Figure 1.2 Chromosomal organisation of the (A) human and (B) mouse α-globin 
loci. The five functional α-globin and α-globin-like genes are shown as labelled red 
boxes. The human genes include HBZ (ζ-globin; expressed in embryonic stages), 
HBM (µ-globin; high mRNA expression, no protein expression detected), HBA1 and 
2 (α-globin; expressed in adult stages) and HBQ1 (θ-globin; low expression in foetal 
stages). The mouse genes include Hba-x (ζ-globin; expressed in embryonic stages), 
Hba-a1 and 2 (α-globin; expressed in adult stages) and Hbq-1a and b (θ-globin; 
lowly expressed in foetal stages). Other mouse and human genes in the locus are 
shown as labelled blue boxes. Genes shown above the line are transcribed from the 
forward DNA strand, while genes shown below the line are transcribed from the 
reverse strand. A region of conserved synteny is shown in purple and MCS-R (black 
vertical lines) refers to previously annotated multispecies conserved regulatory 
regions. In humanised mice, the region above the human locus, delimited by dashed 
lines, was exchanged from a human bacterial artificial chromosome (BAC) to mES 
cells. In the process of this exchange, one copy of the region above the mouse locus, 
delimited by dashed lines, was deleted. The exchanged regions are flanked by a 5` 
loxP (green triangle) and a 3` lox511 (purple triangle) site. This figure is adapted 
from Wallace et al. (2007).  
 
(Hughes et al., 2005; McGrath and Palis, 2008). A number of multispecies conserved 
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regulation of human α-globin transcription in vivo, Wallace et al. (2007) generated a 
‘humanised’ mouse, in which the ~85 kb mouse α-globin cluster was replaced with 
~117 kb of the orthologous human α-globin cluster (Figure 1.2). The inserted region 
included all the human α-globin regulatory elements, allowing human α-globin 
transcriptional regulation to be studied in vivo (Wallace et al., 2007). A crucial 
difference between the human and mouse α-globin loci is the presence of CpG islands 
at the human α-globin genes that are absent in the mouse (Lynch et al., 2011). This is 
reflected by the fact that the human α-globin locus is bivalent in hES cells while the 
mouse α-globin is not bivalent in mES cells (De Gobbi et al., 2011). In the following 
section, I will discuss the roles of remote regulatory regions in the control of α-globin 
gene expression and in particular focus on data from the humanised mouse model. 
 
1.4.2 Roles of remote regulatory elements 
The long range regulatory elements within the α-globin locus have been well 
characterised in both mice and humans (Higgs et al., 2008). The identification of 
patients with α-thalassemia caused by deletions of α-globin enhancers, has greatly 
contributed to the analysis of α-globin transcriptional control (Hatton et al., 1990; 
Higgs, 2013; Higgs et al., 2008). Genetically engineered enhancer deletions in 
humanised and wild type mice have also been studied to elucidate the contribution of 
these enhancers to α-globin transcriptional regulation (Hay et al., 2016; Wallace et 
al., 2007). Notably, a recent study has shown that only fractional differences in mouse 
α-globin RNA production are observed when individual enhancers in the locus are 
deleted, resulting in no change to the overall haemoglobin levels (Hay et al., 2016).  
In contrast, a much more dramatic phenotype is observed following the 
deletion of the human HS-40 enhancer (Wallace et al. 2007; Vernimmen et al. 2009). 
The HS-40 enhancer in the human α-globin locus is ~60 kb away from the α-globin 
genes (Figure 1.2A). To probe the contribution of the HS-40 enhancer, a humanised 
mouse with a HS-40 deletion was generated (Wallace et al., 2007). Removal of the 
HS-40 enhancer caused a severe reduction in α-globin expression to <2% of normal, 
indicating its critical role in α-globin regulation (Wallace et al. 2007; Vernimmen et 
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al. 2009). Indeed, many lines of evidence have shown that HS-40 is the only 
regulatory domain in the human locus that is capable of enhancing α-globin on its 
own (reviewed in Higgs & Wood 2008). A small number of cases of α-thalassaemia 
have been identified that are caused by homozygous deletions of the HS-40 enhancer 
in patients that have intact α-globin genes (Coelho et al., 2010; Sollaino et al., 2010; 
Wu et al., 2016). These patients present with moderate to severe forms of α-
thalassaemia consistent with the deletion of three of the four α-globin genes, however 
this does not fully equate to the severity of α-globin dysregulation observed in the 
humanised mouse model with a HS-40 deletion.  
Detailed molecular comparisons were made of the α-globin locus in erythroid 
cells from the wild-type humanised mouse (WTH) and the HS-40 deleted humanised 
mouse (ΔHS-40; Figure 1.2; Vernimmen et al. 2011; De Gobbi et al. 2017). 
Immunofluorescence and single cell reverse-transcriptase (RT-) PCR showed that 
only ~50% of terminally differentiated erythroid cells from ΔHS-40 mice express 
detectable levels of human α-globin (Figure 1.3A, B). Furthermore, uncharacteristic 
bivalency is observed at the α-globin genes in erythroid cells from ΔHS-40 mice 
(Figure 1.3C). It is possible that an underlying epigenetically mixed population of 
cells is reflected by the heterogeneous phenotype that is observed in the ΔHS-40 
cells. If this hypothesis were true, the α-globin expressing ΔHS-40 cells would 
feature H3K4me3 at the α-globin genes while the non-expressing ΔHS-40 cells 
would instead feature H3K27me3 at the α-globin genes. Transgenic experiments 
could be used to generate humanised α-globin reporter mice to test this theory. In the 
following section, I will discuss a number of transgenic technologies, including the 
recombineering technologies that were used to generate these humanised mouse 
models. I will also discuss single cell reporter systems that can be used to track gene 
expression in individual cells. 
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Figure 1.3 Heterogeneous α-globin expression patterns in ΔHS-40 humanised 
mouse erythroid cells.  
A. Immunofluorescence staining of WTH and ΔHS-40 mouse humanised red cells 
using an antibody specific for human α-globin.  
B. Single cell RT-PCR analysis in WTH and ΔHS-40 humanised erythroid cells. 
Each lane corresponds to the same single cell. The expression of human α-globin 
(hα) has been compared to mouse β-globin (mβ).  
C. ChIP-qPCR results using the H3K4me3 (top) and H3K27me3 (bottom) antibodies 
indicated in (i) WTH and (ii) ΔHS-40 humanised erythroid cells (Ter119-positive 
cells purified by auto–magnetic-activated cell sorting). The y-axis represents 
enrichment over the input DNA, normalised to a control sequence in the mouse 
GAPDH gene. The x-axis represents the positions of Taqman probes used. The 
coding sequence is represented by the three exons (orange rectangle; Promoter/Ex1, 
Ex2, Ex3) of the human α-globin genes. MEx2 and MGata6 denote control 
sequences in the mouse genome. A deleted region in the humanised mice, 3’ alpha, 
shows no PCR signal. Error bars represent the standard deviation from at least two 
independent ChIPs. This figure is adapted from Vernimmen et al. (2011) and De 
Gobbi et al. (2017).  
α α
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1.5 Genetic editing, epigenetic editing and single cell 
reporters 
Genetic editing has allowed researchers to generate living models with 
specifically designed changes in their genetic code. Recently, the development of 
epigenetic editing has allowed the site-specific modification of the epigenetic 
landscape. These techniques provide the tools to study an innumerable amount of 
biological questions. Single cell reporter systems can be used to monitor gene and/or 
protein expression in a refined manner. The combination of these techniques can 
allow for the isolation of cells expressing particular proteins in a variety of mutated 
backgrounds. In this section I will provide a description of each of these techniques.  
  
1.5.1 Gene targeting 
The first successful gene targeting experiments in ES cells and generation of 
mouse chimeras earned Mario Capecchi, Martin Evans and Oliver Smithies a Nobel 
Prize in Physiology or Medicine in 2007 (reviewed in Capecchi 2005). These 
experiments used recombineering techniques to modify specific genomic loci. More 
recently, nucleases that introduce targeted double stranded breaks (DSBs) to DNA 
have been developed. The earliest of these include zinc-finger nucleases (ZFN) and 
transcription activator-like effector nucleases (TALEN), and are targeted by protein-
DNA interactions (Joung and Sander, 2013; Urnov et al., 2005). CRISPR (clustered 
regularly interspaced short palindromic repeat)/Cas (CRISPR-associated) is the most 
recent nuclease-based technology used in genetic engineering, and is instead based on 
RNA-DNA interactions (Sander and Joung, 2014). In this section I will describe how 
cellular DSB repair mechanisms are required for gene targeting to occur. I will then 




Chapter One: Introduction 32 
1.5.1.1 DSB repair 
DSB repair mechanisms (Figure 1.4) have evolved in the cell to protect the 
genome from loss of integrity. DSBs in the genome can arise from exogenous 
sources, such as ionising radiation or nucleases. The collapse or stalling of a 
replication fork due to the presence of an inter-strand crosslink or a single stranded 
DNA (ssDNA) nick can also lead to DSB formation (reviewed in Chapman et al. 
2012). DSBs are then repaired by one of three mechanisms in mammalian cells: (1) 
the error prone nonhomologous end joining (NHEJ), (2) homologous recombination 
(HR) or (3) microhomology-mediated end joining (MMEJ). NHEJ and HR are the 
two main pathways through which the genetic engineering by site-specific nucleases 
is mediated (Figure 1.4). NHEJ mechanisms promote the direct ligation of double 
stranded DNA (dsDNA) ends and occur throughout the cell cycle. This process is 
error prone and often results in the formation of small insertions or deletions (indels) 
or substitutions. HR occurs mostly during S and G2 phases of the cell cycle, when 
the cell is replicating its DNA and before mitosis occurs, and leads to precise 
homology directed repair (HDR), often between aligned sister chromatids. The DSB 
repair mechanisms that occur in the cell are reviewed in detail in (Chapman et al., 
2012; Symington and Gautier, 2011; Wyman and Kanaar, 2006).  
 
1.5.1.2 Recombineering and recombinase mediated cassette exchange 
Traditional molecular cloning with restriction enzymes and DNA ligases uses 
Escherichia coli (E. coli) as a vehicle in which plasmids can be propagated. A 
RecA/recBCD mutant strain of E. coli is often used as these strains cannot quickly 
degrade linear DNA that enters the cell, however these strains are also recombination 
deficient (Yu et al., 2000). The λ bacteriophage uses homologous recombination to 
repair double stranded DNA breaks (Figure 1.5). A defective λ bacteriophage  
 
Chapter One: Introduction 33 
 
Figure 1.4 DSB repair mechanisms. Two major DSB repair mechanisms in the 
mammalian cell are shown along with two of the major complexes involved in these 
multi-protein processes.  
A. The heterodimer Ku70-Ku80 coats dsDNA ends to protect them from resection 
and recruits the DNA ligase machinery. Error prone NHEJ then occurs, often leading 
to indel or substitution mutations.  
B. The Rad51 protein coats ssDNA after 5` -3` resection by exonucleases and 
mediates strand exchange in HR. The coated 3` ssDNA strand invades a homologous 
template (green lines), for example a sister chromatid or a plasmid vector with 
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Figure 1.5 Homologous recombination using DY380 E. coli cells.  
A. The free end of a PCR product, for example, is recognised as a DSB in the DNA. 
B. Redα is a 5`-3` exonuclease from the λ bacteriophage which digests one strand of 
DNA at a DSB creating a single stranded overhang.  
C. Redβ then binds to and coats the single stranded DNA.  
D. This protein-DNA complex aligns with a homologous template (green lines), for 
example a BAC, and the 3` end becomes a primer for DNA replication.  
E. A gene from the PCR product (blue) becomes integrated into the BAC DNA 
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containing the three λ genes required for recombination, redα, redβ (also called exo 
and bet, respectively) and gam, was inserted into the DY380 E. coli strain that is 
capable of propagating BACs (Lee et al., 2001). Redα is a 5-3` exonuclease that 
resects the DNA at a DSB, creating a 3` single stranded DNA (ssDNA) overhang 
(Figure 1.5B). Redβ then coats the 3` ssDNA overhang and recombination takes 
place via strand invasion (Figure 1.5C) or single stranded annealing. The Gam 
protein inhibits the E. coli RecBCD exonuclease activity if it is present in the cell 
(Muyrers et al., 2000). These λ genes are under the control of the temperature 
sensitive λcI-repressor in DY380 cells (Lee et al., 2001). A brief activation of these 
genes by heat shock is sufficient to induce recombination in the DY380 cells in the 
presence of a homologous template (Lee et al., 2001). Strategies has been developed 
to manipulate sequences in BAC DNA using this recombination-mediated genetic 
engineering technology (recombineering) in the presence of a plasmid with short 
homology arms to the BAC, and a selectable marker which is inserted into the BAC 
(Lee et al., 2001; Muyrers et al., 2001).  
  The development of the Cre-loxP, FLP-FRT and Dre-rox recombination 
systems have been extremely important in developing mammalian gene targeting 
methods (Branda and Dymecki, 2004). The Cre, FLP and Dre site-specific 
recombinases (SSRs) were isolated from bacteriophage P1, Saccharomyces cervisiae 
and bacteriophage P1 related phages, respectively (Anastassiadis et al., 2009; Sauer 
and McDermott, 2004). Each SSR mediates recombination events between a unique 
pair of recombination target sites (RTSs) which are ~34 bp in length and composed 
of two palindromic sequences separated by ~8 bp (Anastassiadis et al., 2009). The 
RTSs, loxP, FRT and rox, can only recombine with another copy of the same RTS 
(Anastassiadis et al., 2009; Branda and Dymecki, 2004). Alternative RTSs have been 
developed in which substitutions are made within the spacer region that generate a 
new specific target site, compatible with the same recombinase. For example, the F3 
RTS variant of FRT can only recombine with other copies of F3 but not FRT, and the 
recombination of both RTSs is mediated by FLP (Schlake and Bode, 1994). The 
SSRs mediate recombination between a pair of RTSs and, depending on the 
orientation of the RTSs, this can lead to the deletion, insertion, inversion or 
translocation of the intervening DNA sequence (Branda and Dymecki, 2004). This 
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powerful technology has been adapted for use in gene targeting strategies in which 
recombinase mediated cassette exchange (RMCE) allows the manipulation of 
chromosomal DNA in mammalian cells (Figure 1.6).  
BAC recombineering is used in combination with RMCE to enable gene 
targeting. BAC libraries contain thousands of large genomic loci (>100 kb in length) 
from a variety of species. BAC recombineering can be used to insert, replace or 
manipulate specific genomic loci in a BAC. The resulting recombinant DNA with 
long, ~10 kb homology arms, can be then retrieved into homology directed repair 
(HDR) donor plasmids that contain RTSs for use in gene targeting strategies (Lee et 
al., 2013). Gene targeting plasmids contain selectable markers, RTSs, and long, ~10 
kb homology arms to a genomic locus. These targeting plasmids can be transfected 
into mammalian cells where homologous recombination can cause the integration of 
the targeting cassette at a particular genomic locus (Figure 1.6A). The targeted cells 
can then be transfected with the HDR donor plasmid. RMCE can then occur between 
the compatible RTSs on the HDR donor plasmid and targeted locus in the presence 
of an appropriate SSR (Figure 1.6B). This leads to the replacement of the targeting 
cassette with the HDR cassette. Any remaining selectable markers integrated with 
the HDR cassette and flanked with RTSs can then be removed in the presence of an 
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Figure 1.6 Recombinase mediated cassette exchange (RMCE) in mammalian 
cells. 
A. Recombination occurs between the ~10 kb of homologous regions (green) in both 
the targeting vector (ellipse) and the genomic DNA (blue). This recombination 
mediates the insertion of a selection marker (SM1) flanked with RTSs (orange 
rectangles).  
B. Recombination, in the presence of SSR A, occurs between the RTSs (orange 
rectangles) in the HDR donor vector (ellipse) and in the genomic DNA. This 
recombination mediates the exchange of the RTS flanked DNA.  
C. Recombination, in the presence of SSR B, occurs between the RTSs (red 
rectangles) in the genomic DNA and mediates the removal of the second selection 
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1.5.1.3 TALEN technology 
TALEs were discovered in the plant pathogenic bacteria Xanthomonas. 
TALEs naturally act to trigger disease by binding specific host genes and mimicking 
endogenous TFs to active them. They are composed of a N-terminal domain, a 
central domain of tandem repeats approximately 34 amino acids in length and a C-
terminal domain which includes a nuclear localisation signal and an acidic 
transcriptional activation domain (Boch et al., 2009). The most C-terminal tandem 
repeat contains only ~20 amino acids and so is termed the last half repeat (Boch et 
al., 2009). Within the tandem repeats, two hypervariable amino acids at position 12 
and 13, termed the repeat-variable diresidue (RVD), confer specificity of target 
binding. Each RVD corresponds to a single nucleotide, with some degeneracy in the 
cipher (Boch et al., 2009; Moscou and Bogdanove, 2009). The decoding of this 
cipher enabled the construction of synthetic TALE arrays that could bind specific 
DNA target sites (Boch et al., 2009).  
Many groups began fusing a synthetic TALE to the nuclease FokI (TALEN), 
a restriction enzyme that requires dimerization to cleave DNA. Two TALENs could 
then be targeted to each DNA strand to generate a DSB, thus triggering the NHEJ or 
HR repair pathways of the cell. In this way, indels can be generated at specific 
locations or, in the presence of a HDR donor vector, sequences can be integrated into 
the target genome (Cermak et al., 2011; Christian et al., 2010; Li et al., 2011; Miller 
et al., 2011).  
 
1.5.1.4 CRISPR/Cas9 technology 
A recently identified RNA guided endonuclease is being used as a tool to 
genetically engineer almost any target sequence in a number of species with relative 
ease (Le Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013a). The CRISPR/Cas 
system is a natural prokaryotic adaptive immune system identified in a large range of 
bacterial and archael hosts. The CRISPRs are in part derived from foreign DNA and 
guide the Cas endonucleases to find and cleave invading DNA strands. Three types of 
CRISPR-Cas systems have been described and the most well characterized and 
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widely used is a Type II system derived from the Streptococcus pyogenes Cas protein 
9 (Cas9). 
Short single guide RNAs (sgRNAs) contain a scaffold and a 20 nt guide or 
seed sequence, which directs Cas9 to any genomic target sequence preceding a 5`-
NGG or -NAG protospacer adjacent motif (PAM) (Hsu et al., 2013; Jinek et al., 
2012). The PAM proximal 8-12 bp of the sgRNA appear to confer the most 
specificity in some studies (Hsu et al., 2013; Mali et al., 2013a) yet it seems the entire 
20 bp target sites and the PAM sequence can also contribute to specificity 
(Pattanayak et al., 2013). The Cas9 nuclease creates a DSB in the target DNA 3-4 nt 
upstream of the PAM. Cas9 contains two nuclease domains; the HNH domain, which 
cleaves the complementary strand, and a RuvC-like domain, which cleaves the non-
complementary strand (Jinek et al., 2012). The mutation of the RuvC-like domain 
converts the Cas9 into a nicking enzyme, Cas9n, while the mutation of both nuclease 
domains yields a catalytically dead enzyme, dCas9 (Le Cong et al., 2013; Mali et al., 
2013a). 
The CRISPR/Cas9 system is now widely used as a genome-editing tool. DSBs 
caused by the targeting of a single sgRNA in combination with Cas9, or by the 
targeting of two sgRNAs in combination with Cas9n, can be repaired via the NHEJ or 
HR pathways, leading to indel mutations or HDR (Figure 1.4). The ease and 
versatility of genomic engineering allows the creation of multiple knockout mutations 
(Hwang et al., 2013; Wang et al., 2013), targeted genomic rearrangements which 
model those occurring in cancer cells (Choi and Meyerson, 2014) and the site-specific 
insertion of DNA sequences including specific mutations, antibody tags or 
fluorescent genes (Ran et al., 2013a; Yang et al., 2013).  
The site-specific activity of TALEN and CRISPR-Cas9 technology has 
provided efficient tools for genetic editing. Furthermore, many researchers have 
begun to use the nuclease deficient forms of this technology (TALE and 
CRISPR/dCas9) as DNA binding platforms to which a range of activating, repressing 
and chromatin modifying domains can be fused. In the following section I will 
discuss these novel epigenetic editing technologies and briefly describe some of the 
recent discoveries they have allowed.   
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1.5.2 Epigenetic editing 
Many correlations have been made between the presence of particular 
epigenetic marks and changes in transcription. However, it still remains unclear 
whether some of these marks have a causative role in modulating expression rates or 
if their role is more important in maintaining a memory of a transcriptional state (see 
section 1.1.1, pp. 2; section 1.1.2 pp. 5). Recent technological advances have allowed 
the generation of site-specific alterations to the epigenetic landscape. The careful 
description of any resulting phenotypes could elucidate the function of these 
epigenetic marks. In this section, I will focus on TALE and dCas9 fusions that cause 
the activation or the repression of gene transcription and that, in the majority of 
cases, mediate the site-specific change of epigenetic marks.  
 
1.5.2.1 Targeted transcriptional activation using DNA-binding domain 
fusions 
A number of different activation domains have been used in DNA-binding 
domain fusions to mediate target gene activation (reviewed in Thakore et al. 2016). 
VP64 consists of four copies of the viral protein, VP16, which recruits a number of 
activating complexes, including histone acetlytransferases (Hall and Struhl, 2002). 
The p65 subunit of the NF-κB transcription factor complex and the human heat 
shock factor 1 (HSF1) have also been shown to mediate the transactivation of target 
genes (Konermann et al., 2014; Schmitz and Baeuerle, 1991). A TALE or the 
nuclease deficient dCas9 can be directly fused to an activation domain and recruited 
to a target locus mediating robust gene transactivation (Mali et al., 2013a; Miller et 
al., 2011). More recently, a number of technical modifications have been made that 
mediate much stronger gene activation with this system. The MS2 bacteriophage 
coat protein binds to a specific stem loop RNA structure from a viral genome 
(Peabody, 1993). Multiple copies of this target stem loop structure can be added to 
the sgRNA scaffold structure, providing a binding platform for dCas9, as well as 
MS2. The dCas9 and MS2 proteins can be fused to different transcriptional activators 
and the recruitment of these in tandem causes higher transcriptional activation than 
recruitment of an individual activation domain (Konermann et al., 2014). Similarly, 
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the “SunTag” protein scaffold can recruit multiple copies of a specifically designed 
antibody that can be fused to activation domains (Tanenbaum et al., 2014).  
It remains unclear what the effects of site-specific targeting of these 
activation domains have on the underlying epigenetic modifications. The majority of 
studies focus on mRNA expression changes when using these activators and ignore 
potential changes to the epigenetic landscape. Targeting the VP64 transactivation 
domain to enhancers has been shown to result in some enrichment of H3K27ac and 
H3K4me1 at the Oct4 distal enhancer and the β-globin HS2 enhancer (Gao et al. 
2013; Hilton et al. 2015). VP64 targeting to the Oct4 distal enhancer was also shown 
to enhance enrichment of H3K27ac and H3K4me3, and a depletion of H3K27me3 at 
the Oct4 TSS (Gao et al., 2013). Another study used a panel of four guide RNAs 
targeting a promoter in cells expressing a dCas9 fused on both the C- and N-termini 
to VP64 (Black et al., 2016).  Gene expression was induced by 100,000 fold but 
H3K4me3 was only enriched by 5-20 fold (Black et al., 2016). However, a mild ~20 
fold induction of gene expression by a ZF–VP64 fusion targeting the gene promoter 
was not sufficient to induce H3K4me3 enrichment at the promoter (Cano-Rodriguez 
et al., 2016). From such a small number of studies it is hard to draw concrete 
conclusions although it seems that epigenetic changes at a gene promoter tend to 
occur when a transcriptional activator domain induces substantial changes to gene 
expression.  
Other studies have taken the different approach of directly fusing epigenetic 
modifiers to DNA binding domains and searching for a resulting change in 
epigenetic landscape and gene transcription. A fusion of the catalytic core of the 
histone acetyltransferase p300 to dCas9 mediates the targeted enrichment of 
H3K27ac at sgRNA binding sites (Hilton et al., 2015). Targeted enrichment of 
H3K27ac at enhancers and promoters is sufficient to induce high levels of up to 
~10,000 fold induction of target gene expression (Hilton et al., 2015). DNA 
demethylation by TET1 fusions targeted to gene promoters can also cause induction 
of expression at the target gene (Konermann et al., 2013; Maeder et al., 2013a). Site-
specific targeting of the meiotic histone methyl transferase, PRMD9, can cause 
significant enrichment of H3K4me3 (Cano-Rodriguez et al., 2016). This H3K4me3 
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enrichment is sometimes, but not always, sufficient to cause induction of target gene 
expression (Cano-Rodriguez et al., 2016). This evidence suggests that H3K4me3 
may only be instructive for gene transcription in a context dependent manner. In the 
following section I will discuss DNA binding domain fusions to repressive domains, 
and to epigenetic editing enzymes associated with gene repression.  
 
1.5.2.2 Targeted transcriptional repression using DNA-binding domain 
fusions 
The gene specific repression of expression is an important technique that can 
help to elucidate the specific function of a gene or be used for clinical applications. 
For some time, various groups have used tailored small RNAs to knock-down 
specific genes. More recently, DNA binding domain fusions to repression domains 
have been used for the same purpose (Boettcher and McManus, 2015). The simple 
binding of dCas9 to a gene coding region can cause an up to 1,000 fold reduction of 
gene expression via the steric inhibition of transcriptional machinery (Qi et al., 
2013). The Krüppel-associated box (KRAB) domain is often used in DNA-binding 
domain fusions as it triggers the recruitment of a cascade of proteins associated with 
transcriptional repression, beginning with the KRAB associated protein 1 (KAP1). 
KAP1 then sequentially recruits enzymes associated with the deposition of 
H3K9me2/3 (SETDB1, G9A), the demethylation of H3K4 (LSD1), histone 
deacetylation (the NuRD complex) and DNA methylation (DNMT3A/B) (Groner et 
al., 2010). Fusions of the KRAB domain to ZFs, TALEs and dCas9 mediate the 
robust silencing of targeted genes (Gao et al., 2013; Gilbert et al., 2014; Groner et al., 
2010; Klann et al., 2017). However, transient expression of these fusion proteins 
does not usually result in stable repression of transcription (Amabile et al., 2016). 
Some evidence has shown that expression of DNMT3A/B fusion proteins may 
support prolonged gene repression (Rivenbark et al., 2012; Stepper et al., 2016). A 
recent report achieved the stable repression of a target for over 40 days in a cell line 
following transient transfection of a combination of dCas9-KRAB, -DNMT3A and -
DNMT3L fusions (Amabile et al., 2016). This repressor domain combination 
mediated an enrichment of H3K9me3 and CpG methylation, and depletion of 
H3K4me3 and PolII occupancy at the target gene (Amabile et al., 2016).  
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The site-specific targeting of epigenetic enzymes associated with gene 
repression has revealed mechanistic insights into the function of these marks. The 
targeted removal of H3K4me1/2 at enhancers by LSD1 fusions to DNA binding 
domains is sufficient to cause a reduction in the enhancer target gene expression, 
indicating the importance of this mark in enhancer mediated gene activation (Kearns 
et al., 2015; Mendenhall et al., 2013). The site-specific targeting of a number of 
PRC1 components results in the deposition of H2Aub and the subsequent recruitment 
of PRC2 components, supporting the role of PRC1 in PRC2 recruitment (Blackledge 
et al. 2014). A recent report tested the capability of EZH2 fusions to dCas9 in 
repressing gene transcription (O’Geen et al., 2017). EZH2 fusions were sufficient to 
cause the site-specific deposition of H3K27me3 (O’Geen et al., 2017). However, 
some repression was observed from fusions of catalytically inactive forms of EZH2 
that could not mediate H3K27me3 deposition (O’Geen et al., 2017). Furthermore, the 
rate of gene repression was not amplified in the presence of H3K27me3 enrichment, 
and the relative amount of repression was gene target and cell type dependent 
(O’Geen et al., 2017). This suggests that H3K27me3 may not be instructive of gene 
repression, and that EZH2 may mediate gene repression by other mechanisms 
independent of the H3K27 methylase activity.  
The use of DNA binding domains as platforms for testing the effects of 
catalytic domain fusions on gene expression is promising. Likewise, DNA binding 
platforms have been modified for use in monitoring transcriptional activity. In the 
following section, I will discuss these technologies and others that have been 
developed for visualising gene expression on a single cell basis.   
 
1.5.3 Single cell reporter systems 
Heterogeneous gene expression is regularly reported in apparently 
homogenous cell populations. This heterogeneity can occur within a cell; monoallelic 
gene expression has been reported to occur at >4,000 genes in humans (Savova et al., 
2016). There is also much evidence of heterogeneous gene expression and protein 
accumulation between cells in populations of pluripotent and multipotent stem cells 
 
Chapter One: Introduction 44 
(reviewed in Torres-Padilla & Chambers 2014; Nimmo et al. 2015). It has been 
suggested that this heterogeneous gene expression is a developmental mechanism 
required for the priming of different lineages, leading to increased differentiation 
diversity (Torres-Padilla and Chambers, 2014). The first description of heterogeneous 
gene expression arose from single cell multiplexed PCR and today has culminated in 
single cell RNA-seq (reviewed in Nimmo et al. 2015). Although informative, these 
techniques do not allow for the visualisation of heterogeneous gene expression within 
the cell. In this section, I will briefly describe some of the technologies that have been 
developed to facilitate the tracing of gene expression on a single cell basis.  
Fluorescent proteins and dyes (fluorophores) are useful tools that emit light 
when excited at a particular wavelength. Using the appropriate combination of lasers, 
multiple fluorophores can be detected in tandem, allowing for multiplexing (Kremers 
et al., 2011). Many groups have used transgenic techniques to generate fusions of a 
gene of interest to a fluorescent reporter gene. For example, in frame fusions of two 
different fluorescent reporter genes to the start codon of β- and γ-globin were 
generated in the K562 erythroleukaemia cell line, which shows heterogeneous and 
low expression of β-globin (Voit et al., 2014). Firefly luciferase is sometimes used as 
a fluorescent reporter in the presence of its substrate, luciferin, as it has a shorter half-
life than most other fluorescent reporter proteins (Suter et al., 2011). When transgenic 
techniques are not feasible, gene expression can be visualised in large populations of 
live cells through the use of nano-flare technology (also commercially available under 
the name SmartFlare; Seferos et al. 2007). Nano-flares are 13 nm gold particles to 
which multiple oligonucleotides that are complementary to a target RNA transcript 
are bound. Fluorescent dyes are bound to the oligonucleotides that are quenched as 
long as they remain in close proximity to the core gold nanoparticle. However, when 
the nano-flares enter a cell via receptor-mediated endocytosis, the binding of target 
RNA facilitates the release of the fluorescent dye (Seferos et al., 2007). This permits 
the user to detect, and potentially isolate, live cells that are actively transcribing the 
target RNA.  
The above techniques allow the detection of RNA or protein expression in 
single cells. However, the detection of where and when transcription occurs within a 
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cell is also a useful method. The cellular localisation of transcriptional activity can be 
observed through the in situ hybridisation of multiple fluorescent probes to a 
particular RNA target (RNA-FISH; Femino et al. 1998; Bartman et al. 2016). 
Although useful and quantitative, RNA-FISH requires the fixation of cells before in 
situ hybridisation. This means vast numbers of cells must be analysed before useful 
conclusions about the temporal dynamics of transcription are made. Other methods 
have been developed that allow the real time imaging of transcription in a living cell. 
As described previously (section 1.5.2.1, pp. 40), the MS2 system can be used to 
mediate the site-specific localisation of the MS2 binding protein to specific RNA 
stem-loop structures (Peabody, 1993). Transgenic techniques can be used to integrate 
these binding sites into genomic DNA (Bakstad et al., 2012). This allows the 
visualisation of transcriptional bursting in real time via the binding of an MS2 protein 
fused to a fluorescent reporter (Bertrand et al., 1998; Fukaya et al., 2016). The PP7 
bacteriophage coat binding protein binds to a different RNA stem loop sequence and 
so can be multiplexed with the MS2 system (Fukaya et al., 2016; Larson et al., 2011).  
The use of single cell reporter systems has facilitated the advancement of 
knowledge in a number of areas. For example, the visualisation of transcription 
following enhancer looping to target genes showed that enhancers are involved in the 
regulation of transcriptional bursting (Bartman et al., 2016; Fukaya et al., 2016). 
Transgenic reporter cell lines are extremely useful tools for isolating expressing and 
non-expressing cells within apparently homogenous cell populations (Chambers et 
al., 2007). This allows for the detailed comparison of sub-populations of cells that 
may have underlying differences leading to heterogeneous gene expression.  
 
1.6 Summary and outline of thesis 
The humanised mouse model (WTH), in which ~120 kb of the human α-globin 
locus has replaced one of the mouse α-globin loci, is an important tool for studying 
human α-globin transcriptional regulation (Wallace et al., 2007). The deletion of the 
major HS-40 α-globin enhancer from the humanised locus (ΔHS-40) reduces human 
α-globin expression to <2% of normal levels (Vernimmen et al., 2009). It is also 
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known that the HS-40 plays an important role in the removal of the PcG proteins 
from the α-globin genes during differentiation (Vernimmen et al., 2011). Analyses of 
the ΔHS-40 mouse model revealed that bivalency at the α-globin genes in normal 
hES cells is not resolved in ΔHS-40 erythroid cells (De Gobbi et al., 2011; 
Vernimmen et al., 2011). Furthermore, α-globin is heterogeneously expressed in 
ΔHS-40 erythroid cells (De Gobbi et al., 2017). Moreover, it was proposed that this 
epigenetically mixed population of cells underlies the heterogeneous α-globin 
expression pattern in ΔHS-40 erythroid cells. If this were the case, it would reveal an 
important new function of enhancers in the maintenance of homogenous epigenetic 
landscapes via the consistent removal of PcG proteins in all cells.  
To determine the true nature of bivalency at the α-globin locus, a reporter 
system for monitoring α-globin expression in live WTH and ΔHS-40 erythroid cells 
was required. Establishment of a reporter system in humanised mES cells would 
allow erythroid cells to be isolated based on their α-globin expression level. Erythroid 
cells could be obtained from in vitro differentiation of the humanised mES cells. 
Primary erythroid cells could also be isolated from mouse lines generated from the 
humanised mES cells. ChIP-qPCR analyses could then be performed on expressing 
vs. non-expressing ΔHS-40 erythroid cells. This would determine if H3K4me3 was 
the only mark found at α-globin in expressing cells, and if H3K27me3 was the only 
mark found at α-globin in non-expressing cells.  
In this thesis, I first isolated and characterised suitable WTH and ΔHS-40 
humanised mES cell subclones to perform gene-targeting experiments on. I also 
optimised a robust in vitro differentiation protocol for the generation of erythroid 
cells (Chapter 3, pp. 79). Next, I designed gene-targeting strategies for generating a 
fluorescent reporter knock-in at human α-globin 2 (HBA2) in the humanised mES cell 
subclones (Chapter 4, pp. 99). Initially, recombineering strategies were designed to 
achieve a knock-in using RMCE techniques. However, due to technical difficulties 
with BAC targeting using the RMCE strategy, and due to the recent advent of the 
reportedly fast and efficient CRISPR/Cas9 gene editing technologies, a CRISPR/Cas9 
strategy was implemented instead. To this end, I generated and validated a number of 
CRISPR/Cas9 tools for generating a reporter knock-in at the HBA2 gene (Chapter 4, 
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pp. 99). Using these tools, I performed a number of gene targeting attempts using a 
WTH humanised mES cell subclone (Chapter 5, pp. 132). A number of clones were 
isolated that contained a successful knock-in of the reporter cassette. This marked a 
significant step forward in the generation of a fluorescent reporter knock-in in a ΔHS-
40 background. Future work will include the completion of the remaining gene 
targeting steps, generation of mouse colonies from these mES cell lines and analysis 
of primary erythroid cells from these mice. 
While the nature of bivalency at the human α-globin genes in ΔHS-40 cells is 
unclear, so too is the true function of bivalency in ES cells. It has been proposed that 
the function of bivalency is to poise developmental genes for timely activation or 
permanent repression (Bernstein et al., 2006). However, some evidence to the 
contrary cast doubt on this hypothesis (discussed in section 1.2.4, pp. 18). The site-
specific manipulation of bivalent marks in ES cells and analysis of any dynamic 
changes in expression during differentiation of these cells would reveal information 
about the function of bivalency during development. Here, I designed and developed 
a cloning strategy that allows the fast generation of epigenetic editing tools that can 
bind to specific genomic loci (Chapter 6, pp. 161). A validated TALE targeting the 
bivalent mouse promoter of Nrp1 had already been published (Therizols et al., 2014) 
and so I generated a number of expression vectors containing TALEs that bind to the 
Nrp1 promoter, and are fused to enzymatic regions involved in catalysing the 
deposition or removal of bivalent histone marks. I tested the effects of these TALE 
fusions on Nrp1 expression and histone methylation status in humanised mES cells. 
Notably, one of these TALE fusions, containing the H3K27me3 demethylase Jmjd3, 
was sufficient to elicit a transcriptional response at the Nrp1 gene. These experiments 
have provided an important foundation for future studies, in which bivalent histone 
modifications would be manipulated in ES cells and the effects of this could be 
monitored during in vitro differentiation. For example, the bivalent state at human α-
globin could be manipulated in WTH mES cells and the effects of this on human α-
globin expression dynamics could be monitored during in vitro differentiation of 
these cells. Finally, the results of this thesis are summarised and discussed in Chapter 
7, pp. 209).  
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Chapter 2 Materials and Methods 
2.1 DNA procedures 
2.1.1 Genomic DNA (gDNA) isolation 
2.1.1.1 GDNA isolation from mES cells for T7 Endonuclease I Assay 
Cells were harvested 48 h after transfection and gDNA was isolated. A cell 
pellet was resuspended in ice-cold cell lysis buffer (140 mM NaCl, 1.5 mM MgCl2, 
10 mM Tris pH 8.0, 0.5% NP-40) and incubated on ice for 5 min. The lysed cells 
were pelleted, washed with ice-cold PBS and resuspended in 1 volume of Proteinase 
K Buffer (100 mM Tris pH 7.5, 12.5 mM EDTA, 150 mM NaCl, 1% SDS) with 200 
µg/ml fresh Proteinase K (Promega). The proteinase K digestion was incubated at 
37°C overnight. The DNA was extracted using phenol:chloroform  and ethanol 
precipitated (see section 2.1.2, pp. 49).  
 
2.1.1.2 GDNA isolation from mES cells for PCR screening 
Frozen 96 well plates containing mES cells were defrosted at room 
temperature. Quick Extract Buffer (50 µl; EpiCentre) was added to each well and 
mixed by pipetting and transferred to a 96 well PCR plate. This plate was incubated 
in a thermocycler under the following conditions; 65°C for 15 min, 98°C for 8 min. 
A small volume of the crude extract (1-2 µl) was used in PCR screening and the 
extracts were stored at -20 to 4°C.  
 
2.1.1.3 GDNA isolation from mES cells for Southern blotting 
Cells at ~100% confluency in a 6 well plate were washed twice with PBS. A 
volume of 500 µl of lysis buffer (10 mM Tris, 10 mM EDTA, 0.1% SDS) with 
freshly added Proteinase K (0.1 mg/ml) was added to each well. The plates were 
sealed tightly with parafilm and incubated at 37°C overnight.  
The following day, lysates were transferred to a 1.5 ml eppendorf tube. A 
volume of 1 ml of DNA isolation solution (70% acetone, 5% DMF, 25% H2O) that 
had been stored at -20°C was added to each tube. The tubes were vortexed briefly 
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until a white DNA pellet precipitated out of solution. The pellet was transferred with 
a pipette tip to a new 1.5 ml eppendorf containing 0.5 ml 70% EtOH and placed on a 
shaker for 2 h. Samples were then centrifuged for 15 min at 13,000 rpm. The 
supernatant was discarded and a speedvac was used to remove as much ethanol as 
possible. The pellet was resuspended in 50 µl TE buffer and incubated at 55°C for 2 
h. In some cases, a phenol:chloroform extraction and ethanol precipitation was then 
performed on the samples (see section 2.1.2, pp. 49). The concentration and purity of 
DNA samples was determined using a Nanodrop (Thermo Scientific).  
 
2.1.2 Phenol chloroform extraction and ethanol precipitation 
of DNA 
A solution of phenol:chloroform (1/1 volume) pH 8.0 (Sigma) was added to 1 
volume of cell lysate after Proteinase K digestion. The samples were briefly vortexed 
and centrifuged for 3 minutes (min) at 16,000 rcf. The aqueous top phase containing 
DNA was transferred to a new tube. Chloroform (1 volume; Sigma) was added to the 
sample to remove any remaining phenol traces. The samples were briefly vortexed 
again and centrifuged for 3 min at 16,000 rcf. The aqueous top phase containing 
DNA was transferred to a new tube. The DNA was precipitated by the addition of 0.1 
volumes of 3 M NaOAC pH 5.5 (Ambion) and 2 volumes of 100% Ethanol. The 
samples were incubated at -20°C for at least 30 min and centrifuged at 16,000 rcf for 
up to 60 min at 4°C. The supernatant was removed and the DNA pellet was washed 
in 1 ml 70% Ethanol. The samples were centrifuged at 16,000 rcf for 30 min at 4°C. 
The supernatant was removed and the DNA pellets were left to air dry completely 
before resuspension in an appropriate volume of nuclease free water (NFW; Sigma).  
During the phenol:chloroform extraction of DNA samples for Southern 
blotting, the vortexing steps described above were not performed. Instead, the 
samples were incubated on a tube rotator for at least 20 min.  
 
2.1.3 Polymerase Chain Reaction (PCR)  
Routine PCR reactions were performed with DreamTaq Green DNA 
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polymerase (Thermo Fisher Scientific) or an in-house generated Taq Polymerase 
(Engelke et al., 1990; Pluthero, 1993). A typical 25 µl PCR reaction contained 2.5 µl 
10x DreamTaq Green reaction buffer or 10x Thermopol Buffer (200 mM Tris-HCl 
pH 8.8, 100 mM (NH4)2SO4, 100 mM KCl, 20 mM MgSO4, 1% TritonX100), 0.5 µl 
dNTP (10 mM), 2.5 µl each of forward and reverse primers (10 µM), 0.125 µl 
DreamTaq DNA Polymerase and 10-100 ng template DNA, with the final volume 
made up to 25 µl with ddH2O. PCR reactions for cloning, recombineering or the 
generation of Southern blot probes, etc. were performed using Q5 High Fidelity 
DNA Polymerase (NEB). A typical 25 µl Q5 PCR reaction contained 5 µl 5x Q5 
reaction buffer, 0.5 µl dNTP (10 mM), 1.25 µl each of forward and reverse primers 
(10 µM), 0.25 µl Q5 High Fidelity DNA Polymerase and 1-100 ng template DNA, 
with the final volume made up to 25 µl with ddH2O. Certain PCR reactions were 
optimized by supplementation with 1 M final concentration of Betaine (Sigma). The 
prepared reactions were incubated in a thermocyler according to the manufacturers 
instructions.  
 
2.1.4 Real Time Quantitative PCR (qPCR) 
QPCR was performed on DNA templates using either Taqman Universal 
PCR Master Mix (Applied Biosystems) or SYBR Green PCR Master Mix (Applied 
Biosystems). Briefly, for each Taqman qPCR reaction (performed in technical 
duplicates), 12.1 µl Taqman Universal PCR Master Mix was added to approximately 
10 ng cDNA, 0.2 µM forward and reverse primers, 0.1 µM Probe labelled with 5`-6-
FAM and 3`-TAMRA in a final volume of 25 µl. For each SYBR Green qPCR 
reaction (performed in technical duplicates), 12.5 µl SYBR Green PCR Master Mix 
was added to approximately 10 ng cDNA or 1 µl ChIP material and 0.2 µM forward 
and reverse primers in a final volume of 25 µl. Reactions were assembled on ice in a 
MicroAmp Fast Optical 96 well reaction plate (Applied Biosystems) and plates were 
sealed using a MicroAmp Optical adhesive film (Applied Biosystems). Plates were 
centrifuged briefly and qPCRs were performed on a 7500 Real-Time PCR System 
(Applied Biosystems) according to manufacturers recommendations.  
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Previously published primer sets were used where possible (Anguita et al., 
2004; De Gobbi et al., 2011) or designed using Primer 3 online software 
(Untergasser et al., 2012). Designed primer sets were analysed using the IDT online 
OligoAnalyser Tool (PrimerQuest® program, IDT, Coralville, USA. Retrieved 12 
December, 2012. http://www.idtdna.com/Scitools) and where possible followed the 
following restrictions; 20 bp in length, GC content 20-80%, Tm=58-60°C, no more 
than two G/C at 3` end, Hairpin Tm <40°C, self/hetero-dimer ΔG>-8 kcal/mole. 
Primer sets were tested by performing a standard curve (with technical triplicate 
wells) on relevant target template and confirmed to have an r-squared value of ≥0.99 
and efficiency of 80-120%. PCR products were run on a 3% agarose gel to ensure a 
single band of the expected size was produced. A table of the primer sets used in this 
thesis can be found below in Table 2.1. For mouse Nrp1 expression analysis, a 
PrimeTime Std qPCR Assay Mm.PT.58.9810806 for use with Taqman chemistry 
spanning Nrp1 exon 12-13 was used.  
 
Table 2.1 qPCR Primer and Probe sequences. 
Primer Name Chemistry Sequence 5` - 3` 
Human UBC SYBR F: ATTTGGGTCGCGGTTCTTG 
    R: TGCCTTGACATTCTCGATGGT 
Human alpha globin 
(ex3) SYBR 
F: ACCTCCCCGCCGAGTTC 
    R: AGGCTCCAGCTTAACGGTATTTG 
HS-40  Taqman F: CAGGCTCCAGGCCCATATC 
  	  	   R: CCTCCTGCACTGTCCTTTGAC 
  	  	   P: TGCCCAAGAGCTCCTTCTGCAACC 
Human 5' alpha Probe Taqman F: GACCTCCTGGTGCTTCTGCTT 
  	  	   R: CCAGCATGGATTCCAGGACTT 
    P: AAACGTCCCTGTCCCCGGTGCT 
Human 3' alpha Probe Taqman F: TCCAGGAAGCCCTCAGACTAAC 
  	  	   R: CTCTAACCATCACACAAGTACACACAGA 
  	  	   P: CTGGTCACCTTGAATGCCTCGTCCA 
mCherry Taqman F: AAGACCACCTACAAGGCCAAGAA 
  	  	   R: GGAGGTGATGTCCAACTTGATGT 
    P: CTGCCCGGCGCCTACAACGTC 
The table is continued on the next page. 
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Table 2.1 Table continued. 
Primer Name Chemistry Sequence 5` - 3` 
Human alpha globin Ex3 Taqman F: ACCTCCCCGCCGAGTTC 
  	  	   R: AGGCTCCAGCTTAACGGTATTTG 
  	  	   P: TTCACCCCCGCGGTGCATG 
Neomycin Taqman F: TGCCGAGAAAGTATCCATCATG 
  	  	   R: GTTTCGCTTGGTGGTCGAAT 
    P: CATACGCTTGATCCGGCTACCTGCC 
Mouse UBC SYBR F: AGGTCAAACAGGAAGACAGACGTA 
  	  	   R: TCACACCCAAGAACAAGCACA 
Mouse alpha globin Ex3 SYBR P: AGGCATCAGGGTGTCCACTTT 
    F: CACAGAGGCAAGGAATTTATCCA 
Mouse beta globin Ex1 SYBR R: CCAATCTGCTCACACAGGATAGAG 
  	  	   P: AGCAAATGTGAGGAGCAACTGA 
Mouse alpha globin Ex2 Taqman F: CACCAAGACCTACTTCCCTCACTT 
  	  	   R: AGAGCATCGGCGACCTTCT 
    P: CCACGGCTCTGCCCAGGTCAAG 
Mouse CpG beta actin Taqman F: CGGTGTGGGCATTTGATGA 
  	  	   R: CGTCTGGTTCCCAATACTGTGTAC 
  	  	   P: AAGATGGACCTAATACGGCTTTTAACACCCG 
Mouse GAPDH  Taqman F: CAAGGCTGTGGGCAAGGT 
  	  	   R: TCACCACCTTCTTGATGTCATCA 
    P: ACGGGAAGCTCACTGGCATGGC 
Nrp1 Upstream A SYBR F: ACAACACCTGCTCCTCTGTT 
  	  	   R: TGGGAAGAAAGGGGAAGCAA 
Nrp1 Upstream B SYBR F: ACGAGCAGCCTAGTTCAGTT 
    R: GTCACTAGGGAGCAGGTTGT 
Nrp1ex2A SYBR F: GGGTCACACGGAGGGTTTAT 
  	  	   R: AGATCTCTTCCCTGCAACCA 
Mouse CpG Actin SYBR F: CGGTGTGGGCATTTGATGA 
    R: CGTCTGGTTCCCAATACTGTGTAC 
Mouse Gata6 SYBR F: GGTTGGACGTGAGGTTTTGC 
  	  	   R: GAAAGTGAGATGCCAGGAAAGG 
Mouse 5' alpha1 SYBR F: ACTAAGACCAGCTGTGCCAGATG 
    R: TTCCAAAGGGTGGCCAATT 
Mouse 3' alpha2 SYBR F: TGGCTCCGTGCATTTTCC 
  	  	   R: CCCTTCCAGAGAGTGGGTAAGG 
Mouse GAPDH SYBR F: CAAGGCTGTGGGCAAGGT 
    R: TCACCACCTTCTTGATGTCATCA 
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2.1.4.1 Statistical analysis of qPCR data 
The absolute Ct values from the qPCR runs were obtained from the 7500 
Real-Time PCR System (Applied Biosystems). Statistical analyses of the Ct values 
were performed using the 7500 Real-Time PCR System (Applied Biosystems), Excel 
(Microsoft) or GraphPad (Prism) software packages. Briefly, the average value of the 
technical replicates was determined. The Ct value of a gene of interest was 
normalised to a reference (housekeeping) gene (ΔCt). The ΔCt values were 
normalised to the average of the ΔCt values of all the replicates of a reference sample 
(ΔΔCt). The fold change in gene expression was calculated using the following 
formula; 
Fold change in gene expression = 2-ΔΔCt 
 (Schmittgen and Livak, 2008). A one-way analysis of variance (ANOVA) was 
performed using the GraphPad (Prism) software package. A paired two-tailed t-test 
was performed using the Excel (Microsoft) or GraphPad (Prism) software packages. 
A P value of ≤0.05 was determined to indicate statistical significance. Dot plots were 
generated using the GraphPad (Prism) software package and bar charts were 
generated using the Excel (Microsoft) software package.  
 
2.1.5 DNA digestion with restriction enzymes  
Restriction digests were performed with recombinant enzymes obtained from 
either Roche, NEB or Promega using the supplied reaction buffers. DNA fragments 
were analysed by agarose gel electrophoresis on 0.8-3% agarose gels with TAE 
(Tris-acetate EDTA) buffer, stained with 1x SYBR Safe (Thermo Fisher Scientific) 
or 1x GelRed (Biotium) and visualised under a blue light transilluminator or UV 
lamp. 
 
2.2 RNA procedures 
2.2.1 RNA extraction 
Where possible, a cell pellet of 5 x 106 cells was washed two-three times in 
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PBS before either snap freezing on dry ice or homogenizing in 350 µl lysis Buffer 
RLT (Qiagen) and then snap freezing on dry ice. Samples were stored at -80°C for 
later processing. Frozen samples were defrosted quickly by incubating briefly in a 
37°C water bath and RNA was extracted with either an RNA Easy Mini (for samples 
containing >5 x 106 cells) or an RNA Easy Micro Kit (for samples containing ≤5 x 
106 cells) (Qiagen) following the manufacturers recommendations. Immediately 
following RNA elution from the spin columns the samples were treated with DNaseI 
using a DNA free DNaseI kit (Invitrogen) to remove any traces of contaminating 
genomic or plasmid DNA. Directly following DNaseI treatment RNA samples were 
aliquoted to avoid multiple freeze/thaw cycles and snap frozen on dry ice. An aliquot 
of each sample was immediately tested on a Bioanalyzer (Agilent) using either an 
RNA ScreenTape or a High Sensitivity RNA ScreenTape (Agilent) to determine 
RNA concentration and quality. Only samples with a RNA integrity number of ≥7 
were used in further experiments.  
 
2.2.2 Reverse transcriptase 
Reverse transcriptase (RT) reactions were performed using the SuperScript III 
Reverse Transcription Kit (Invitrogen) on RNA samples to generate cDNA templates 
according to manufacturers recommendations. Briefly, a reverse transcription 
reaction contained 2.5 µM Random Hexamers, 0.5 µg Oligo dT (12-18 nt), 5mM 
DTT, 1x First Strand Buffer, 1 µl RNase OUT, 1 µl SuperScript Reverse 
Transcriptase and equal quantities of RNA for each sample, made to a total volume 
of 20 µl with NFW. RT negative reactions were also performed in which the 
SuperScript Reverse Transcriptase was replaced with NFW.  
 
2.3 Chromatin immunoprecipitation procedures  
2.3.1 Sonication of MES cells for ChIP 
A known number of mES cells (less than 8 x 106 cells) were pelleted in a 1.5 
ml nuclease free eppendorf tube and washed two to three times in PBS. The cell 
pellet was resuspended in 1 ml fix solution to crosslink DNA to protein complexes (1 
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ml room temperature complete mES cell media supplemented with 13.16 µl 
Formaldehyde solution 36.5-38% (Sigma)) and incubated for exactly 15 min at room 
temperature on a rotating wheel. Glycine was added to a final concentration of 125 
mM to quench the formaldehyde reaction and samples were incubated for 5 min at 
room temperature on a rotating wheel. All further steps were performed on ice. The 
fixed cells were pelleted by spinning at 1000 rcf for 5 min at 4°C and washed three 
times in ice-cold PBS. The cell pellet was then resuspended in 300 µl SDS Lysis 
Buffer (Millipore) supplemented with 1x complete EDTA-free Protease Inhibitor 
cocktail (Roche). The cell lysates were transferred to 1.5 ml Bioruptor Pico 
Microtubes with Caps (Diagenode) and incubated at room temperature for 2 min 
followed by a 10 min incubation on ice. Samples were sonicated for 7 min (30 sec 
on/30 sec off x 14 cycles) in a Bioruptor Pico sonication device (Diagenode) pre-
cooled to 4°C. Before and after sonication, samples were warmed slightly such that 
the SDS had not precipitated. The sonicated chromatin samples were transferred to 
1.7 ml Maxymum Recovery Snaplock Polypropylene Tubes (Axygen) and 
centrifuged at 16,000 rcf for 10 min at 4°C. The cleared chromatin was aliquoted into 
new tubes, snap frozen on dry ice and stored at -80°C.  
 
2.3.2 Assessment of sonicated chromatin quality  
A volume of 0.2 M NaCl was added to an aliquot of sonicated crosslinked 
chromatin. The crosslinks were reversed by heating to 65°C overnight in a 
thermomixer (Eppendorf) set to 1000 rpm. A phenol:chloroform extraction and 
ethanol precipitation of DNA was performed on samples. The concentrations of the 
DNA samples were determined using a nanodrop spectrophotometer and 1-3 µg of 
each sample was run on an agarose gel to determine sonication quality.  
 
2.3.3 Chromatin immunoprecipitation (ChIP) 
A sample of chromatin was defrosted at room temperature and diluted in 
ChIP dilution buffer (Millipore) supplemented with 1x “complete” EDTA-free 
Protease Inhibitor cocktail (Roche). Aliquots of 1 ml diluted chromatin were 
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transferred into 1.7 ml Maxymum Recovery Snaplock Polypropylene Tubes 
(Axygen). A sample of 50 µl of the diluted chromatin was stored at -20°C as an input 
control. A volume of 60 µl of salmon sperm DNA/Protein A/agarose slurry 
(Millipore) was added to the diluted chromatin and the samples were incubated at 
4°C on rollers for 30-45 min in a “pre-clearing” step. The samples were centrifuged 
at 2000 rcf for 3 min at 4°C and the supernatant was transferred to a new pre-cooled 
tube. The appropriate antibody was then added (see Table 2.2 for the antibody 
details) to the diluted chromatin and these samples were incubated overnight at 4°C 
on rollers. A volume of 65 µl of salmon sperm DNA/Protein A/agarose slurry 
(Millipore) was added and the samples were incubated for 1 h at 4°C on rollers.  
The agarose slurry was pelleted as before and washed with 1 ml for 5 min at 
4°C on rollers. The slurry was washed sequentially with Low salt immune complex 
wash buffer (Millipore), High salt immune complex wash buffer (Millipore) and 
LiCl immune complex wash buffer (Millipore). The agarose slurry was then washed 
twice with TE (Millipore). The DNA was recovered from the agarose slurry by the 
addition of 250 µl freshly prepared elution buffer (0.2 µm filtered 0.1 M NaHCO3, 
0.4% Ultrapure SDS (National Diagnostics)) and incubation at 37°C with shaking at 
1000 rpm for 15 min. The supernatant was recovered from the tube without 
disturbing the agarose pellet and the elution was repeated a second time.  
The chromatin crosslinks of the ChIP and the input samples were reversed by 
the addition of 0.2 M NaCl and incubation for 4 h at 65°C. To digest the proteins, 10 
mM EDTA, 40 mM Tris pH 6.5 and 20 µg proteinase K (Promega) were added to 
each tube and the samples were incubated for 1 hr at 45°C. A phenol:chloroform 
extraction and ethanol precipitation was preformed as previously described (section 
2.1.2, pp. 49) with the incubation of precipitated DNA with 20 µg Glycogen (Roche) 
at -20°C overnight before washing of the DNA pellet. The air-dryed DNA pellet 
from the ChIP samples was resuspended in 40 µl NFW and the input control samples 
were resuspended in 200 µl NFW at 4°C overnight. An aliquot of 1 µl was used per 
qPCR reaction and technical duplicates were performed on all qPCR reactions.   
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Table 2.2 Details of antibodies used in ChIP protocols. A quantity of 2.5 µg of 
either antibody was added to each 1 ml sample of diluted chromatin. 
 
 
2.4 Southern blotting procedures 
2.4.1 Southern blotting  
A typical 50 µl Southern blot restriction digestion reaction contained 5 µl 10x 
reaction buffer from supplier, 5 µl high concentration restriction enzyme (eg. 50 
units/µl BamHI, Invitrogen), 1 µl Spermidine (50 mM, Acros Organics) and 10 µg 
mES cell gDNA, with the final volume made up to 50 µl with ddH2O. The gDNA 
was typically digested for 24 h with addition of 1 µl fresh restriction enzyme after 
approximately 8 h. The digested samples were migrated on a 0.8% agarose gel with 
TBE buffer (Tris-borate EDTA) precast with SYBR Safe (Thermo Fisher Scientific) 
at 15 V for 24-96 h and visualized using a blue light transilluminator.  
The DNA was depurinated by washing the gel gently for 30 min with 0.25 M 
HCl. The HCl was removed and the gel was rinsed briefly with ddH2O. The DNA 
was denatured by gentle shaking the gel with 1 M NaOH for 40-50 min. The NaOH 
was removed and the gel was rinsed briefly with ddH2O. The gel was then soaked in 
neutralizing buffer (1.5 M NaCl, 0.5 M Tris-HCl pH 7.5) for 1.5 h. The 
neutralisation buffer was removed and the gel was rinsed briefly with ddH2O. The 
DNA was transferred to a positively charged nylon Amersham Hybond-XL 
membrane (GE Healthcare) overnight by capillary action in 6x SSC (0.9M NaCl, 
90mM tri-sodium citrate dehydrate, pH 7.0). Briefly, the transfer assembly was 
constructed by placing an absorbent sponge in a large tray of transfer buffer. A layer 
of Whatman paper, the agarose gel and the nylon membrane were then placed, in that 
order, on top of the absorbent sponge. To draw the transfer buffer through the 
agarose gel, another layer of whatman paper and stacks of absorbent paper towels 
were placed on top of the nylon membrane. The next morning the membrane was 
Antibody Supplier Product1Number Lot Species Dilution
H3K4me3 Millipore 15*10C*E4 NG1715786 Rabbit8monoclonal 1:400
H3K27me3 Millipore 07*449 DAM1641103 Rabbit8polyclonal 1:400
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allowed to air dry and the DNA was crosslinked using a UV Stratalinker 2400 
(Stratagene) and by baking the membrane at 65°C for 2 h.  
2.4.2 Radioactive labeling of DNA probes  
The probe DNA fragments were prepared by Q5 High Fidelity PCR followed 
by gel purification or by plasmid restriction digest followed by PCR purification. The 
probes were labelled with the High Prime DNA labelling kit (Sigma Aldrich). A 
quantity of 25 ng of double stranded probe DNA was made up to 14 µl (final 
volume) with ddH2O. The probe DNA was denatured for 10 min at 99°C and snap 
cooled on ice for 5 min. High Prime was mixed well and 4 µl was added to the 
cooled probe DNA with 2 µl 32P-labeled dCTP, 3000 Ci/mmol, 10 mCi/ml (Perkin-
Elmer). This reaction mixture was incubated at 37°C for 30 min for labelling to 
occur. The labelled probe was purified from unincorporated nucleotides using an 
Illustra G-50 Nick Sephadex column (GE Healthcare) according to manufacturers 
instructions. The purified probe was denatured for 10 min at 99°C and snap cooled 
on ice for 5 min prior to hybridisation.  
 
2.4.3 Southern hybridization 
The hybridisation steps were performed in cylindrical hybridisation bottles 
using rotating hybridisation ovens. The nylon membranes were wetted in 2x SSC and 
prehybridised/blocked for at least 4 h while rotating at 65°C in 20 ml pre-warmed 
hybridisation buffer (500 mM Sodium Phosphate, 7% SDS) and 2 mg Salmon Sperm 
DNA (Sigma Aldrich), which was first denatured for 10 min at 99°C and snap cooled 
on ice for 5 min. The entire volume of the eluted purified labeled probe and 1 mg 
Salmon Sperm DNA were prepared for hybridisation by denaturation at 99°C for 10 
min and snap cooling on ice for 5 min. Following prehybridisation, the buffer was 
removed and 20 ml hybridisation buffer was added to the hybridisation bottles 
followed by the prepared labelled probe and the Salmon Sperm DNA. The 
hybridisation was performed overnight while rotating at 65°C. 
The following day the hybridization buffer was removed and the membranes 
were washed while rotating at 65°C with a range of prewarmed 0.1% SDS buffer 
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containing 6x to 0.1x SSC. The washed membranes were blotted with absorbent 
tissue and sealed tightly with saran wrap to ensure they would not dry out.  
2.4.4 Autoradiography 
The membranes were either exposed to a storage phosphor cassette for at 
least 4 h and visualised on a Typhoon phosphoimager (GE Healthcare) or exposed to 
conventional radiographic film (Kodak) and developed using Kodak processors 
(Xograph). 
 
2.4.5 Southern membrane stripping 
When required, Southern membranes were stripped by washing approximately 
ten times with boiling 0.1% SDS, 0.1x SSC for 3 min. The stripped membranes were 
blotted with absorbent tissue and sealed tightly with saran wrap to ensure they would 
not dry out. The stripped membranes were then exposed to a storage phosphor 
overnight and visualised on a Typhoon phosphoimager (GE Healthcare) the next day 
to ensure the labeled probe had been completely removed before reprobing that day.  
 
2.5 Protein procedures 
2.5.1 Preparation of whole cell protein lysate 
Cells were harvested, counted and pellets were frozen on dry ice and 
transferred to a -80°C freezer for long-term storage. The frozen cell pellets were 
defrosted on ice and resuspended in residual PBS. To lyse the cells, a solution of 2% 
SDS in PBS, pre-heated to 95°C, was added to the cell suspension in a 1:1 ratio and 
mixed. The lysate was incubated at 95°C for 5-10 min. The sample was pipetted well 
and vortexed to ensure homogeneity. The protein concentration was determined 
using a Direct Detect Assay-free Card (Millipore) or a Micro BCA Assay Kit 
(Thermo Scientific) according to manufacturers instructions. Where required, the 
samples were diluted and stored at -80°C for later use. 
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2.5.2 Protein gel electrophoresis  
Reducing sample buffer (0.126 M Tris pH6.8, 5% SDS, 19.7% Glycerol, 
10.2% 2-Mercaptoethanol, 0.02% bromophenol blue) was added in a 1:1 ratio to 
whole cell protein lysates. A precast Novex NuPAGE 4-12% Bis-Tris Gel (Life 
Technologies) was placed in a Mini-Protean Tetra Cell Gel Electrophoresis tank 
(Biorad). The tank was filled with 1x MOPS SDS running buffer (Life 
Technologies). A quantity of 10 μg of sample in 1x Sample Buffer was loaded per 
well alongside 3-7 μl PageRuler Plus Prestained Protein Ladder, 10 to 250 kDa 
(Thermo Scientific).  The gel was run for 40 min at 70 V and 80 min at 120 V.  
 
2.5.3 Western Blotting  
Following completion of protein separation by gel electrophoresis, the 
proteins were transferred from the gel to Immobilon-PVDF Transfer membrane 
(Millipore) in 1x Blot Buffer (25 mM Tris, 0.2 M Glycine, 20% Methanol) using the 
Mini Trans-Blot Electrophoretic Transfer Cell System (Biorad). The samples were 
generally transferred at a constant current of 200 mA for 2 h. The protein membrane 
was generally blocked overnight by incubation in 5% Milk (Oxoid) in freshly 
prepared TBST (0.15 M NaCl, 0.01 M Tris-HCl pH 8.0, 0.1% Tween20) with gentle 
shaking at room temperature.  
 
2.5.4 Chemiluminescence 
The blocked membranes were washed three times for 5 min in TBST with 
gentle shaking. The membrane was then transferred to a 50 ml Falcon tube and 
incubated for 3 h at room temperature on rollers with 5 ml diluted primary antibody 
(see Table 2.3 for details) in 10% synthetic milk (KPL) in TBST. The membrane was 
then washed three times for 5 min in TBST on rollers. The membrane was incubated 
for 30 min at room temperature on rollers with an appropriate diluted (1/2000) 
secondary antibody conjugated to horseradish peroxidase (HRP) (Dako) in 10% 
synthetic milk (KPL) in TBST. The membrane was then washed three times for 5 
min in TBST on rollers. The HRP enzyme activity was detected by incubation of the 
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membrane with Pierce ECL Western Blotting Substrate (Thermo Scientific) followed 
by exposure in a dark room to radiographic films (Kodak) for 10 sec - 5 min. After 
this, the membrane was washed three times for 5 min in TBST on rollers to remove 
the substrate. Each membrane was then incubated for 30 min with the diluted 
(1/50,000) β-Actin primary antibody conjugated to HRP (Sigma) as a loading 
control. The HRP enzyme activity was detected as before.  
Table 2.3 Details of antibodies used in Western blotting protocols. 
 
2.6 Molecular cloning techniques 
2.6.1 Culture and storage of E. coli 
Typically, chemically competent DH5α (prepared in house or Library 
Efficiency DH5α Competent E. coli (Thermo Fisher Scientific)) or were expanded in 
LB medium in liquid or agar cultures at 37°C. DY380 E. coli strains were also used 
for recombineering procedures and were expanded in LB medium in liquid or agar 
cultures at 30-32°C. Antibiotics, IPTG and X-gal was supplemented, as required, at 
the concentrations listed below in Table 2.4. Liquid cultures were initiated from a 
single colony of streaked bacterial agar culture. Liquid cultures were expanded in a 
volume of 3 ml for minipreps and maxi prep starter cultures and 200-250 ml for 
maxiprep cultures. Maxiprep starter cultures were incubated for 4-6 h with vigorous 
shaking (200-220 rpm) and, subsequently, 1 ml of starter culture was used to 
inoculate a full volume of maxi prep culture. Mini- and maxiprep cultures were 
incubated overnight with vigorous shaking (200-220 rpm). For long term storage, 
fresh bacterial pellets were resuspended in 15% glycerol in LB. Aliquots were 
divided between 1.5 ml eppendorfs, snap frozen on dry ice and stored at -80°C.  
  
Antibody Supplier Product1Number Lot Species Dilution
FLAG Sigma F7425 086M4803V Rabbit4polyclonal4 1:1000
HBA Santa4Cruz scB31110 D2710 Goat4polyclonal 1:1000
mCherry Abcam ab183628 GR157435B31 Rabbit4polyclonal4 1:2000
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Table 2.4 Supplements used in the culture of E. coli. 
	  
Concentration	  
Supplement	   Stock	  (mg/ml)	   Working	  (μg/ml)	  
Chloramphenicol	   34	   12.5	  
Gentamycin	   50	   2	  
	   	  
4	  
Ampicilin	   100	   100	  
Tetracyclin	   10	   Liquid:	  4	  
	   	  
Solid:	  5	  
Spectinomycin	   50	   50	  
Kanamycin	   50	   50	  
X-­‐gal	   50	   20	  
	   	   	  IPTG	   100	  mM	   100	  μM	  
 
2.6.2 Transformation of chemically competent bacterial cells  
A quantity of 1-10 ng double stranded plasmid DNA or 50% of ligation 
mixtures were transformed into 20-50 µl DH5α E. coli cells. The cells were defrosted 
from -80°C on ice. The DNA was added and gently mixed with the cells and 
incubated on ice for 15-30 min in a 1.5 ml eppendorf. The transformation of DNA 
into cells was achieved by applying a heat shock of 42°C for 45 sec to the cells in a 
water bath followed by incubation on ice for 2 min. Heat shocked cells were mixed 
with 800 µl SOB medium and incubated for up to 1 h with vigourous shaking. A 
volume of 100 µl of expanded cells were spread onto LB agar supplemented with the 
appropriate antibiotic and incubated overnight at 37°C. 
 
2.6.3 Miniprep BAC purification 
Individual DY380 bacterial colonies were picked using a sterile pipette tip 
and inoculated into a 1 ml LB liquid starter culture, supplemented with the 
appropriate antibiotics. The starter cultures were incubated at 30°C for 4-6 h with 
vigorous shaking (200-220 rpm). A 10ml LB liquid culture, supplemented with the 
appropriate antibiotics, was inoculated with 100 µl of starter culture and incubated at 
30°C overnight with vigorous shaking (200-220 rpm). 
 
Chapter Two: Materials and Methods  63
The next day, bacterial cultures were pelleted at 5,000 rpm for 5 min. The 
pellets were resuspended in 250 µl Buffer P1 (Qiagen) in four 1.5 ml eppendorf 
tubes. Next, 250 µl Lysis Buffer P2 (Qiagen) was added and the samples were mixed 
by inversion four to eight times. Less than 5 min after the addition of lysis buffer, 
250 µl of neutralization buffer N3 (Qiagen) was added and samples were mixed by 
inversion four to eight times. The supernatant was cleared by two rounds of 
centrifugation at 13,200 rpm for 5 min and transfer of supernatant to new eppendorf 
tubes after each round. The DNA was precipitated by mixing the cleared supernatant 
with 750 µl isopropanol followed by incubation on ice for 10 min. The precipitated 
DNA was pelleted by centrifugation at 13,200 rpm for 10 min, washed with 70% 
Ethanol, pelleted again and resuspended in 20 µl TE (10 µM Tris pH 8.0, 1 µM 
EDTA) following airdrying of the pellet for up to 1 h. 
 
2.6.4 Miniprep plasmid purification 
Plasmid DNA was isolated from 3 ml cultures using a GeneJET Plasmid 
Miniprep Kit (Thermo Scientific) according to manufacturers instructions. 
 
2.6.5 Maxiprep plasmid purification  
Plasmid DNA was isolated from 200-250 ml cultures using an EndoFree 
Plasmid Maxiprep Kit (Qiagen) according to manufacturers instructions. 
 
2.6.6 Colony PCR 
Typically, 96 bacteria colonies were picked from an LB agar plate using 
individual sterile pipette tips. Each tip was touched onto the surface of a fresh LB 
agar master plate, supplemented with the appropriate antibiotic, and also dipped into 
a single tube of a 96 well PCR plate containing 50 µl ddH2O. The PCR plate was 
sealed and the cells were lysed by incubation at 95°C for 10 min in a thermocycler. 
A volume of 2 µl of cell lysate was used as a template for screening PCRs. The 
master LB agar plate was incubated overnight at 30°C or 37°C and the plasmid DNA 
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was isolated from PCR positive clones by miniprep plasmid purification from the 
master plate colonies.  
 
2.6.7 Recombineering  
For recombineering experiments, an E. Coli strain (DY380) modified to 
express the recombination proteins Redα, Redβ and Gam from the λ phage in the 
bacterial genome was used. Briefly, a PCR product was generated from a plasmid 
containing the desired antibiotic selection cassette using primers that introduced two 
50 bp homology arms to the DNA sequence of the BAC where the insertion is 
required. The purified PCR product containing the insertion cassette was digested 
with DpnI for 1-4 h at 37°C to degrade any methylated original plasmid template. The 
digested PCR products were run on an agarose gel and the desired fragments were gel 
purified. A volume of 30 µl of fresh liquid culture of DY380 cells containing a BAC 
was added to 1.4 ml LB in 1.5 ml ependorf tubes with pierced lids. The cultures were 
incubated at 32°C with vigourous shaking (1000 rpm) on a Thermomixer C 
(Eppendorf) until the optical density at 600 nm reached ~0.6 (approximately 105 
min). The recombinase genes were induced by immediate incubation at 42°C for 15 
min. The cells were then transferred to the cold room on ice where all the following 
steps were carried out using materials and equipment which had all been pre-cooled 
to 4°C.  
The cells were transferred to new 1.5 ml eppendorfs and pelleted at 13,000 
rpm for 30 sec. The supernatant was discarded and cells were resuspended in 1 ml 
ddH2O. The cells were pelleted, resuspended and pelleted again as before. The final 
cell pellet was resuspended in 20 µl ddH2O and 5 µl of 100 ng/µl DpnI digested and 
the purified PCR product was added and mixed gently with cells. A volume of 25 µl 
of the cells/DNA mixture was transferred to electroporation cuvettes with 0.1 cm 
electrode gap (BioRad). The electroporation was performed using a Micropulsar 
with bacterial settings (BioRad). Immediately following electroporation, the cells 
were collected by washing gently with 1 ml SOC medium (Invitrogen) and 
incubated at 30°C with vigorous shaking (200 rpm) for 1 h. A volume of 100 µl of 
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electroporated cells was then spread onto LB agar plates, supplemented with the 
appropriate antibiotic, and incubated at 30°C for 24-48 h.  
 
2.6.8 Purification of DNA fragments 
DNA fragments were purified following agarose gel electrophoresis by 
visualization of the correct band using a blue light transilluminator and excision of 
the desired fragment using a sterile razor blade. The DNA was purified from the gel 
fragment using a GeneJET Gel Extraction Kit (Thermo Scientific) according to 
manufacturers instructions. DNA amplicons or restriction fragments were typically 
purified from any contaminants using a GeneJET PCR Purification Kit (Thermo 
Scientific) according to manufacturers instructions. Briefly, both of these techniques 
use silica membranes within spin columns to capture the DNA allowing washing 
with 70% ethanol before elution in ddH2O or TE.  
 
2.6.9 Ligation of DNA fragments 
A linearised plasmid vector DNA was dephosphorylated with Calf Intestinal 
alkaline Phosphatase (CIP) or recombinant Shrimp Alkaline Phosphatase (rSAP; 
NEB) at 37°C for 1 h to prevent plasmid religation. Double stranded insert DNA was 
phosphorylated using T4 Polynucleotide Kinase (T4 PNK; NEB) in the presence of 1 
mM ATP for 30 min at 37°C. The vector and insert DNA fragments were purified 
using a PCR cleanup kit (see above). The DNA concentration was determined by 
visual comparison to a standard on an agarose gel. Subsequently, 50-100 ng vector 
DNA was ligated at 16°C overnight with a 3-20x molar excess of insert DNA using 2 
µl 10 mM ATP, 2 µl 10x T4 DNA Ligase Buffer, 2 µl T4 DNA Ligase (NEB) in a 
total volume of 20 µl made up with ddH2O. The next day, 10 µl of the ligation 
reaction was transformed into chemically competent E.coli cells. 
 
2.6.10 CRISPR sg-RNA Cloning 
The CRISPR sgRNA oligos were designed using an online tool, 
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crispr.mit.edu. The single stranded DNA oligos containing the sgRNA sequence 
were synthesised by Eurogentec and cloned into Cas9 plasmids as previously 
described (Ran et al., 2013a). Briefly, sgRNA oligos were phosphorylated with T4 
Polynucleotide Kinase (NEB), annealed in a thermocycler and digested with BbsI 
(NEB). The double stranded digested oligos were then ligated into the plasmid 
pSpCas9(BB)-2A-GFP-(PX458), received as a gift from Dr. P. Hohenstein 
(University of Edinburgh), which was also digested with BbsI. The ligation reactions 
were transformed into chemically competent E.coli and the isolated plasmids were 
screened by Sanger sequencing. 
 
2.6.11 T7 endonuclease I assay 
WTH3 mES cells were transfected by nucleofection with (i) a construct 
containing Cas9 and sgRNA-A and (ii) a vehicle control containing transfection 
reagent and TE. Positively transfected cells from (i) were sorted by FACS 24 h after 
nucleofection. The cells were harvested 48 h after transfection and gDNA was 
isolated from the cells. A primer set was designed to amplify a DNA region of 
approximately 500 bp that was predicted to undergo mutation via CRISPR/Cas9 
activity. A PCR reaction was performed using Phusion High Fidelity Polymerase 
(NEB). The PCR reaction was purified and eluted in 50 µl EB buffer (Qiagen). A 
volume of 18 µl purified PCR product was mixed with 2 µl Buffer 2 (NEB) and 
reannealed using the following cycling parameters in a thermocycler; 95°C 7 min, 
ramp to 85°C at 2°C/sec, 85°C for 30 sec, 12 cycles of (85°C for 30 sec (decrease 
5°C/cycle), ramp to 80°C at 0.3°C/second, 80°C for 30 sec (decrease 5°C/cycle)). 
Next, 10 µl reannealed PCR product was immediately digested with 0.5 µl T7 
Endonuclease I (NEB), 0.5 µl Buffer 2 (NEB) and 4 µl ddH2O at 37°C for 15 min. 
An aliquot of 10 µl of undigested purified PCR product was run on a 3% agarose gel 
stained with 1x GelRed (Biotium) alongside 15 µl of T7 digested purified PCR 
product. The gels were imaged and the relative band intensities were estimated using 
Image J software. The indel frequency was estimated as previously described using 
the formula  
100 x (1-(1-(b+c)/(a+b+c))1/2) 
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where “a” is the integrated intensity of the undigested PCR product and “b” and “c” 
are the integrated intensities of each digested product (Ran et al., 2013b).  
 
2.6.12 Gibson assembly 
A 10µl aliquot of Gibson Assembly master mix (100 mM Tris-HCl, 10 mM 
MgCl2, 0.2 mM each dNTPs, 0.5 U Q5 High Fidelity DNA Polymerase (NEB), 0.16 
U 5’ T5 exonuclease (Epicentre)) was thawed on ice. The DNA plasmid template 
(50-100 ng) was added along with equimolar amounts of the other assembly DNA 
components and the volume was made up to 20 µl with ddH20. The Gibson assembly 
reaction was incubated at 50°C for 1 h and then stored on ice. A volume of 3 µl of 
the reaction mix was transformed into chemically competent DH5α cells as described 
above (Gibson et al., 2009). 
 
2.6.13 Site directed mutagenesis (SDM) 
Site directed mutagenesis primer pairs were designed using previously 
outlined recommendations (Zheng et al., 2004). Briefly, the targeted mutations were 
included in both the forward and reverse primers and were located up to 4 bp away 
from the 5` primer terminus and at least 6-8 bp away from the 3` terminus. At least 8 
non-overlapping bases were included at the 3` end of each primer with at least one G 
or C nucleotide at each terminus. A mutation content of up to 17.5% was included in 
each of the primers.  
A typical 50 µl SDM Q5 PCR reaction contained 10 µl 5x Q5 reaction buffer, 
1 µl dNTPs (Promega; 10 mM), 1 µl each of the forward and reverse primers (10 
mM), 0.5 µl of Q5 High Fidelity DNA Polymerase, 100 ng template DNA with the 
final volume made up to 50 µl with ddH2O. A PCR reaction with 18 amplification 
cycles was performed in a thermocycler. The PCR reactions were purified and 
digested with the restriction enzyme DpnI for 1-2 h at 37°C to degrade any 
methylated original plasmid template. DpnI was deactivated by incubation at 80°C 
for 20 min. The digested PCR products were run on an agarose gel to confirm 
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successful PCR amplification and 1 µl of the digested PCR product was transformed 
into DH5α cells.  
 
2.6.14 Golden gate assembly of TAL plasmids 
The TALEs were designed using the online tool TAL Effector Nucleotide-
Targeter 2.0 (Doyle et al., 2012). The TALE array plasmids were constructed using 
previously described protocols (Cermak et al., 2011). Briefly, a 20 µl reaction was 
prepared with 150 ng each of plasmids containing RVD 1-10 and RVD 11-20 mixed 
with 1 µl of the Type IIS restriction enzyme BsaI (10 U, NEB), 1 µl T4 Ligase 
(2000U, NEB), 1x T4 Ligase Buffer (NEB) and either 150 ng pFusA or pFusB, 
respectively. This reaction was incubated in a thermocycler for 1-10 cycles of 37°C 
for 5 min and 16°C for 10 min followed by 50°C for 5 min and 80°C for 5 min. Next, 
1 µl of 10 mM ATP and 1 µl of Plasmid Safe nuclease (Epicentre) were then added 
and the reaction was incubated in a thermocycler for 37°C for 1 h. A volume of 10 µl 
of this reaction mixture was transformed into DH5α cells and the transformed cells 
were plated on LB agar plates prepared with 0.1 mM IPTG, 20 µg/ml X-gal and 50 
µg/µl Spectinomycin. The plates were incubated at 37°C overnight (and sometimes 
for another 24 h at 4°C to intensify the X-gal staining) and approximately 10 white 
colonies were picked and screened by restriction digestion and Sanger sequencing.  
A modified version of pTAL-2 (Cermak et al., 2011), hereafter referred to as 
the TALE-Fusion-Expression vector (pTFE) was generated by molecular cloning 
techniques. Following screening, the TALE array plasmids, the appropriate Last 
Repeat Variable Domain plasmid (Cermak et al., 2011), pTFE and the kanamycin 
resistant subcloning plasmids were digested overnight with an excess of Fast Digest 
BsmBI (Thermo Scientific) in 1x T4 Ligase Buffer (NEB). The complete digestion 
was confirmed by visualising an aliquot of the digested product on an agarose gel. 
Next, 25 ng of digested pTFE and equimolar amounts of all the other plasmids 
containing the inserts required in the final construct were mixed with 1 µl of T4 
Ligase (2000 U, NEB) and 1x T4 Ligase Buffer (NEB) in a final volume of 20 µl. 
The ligation reaction was incubated at 16°C overnight and 10 µl of this reaction was 
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transformed into DH5α cells. The transformed cells were plated on LB agar plates 
prepared with 0.1 mM IPTG, 20 ng/ml X-gal and 100 µg/µl ampicilin. The plates 
were incubated at 37°C overnight (and sometimes for another 24 h at 4°C to intensify 
X-gal staining) and white colonies were picked and screened by PCR, restriction 
digestion and Sanger sequencing.  
 
2.7 Mammalian cell culture 
2.7.1 MES cell culture conditions 
Unless otherwise described, mES cells were cultured in Glasgow MEM 
(BHK-21; Life Technologies) supplemented with 10% batch tested Foetal Calf 
Serum (FCS; Globalfarm; batch tested for culture with mES cells), 2 mM L-
Glutamine (Life Technologies), 0.1 mM MEM non-essential aminoacids (Life 
Technologies), 1 mM Sodium Pyruvate (Life Technologies), 0.1 mM 2-
Mercaptoethanol (Life Technologies) and typically 0.2% Leukemia Inhibitory Factor 
(LIF) prepared by Shahida Sheraz (University of Edinburgh). At times, complete 
mES cell culture media was supplemented with 100 U/ml penicillin-streptomycin 
(Life Technologies). Tissue culture treated plates (Corning) were prepared for mES 
cell culture by coating with sterile 0.1% gelatin (Sigma) in ddH20 and incubation at 
37°C for at least 15 min. Gelatin was aspirated off before the addition of cells/culture 
media.  
The mES cells were typically split 1:5 every 48 h and incubated at 37°C, 5% 
CO2 in humid conditions. Briefly, cell monolayers were washed twice with sterile 1x 
PBS (Oxoid) and then incubated for 3 min at 37°C with TrypLE Express (Life 
Technologies). The enzymatic reaction was quenched by the addition of cell culture 
media containing 10% FCS. The cells were harvested and centrifuged at 1000 rcf for 
3 min. The cell pellet was resuspended with 1 ml fresh media with pipetting at high 
velocity to make a single cell suspension. The cells were diluted to the desired 
concentration and transferred to gelatinised plates (Corning).  
For long-term storage, the fresh mES cell pellets were resuspended in 10% 
DMSO (Sigma) in FCS and aliquoted into Nunc cryotubes (Thermo Scientific). 
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These were placed in polystyrene boxes in a -80°C freezer for at least 24 h. The 
frozen cells were transferred to a -150°C.  
 
2.7.2 Plat-E cell culture conditions 
Platinum-E (Plat-E) cells, a modified Human Embryonic Kidney 293T 
(HEK293T) cell line (Morita et al., 2000), were received as a gift from Dr. P 
Hohenstein (University of Edinburgh). Plat-E cells were cultured in Dulbecco’s 
MEM (Life Technologies) supplemented with 10% FCS (Life Technologies), 2 mM 
L-Glutamine (Life Technologies), 10 µg/ml Blasticidin (InvivoGen) and 1 µg/ml 
puromycin (Sigma).  
Plat-E cells were typically split 1:10 every 72 h and incubated at 37°C, 5% 
CO2 in humid conditions. Briefly, cell monolayers were washed twice with sterile 
PBS and then incubated for 3 min at 37°C with Trypsin (Life Technologies). The 
enzymatic reaction was quenched by the addition of cell culture media containing 
10% FCS. The cells were harvested and centrifuged at 1000 rcf for 5 min. The cell 
pellet was resuspended with 1 ml of fresh media with pipetting at high velocity to 
make a single cell suspension. The cells were diluted to the desired concentration and 
transferred to new tissue culture plates. 
For long-term storage, fresh Plat-E pellets were resuspended in 10% DMSO 
(Sigma) in FCS and aliquoted into Nunc cryotubes (Thermo Scientific). These were 
placed in polystyrene boxes in a -80°C freezer. These cells were transferred to a -
150°C after at least 24 h. 
 
2.7.3 Counting cells using a haemocytometer  
Cell numbers were estimated by counting with a glass haemocytometer and 
coverslip. Briefly, the cells were mixed to ensure a homogenous distribution and then 
serially diluted where required to an appropriate factor such that ~10-100 cells were 
visible when loaded in each set of 16 corner squares on the haemocytometer. A 
volume of 10 µl of diluted cells were mixed 1:1 with Trypan Blue Solution, 0.4% 
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(Gibco) and 10 µl of this mix was loaded on the haemocytometer. The cells were 
viewed on a microscope under a 10x objective lens. The live, unstained cells were 
counted in each of the four sets of 16 corner squares on the haemocytometer grid. 
The estimated number of viable cells/ml was calculated using the following formula; 
(average viable cell count in 16 corner squares) x 10,000.  
 
2.7.4 Mammalian cell transfection procedures 
2.7.4.1 MES cell nucleofection 
The mES cells were split 24 h before nucleofection. On the day of 
nucleofection, Nucleofector solution (NS) was freshly prepared by adding P2 
Supplement (Lonza) to the Nucleofector Solution (Lonza) in a 1:4.5 ratio. A quantity 
of 3 µg DNA was added to NS to a final volume of 30 µl. The mES cells were 
harvested and counted and 2 x 106 cells were washed once in PBS and the resulting 
pellet was resuspended in 70 µl NS. This cell suspension was added to the DNA/NS 
solution and mixed with pipetting. A volume of 100 µl was transferred to an amaxa 
certified cuvette (Lonza). The cuvette was closed and the cells were transfected using 
the programme A-023 on a Nucleofector (Lonza) machine, which is optimized for 
use with E14 cells. A volume of 500 µl of prewarmed media was immediately added 
to the cuvette and the cells were plated in a gelatinised T25 flask.  
 
2.7.4.2 MES cell electroporation 
The mES cells were split 24 h before electroporation. On the day of 
electroporation, the mES cells were harvested and counted and 1 x 107 cells were 
washed once in PBS and the resulting pellet was resuspended in 400 µl PBS. A 
quantity of 100 µg of plasmid DNA at a concentration of 10 µg/µl was added to the 
cells and mixed with pipetting and 500 µl of the mixture was transferred to a pre-
cooled electroporation cuvette with a 0.4 cm electrode gap (Biorad). The cuvette was 
closed and cells were electroporated (3 µF, 0.8 kV) using an electroporator optimized 
for E14 cells (Biorad). The electroporated cells were incubated for 15 min on ice and 
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were plated in a gelatinised T75 flask.  
2.7.4.3 MES cell lipofection  
The mES cells were split 24 h before lipofection. On the day of lipofection, 4 
µg sterile plasmid DNA was diluted with Optimem (Life Technologies) to a total of 
200µl. In a separate tube, 9 µl Lipofectamine 2000 (Life Technologies) was mixed 
with 191 µl Optimem (Life Technologies). Both of these tubes were vortexed and 
incubated at room temperature for 10 min. The contents from both tubes were mixed 
thoroughly together, vortexed and incubated at room temperature for at least 30 min. 
Meanwhile, 8 x 105 cells were washed three times in PBS and plated in 2 ml 
complete mES cell media without penicillin-streptomycin in a gelatinised well of a 6 
well cluster plate. A volume of 400 µl of the DNA:Lipofectamine mixture was added 
to this well and the contents were mixed with gentle shaking. The cells were 
incubated for 4-6 h and the media was replaced with fresh complete mES cell media 
containing penicillin-streptomycin where required.  
 
2.7.4.4 Plat-E cell transfection 
Plat-E cells were split 24 h before transfection and plated at a density of 5 x 
105 cells per well in a 6 well plate in 3 ml complete medium. A quantity of 3.3 µg of 
plasmid DNA was diluted with Optimem (Life Technologies) to a total of 155 µl. A 
volume of 9.9 µl of FuGENE HD reagent (Promega Corporation) was added directly 
to the diluted plasmid DNA and mixed by vortexing briefly. The solution was 
incubated at room temperature for 10 min. Meanwhile, the Plat-E cells were washed 
gently with sterile PBS and 3 ml of fresh complete media was added to each well. 
The 150 µl of DNA/FuGENE HD complex was gently added to each well. The tissue 
culture plates were rocked gently before placing in the incubator overnight. The 
media was replaced with fresh media 24 h after transfection.  
 
2.7.5 MES cell targeting: picking clones 
The WTH3 mES cells were transfected with equal quantities of a HDR 
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targeting vector and a vector containing sgRNA-A and Cas9 using one of the 
methods described above. Two-three days following transfection, the cells were 
harvested and typically 1 x 106 cells were plated per gelatinised 10 cm tissue culture 
treated dish in complete mES cell media supplemented with 1 µg/ml puromycin 
dihydrochloride (Sigma). The selection was maintained until colonies were picked 
seven to ten days later.  
The media was aspirated from the dish and cells were washed twice with 
PBS. A volume of 10 ml PBS was added to the dish to hydrate the cells during 
picking. Individual mES cell colonies were picked with a sterile fine tip Pasteur 
pipette and transferred into a single well of a 96 “V” well plate (Costar) containing 
30 µl of TrypL-E (Life Technologies). Once a full plate was picked, the cells were 
incubated at 37°C for 5 min. A volume of 70 µl complete mES cell media was added 
to each well using a multi-channel pipette and the total amount was transferred to a 
gelatinised 96 well tissue culture plate containing 100 µl media per well. The next 
day, the media was aspirated off and a fresh 200 µl of media was added. When the 
majority of wells in a plate were 70-80% confluent, the plate was split 1:1 into two 
new 96 well plates. Once these new plates were 70-80% confluent, one was used for 
PCR screening and the other was either split again or frozen down in 10% 
DMSO/FCS.  
 
2.7.6 MES cell karyotyping  
The mES cells were split such that they would be 70-80% confluent in one 
well of a 6 well cluster plate after 24 h. The media was aspirated off the cells and 
Colcemid (Life Technologies) was added 1:100 in fresh media to stop cells at the 
metaphase stage and the cells were incubated at 37°C for 2 h. The cells were 
harvested and pelleted. The cell pellet was resuspended in 5 ml 0.56% KCl (Fisher 
Chemical) pre-warmed to 37°C and incubated in KCl for 12 min at room 
temperature. A volume of 100 µl of fresh fixative (3:1 methanol: acetic acid) pre-
cooled to -20°C was added dropwise with constant agitation to prevent cell 
clumping. The cells were pelleted by centrifugation at 1000 rcf for 3 min and 
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supernatant was removed. The cell pellet was resuspended in the residual buffer and 
1 ml of fixative was added dropwise with constant agitation. The cells were 
incubated on ice for 30 min, pelleted and resuspended in 1 ml of fixative as before. 
An aliquot of 10-12 µl of fixed cells was dropped onto uncoated glass slides (VWR) 
from a height and left to dry. The metaphase spreads were stained for 15 min with 
1:44 Giemsa Stain (Gibco) in water and then washed three times for 5 min in water. 
Once the slides were dried they were mounted with glass coverslips (Academy) 
using Pertex Mounting medium (Cell Path Ltd.) and left to dry overnight. The 
numbers of chromosomes per cell were counted from 10-50 metaphase spreads per 
cell clone using a high-powered 60x microscope (Leica DMRB fluorescent upright 
microscope with Hamamatsu digital camera). 
 
2.8 In-vitro differentiation of mES cells 
2.8.1 EB formation for random differentiation 
The mES cells were split such that they would be 70-80% confluent after 24 
h. The cells were harvested, counted and 1 x 107 single cells were plated (Day 0) in 
non-gelatinised bacterial grade sterile petri dishes (Thermo Scientific) in 10 ml of 
complete mES cell culture media without LIF (-LIF media) to promote spontaneous 
differentiation. After 48 h (Day 2) the cells were gently collected in a 50 ml falcon 
tube and allowed to settle in a tissue culture incubator for 10-15 min. The supernatant 
was removed and cells were gently resuspended in 10 ml fresh -LIF media and plated 
on fresh non-gelatinised bacterial grade sterile petri dishes. The media was changed 
again on Day 4 and 6. On Day 8, approximately twenty embryoid bodies (EBs) were 
carefully collected using a P1000 pipette and transferred to a gelatinised well in a 6 
well cluster plate in fresh –LIF media. After two-seven days, the differentiated cells 
were imaged and EB beating was observed. The media was removed and the cells 
were washed gently with PBS. The cells were incubated with 1 ml of modified 
Leishman Eosin methylene blue solution (Merck) for 5 min. A volume of 1 ml ddH20 
was added and the solution was incubated for an additional 5 min, removed and left 
to dry overnight before imaging.  
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2.8.2 Suspension method 
The mES cells were defrosted on Day -6 in complete mES cell media. The 
cells were split as usual on Day -4 in complete mES cell media. On Day -2, fresh 
Iscove’s Modified Dulbecco’s Medium (IMDM) was prepared by supplementing 
Glasgow MEM (BHK-21; Life Technologies) with 1.5 x 10-4 M Monothioglycerol 
(Sigma), 10% heat inactivated FCS (Globalfarm; batch tested for use with mES cells; 
the defrosted FCS was incubated in a 56°C water bath for 60 min with shaking every 
10 min), 0.2% LIF, 100 U/ml penicillin-streptomycin (Life Technologies) and 2 mM 
L-Glutamine (Life Technologies). The mES cells were harvested and counted and 3 
x 105 cells were aliquoted into one well of a 6 well cluster plate in IMDM on Day -2. 
Unless otherwise stated, EB-Differentiation (EB-Diff) media was prepared on Day 0 
by supplementing Glasgow MEM (BHK-21; Life Technologies) with 3 x 10-4 M 
Monothioglycerol (Sigma), 10% heat inactivated FCS (Globalfarm; batch tested for 
use with mES cells; defrosted FCS was heat inactivated by incubation in a 56°C 
water bath for 60 min with shaking every 10 min unless otherwise stated), 2 mM L-
Glutamine (Life Technologies), 50 µg/ml Ascorbic Acid (Sigma), 0.3 mg/ml 
Transferrin from human serum (Roche), 20x PHFMII (Life Technology), 100 U/ml 
penicillin-streptomycin (Life Technologies). On Day 0 the cells were harvested, 
counted and 4 x 104 cells in a singe cell suspension were plated on non-gelatinised 10 
cm bacterial grade plates with 10 ml EB-Diff medium. The cells were incubated for 
7-8 days before harvesting (see section 2.8.6, pp. 77) and imaging.  
 
2.8.3 Hanging drop method 
The mES cells at standardized passage number were defrosted on Day -6 in 
complete mES cell media. The cells were split as usual on Day -4 in complete mES 
cell media. On Day -2, fresh IMDM was prepared as above. The cells were counted 
and 6 x 105 cells were resuspended in 20 ml IMDM on Day -2. Using a multi-
channel pipette, 10 µl droplets (300 cells per droplet) were pipetted onto the upturned 
lid of a 120 mm sterile square petri dish (Greiner). PBS (10 ml) was added to the 
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bottom of the petri dish so that the cells would remain hydrated. The lid was turned 
over and replaced back on top of the dish and placed in the incubator for 48 h.  
The EB droplets were collected on Day 0 and transferred to a 50 ml falcon 
tube. The EBs were centrifuged at 800 rpm (80 g) for 3 min. The supernatant was 
discarded and the EB pellet was gently resuspended in 20 ml EB-Diff Media and 
transferred to an ungelatinised 10 cm bacterial grade plate. On Day 1, 20 ml EBs 
were gently collected from the plate and split evenly between two gelatinised T75 
tissue culture flasks. Fresh EB-Diff Media (30 ml) was added to each flask. On Day 
7/8 cells were imaged and harvested. 
 
2.8.4 Supplemented EB-Differentiation media 
The EB-Differentiation media was supplemented when described with 1 U/ml 
recombinant human erythropoietin (R&D Systems) prepared in 0.1% tissue culture 
grade BSA (Sigma) in PBS, 50 ng/ml recombinant human Stem Cell Factor 
(PeproTech) prepared in 0.1% tissue culture grade BSA (Sigma) in PBS or 1 µM 
Dexamethasone (Sigma) prepared in 0.1% tissue culture grade BSA (Sigma) in PBS.  
 
2.8.5 Combined method 
The mES cells at a standardized passage number were defrosted on Day -6 in 
complete mES cell media. The cells were split as usual on Day -4 in complete mES 
cell media. On Day -2, fresh IMDM was prepared as described above. The cells were 
counted and 3 x 105 cells were split into one well of a 6 well cluster plate in IMDM 
on Day -2. On Day 0, 6 x 105 cells were resuspended in 20 ml EB-Diff Media. Using 
a multi-channel pipette, 10 µl droplets (300 cells per droplet) were pipetted onto the 
upturned lid of a 120 mm sterile square petri dish (Greiner). PBS (10ml) was added 
to the bottom of the petri dish so that the cells would remain hydrated. The lid was 
turned over and replaced back on top of the dish and placed in the incubator for 48 h.  
EB droplets were collected on Day 2 and transferred to a 50 ml falcon tube. The EBs 
were centrifuged at 800 rpm (80 g) for 3 min. The supernatant was discarded and the 
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EB pellet was gently resuspended in EB-Diff Media and 200 EBs per plate were 
transferred to an ungelatinised 10 cm bacterial grade plate in 10 ml EB-Diff Media. 
The EBs were imaged and harvested on Day 7/8.  
2.8.6 Harvesting erythroid cells from suspended EBs 
On Day 7/8 of differentiation in the suspension or combined method, red blood 
islands were visible within large EBs. The EBs were collected in a 15 ml falcon tube 
and centrifuged at 1000 rcf for 3 min. The supernatant was discarded and the 
resulting pellet was washed twice in PBS. The supernatant was discarded and the 
pellet was resuspended in 3 ml Trypl-E (Life Technology). The cells were incubated 
for 3 min with regular agitation in a 37°C water bath. A volume of 7 ml of 10% heat 
inactivated FCS in PBS was added to quench the Trypl-E. The cells were passed 
through a 21G x1½” syringe three times to complete the EB disaggregation. The 
cells were counted and aliquoted appropriately for downstream purposes.  
 
2.9 Flow cytometry 
2.9.1 Fluorescent activated cell sorting (FACS) 
The cells were prepared for FACS by harvesting and resuspending in 1 ml 
FACS Media (10% FCS in PBS). The cells were passed through a cell strainer 
(Falcon) to prevent clogging in the machine. The cells were kept on ice until they 
were sorted by Bob Fleming or Graeme Roberston (University of Edinburgh) on a 
FACS Aria IIIu 4-laser/11 detector Cell Sorter (BD Biosciences) and directly pooled 
into 15 ml tubes containing normal mES cell media. The sorted cells were then 
plated under normal cell culture conditions.  
 
2.9.2 Ter119 antibody staining and flow cytometry  
The cells were harvested and 1 x 105 cells, washed twice in PBS, were 
aliquoted in 1.5 ml eppendorf tubes. If a dead cell stain was being used, Zombie 
Yellow (BioLegend) was diluted in PBS 1:500 and 1 x 105 cells were resuspended in 
100 µl of this working solution and incubated for 15-20 min on ice, protected from 
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light. A quantity of 0.5 µg Ter119-FITC Rat-anti-mouse antibody stain (BD 
Pharmingen) was directly added to the cells following this incubation. If a dead cell 
stain was not being used, 1 x 105 cells were resuspended in 100 µl of PBS and 1 µl 
Ter119 antibody stain was directly added to this cell suspension. The antibody stain 
was incubated for 40-60 min on ice, protected from light. The cells were washed 
twice in PBS and resuspended in 500 µl FACS media. The cells were kept on ice 
until they were analysed using a LSR Fortessa (BD Biosciences).  
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Chapter 3 Validation of mES Cell Lines and 
Optimisation of In Vitro Differentiation 
3.1 Introduction 
The isolation of mouse embryonic stem cells (mES cells) from the inner cell 
mass of blastocysts and development of cell culture protocols to maintain them in 
vitro was a significant advancement in the study of developmental genetics (Evans 
and Kaufman, 1981; Martin, 1981). In 2007, a Nobel prize for Physiology or 
Medicine was awarded to the principle investigator that led this research, along with 
researchers that completed the first site directed gene targeting of mES cells 
(Doetschman et al., 1987; Thomas and Capecchi, 1987). It had also been 
demonstrated that mES cells could be injected into developing blastocysts and 
transplanted into the uterine horn of pseudopregnant mice to produce chimeras that 
could be bred to homogeneity (Gossler et al., 1986). The combination of these 
findings paved the way for the generation of genome edited mouse models. 
This study aimed to use gene editing techniques to knock-in a 2A-mCherry 
cassette in two previously engineered E14TG2a mES cell lines humanised at the α-
globin locus, with a wild type sequence (Wild Type Humanised; WTH) or a deleted 
enhancer (ΔHS-40) (Wallace et al., 2007). The engineering of these two lines was 
described in Chapter 1 (pp. 28). The mES cell lines carrying the 2A-mCherry 
cassette within the α-globin locus would allow the monitoring of α-globin expression 
in erythroid cells with these two genotypes. Primary erythroid cells could be isolated 
from the generation of mouse lines by blastocyst injection. Erythropoiesis could also 
be studied in vitro through the in vitro differentiation of the mES cell lines.   
A euploid karyotype is important for mES cell differentiation and mouse 
generation. Indeed, mES cell lines with a higher percentage of euploid cells (40 
chromosomes in diploid mES cells) are better able to generate chimeras and 
contribute to germline transmission than lines with a high percentage of cells of 
abnormal karyotype (Longo et al., 1997; Suzuki et al., 1997). A study of 540 mES 
cell lines from 20 different research institutes in Japan showed that 33.5% of these 
lines had abnormal karyotypes (Sugawara et al., 2006). The proportion of aneuploid 
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cells also increases with the number of passages (Gaztelumendi and Nogués, 2014; 
Longo et al., 1997). This has significant implications when a number of different 
gene targeting steps are required to generate new cell lines, as the cells must be kept 
in culture for several passages. A trisomy of chromosome 8 is the most commonly 
observed karyotype abnormality, and has been shown to confer a growth advantage 
to cells harbouring this karyotype (Gaztelumendi and Nogués, 2014; Kim et al., 
2013; Sugawara et al., 2006).  
More recently, mice have also been generated from haploid mES cells (Leeb et 
al., 2012; Zhong et al., 2015). Genetic engineering using haploid mES cells can 
improve the efficiency of ‘clean’ targeting as only one copy of each chromosome 
must be targeted and there is no possibility of generating mutations in the second 
chromosome copy. As only one copy of the mouse α-globin locus is humanised in 
the cell lines used in this study, these targeting experiments enjoy the same 
advantage as targeting a single locus in haploid cells.  
ES cells can be differentiated in vitro towards a number of different lineages. 
Once leukaemia inhibitory factor (LIF) has been removed from ES cell media, the 
cells can be induced to form embryoid bodies (EBs). EBs can be formed in a number 
of different ways including the culture of cells in suspension, in hanging drops and in 
semisolid media, as reviewed in Kurosawa (2007). Correctly formed EBs consist of 
spontaneously differentiated cells mimicking the endoderm, ectoderm and mesoderm 
germ layers (Kurosawa, 2007). Furthermore, EBs can be directed towards a specific 
developmental pathway through the use of particular media additives. In vitro 
differentiation of mES cells has long been used to study the process of 
erythropoiesis. The sequential appearance of primitive followed by definitive 
erythrocytes during in vitro differentiation closely mimics the erythropoiesis 
pathways observed in the developing embryo (Keller et al., 1993; Ma et al., 2008; 
Weiss and Orkin, 1996). Several reports highlight the importance of particular 
cytokines, including Stem Cell Factor (SCF) and Erythropoietin (Epo), and nuclear 
hormone receptors, including the Dexamethasone (Dex) responsive receptor, in the 
in vitro expansion of human erythroid progenitors and in the in vitro differentiation 
of mES cells towards the erythroid lineage (Carotta et al., 2004; Panzenbock et al., 
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1998). EBs can also readily differentiate into other tissue types. For example, 
spontaneous EB contraction or “beating” and molecular characterisation indicates the 
formation of cardiomyocytes (Boheler et al., 2002). Also, small vascular-like 
channels through which red blood cells can travel can form in EBs (Wang et al., 
1992).  
More recently it has been shown that haematopoiesis can also be induced in 
human induced pluripotent stem cells (iPS cells) by the same in vitro differentiation 
methods used on human ES cells (hES cells; reviewed in Lim et al. 2013). Extensive 
sequential cocktails of recombinant cytokines and small molecules have also been 
used to produce high numbers of embryonic erythroid cells in serum and feeder-cell 
free systems, however the ability of these cells to achieve enucleation is severely 
limited (Olivier et al., 2006). The latest methods in expansion of human erythroid 
cells in vitro can produce high, scalable numbers of erythroid cells in which up to 
30% of the population becomes enucleated, a marker of fully mature reticulocytes 
(Trakarnsanga et al., 2017). The development of such methods has important clinical 
implications for the possible in vitro production of functional red blood cells for use 
in transfusions (Giarratana et al., 2011; Migliaccio et al., 2012).  
In this chapter, the karyotype of the WTH and ΔHS-40 mES cell lines was 
characterised and euploid subclones of these two lines were isolated. A robust and 
reproducible in vitro differentiation method for generating erythroid cells was 
optimised using the WTH3 subcloned cell line. The suitability of the humanised 
WTH3 subcloned cell line as a model for gene targeting and the study of human α-
globin expression in vitro was confirmed.  
 
3.2 Results  
3.2.1 Karyotyping and subcloning of humanised mES cell 
lines 
The WTH and ΔHS-40 humanised mES cells were received as a gift from Dr. 
Andrew Smith (University of Edinburgh). These cell lines were expanded and their 
karyotype was determined by counting the number of chromosomes in 
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approximately 25 metaphase spreads per clone (Figure 3.1A). A karyotype of 40 
chromosomes for at least 70% of cells is optimal for mouse diploid ES cells to be 
used in gene targeting and blastocyst microinjection. The WTH clone was 
determined to have a karyotype of 40 chromosomes in approximately 50% of cells 
with approximately 20% of cells showing a karyotype of 41 chromosomes (Figure 
3.1B). The ΔHS-40 clone was determined to have a karyotype of 40 chromosomes in 
nearly 30% of cells with nearly 50% of cells showing a karyotype of 41 
chromosomes (Figure 3.1B).  
To obtain cell lines with improved karyotypes (i.e. a higher proportion of 
cells with 40 chromosomes), the WTH and ΔHS-40 cell lines were subcloned. 
Briefly, cells from both lines were plated at low density (50-100 cells/plate) in 10 cm 
diameter tissue culture plates. The cells were left to expand for approximately 8 days 
and 50 ES cell colonies were picked from each line and expanded. Karyotyping 
assays were performed on 10 WTH subclones (WTH1-10; Figure 3.2A) and 20 ΔHS-
40 subclones (ΔHS-40_1-20; Figure 3.2B). In the subclone WTH3, approximately 
80% cells had a karyotype of 40 chromosomes. Nearly 60% of cells in the subclone 
ΔHS-40_20 showed a karyotype of 40 chromosomes with only 10% of cells in this 
clone showing a karyotype of 41 chromosomes.  
In order to validate the ability of the mES cell subclones WTH3 and ΔHS-
40_20 to randomly differentiate, an EB formation and random differentiation assay 
was performed on these clones. After plating of EBs, the differentiated cells were 
observed growing out from the larger EB mass in both cell lines (Figure 3.2C and D). 
The morphology of these differentiated cells is markedly different from that of 
undifferentiated mES cells (Figure 3.3i and ii). Beating EBs were also observed for 
both cell lines indicating cardiac muscle formation.  
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Figure 3.1 Karyotyping of WTH and ΔHS-40 mES cell lines. 
A. Two examples of Giemsa stained metaphase spreads that were counted for 
karyotyping are shown. Images were taken using a Leica DMRB fluorescent upright 
microscope and Hamamatsu digital camera at 63x magnification. 
B. Karyotyping results of WTH and ΔHS-40 mES cells from approximately 25 
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Figure 3.2 Karyotyping of WTH and ΔHS-40 mES cell subclones and EB 
differentiation assay. 
(A-B) Karyotyping results for subclones WTH1-10 and ΔHS-40_1-20 from 
approximately 25 metaphase spreads per clone. Subclone WTH3 and ΔHS-40_20 
were determined to show the best karyotype of >80% and >50% of cells carrying 40 
chromosomes, respectively, and were used in subsequent experiments.  
(C-D) Example of Leishman’s staining of WTH3 and ΔHS-40_20 cells following EB 
formation differentiation assay show random differentiation of mES cells into a 
variety of cell lineages. These images were taken with a Zeiss axiovert 25s inverted 
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3.2.2 Optimising in vitro differentiation protocols 
3.2.2.1 Suspension method of in vitro differentiation 
The analysis of erythroid cells derived from in vitro differentiation of mES 
cells formed an important aim of this thesis project. To this end, it was important to 
first develop robust and reliable in vitro differentiation protocols that would 
consistently yield high numbers of erythroid cells. The first in vitro differentiation 
protocol tested, here termed the ‘suspension method’, was adapted by the D. Higgs 
lab (WIMM, University of Oxford) from a previously published protocol (Ma et al., 
2008). Briefly, mES cells were defrosted on Day –6, split at least once (Figure 3.3i), 
cultured for one passage in IMDM-ES media (Figure 3.3ii) and then plated in a 
single cell suspension in EB differentiation media in un-gelatinised plates and 
allowed to form EBs for approximately 7 days (Figure 3.3iii) before harvesting for 
downstream analysis.  
The suspension method of in vitro differentiation was used on WTH3 cells, 
and various other clones, in 7 independent biological replicates (data not shown). 
Using this method, it was possible to recover EBs with visible red blood islands on 
occasion (Figure 3.3iii). However, the cell numbers recovered and number of EBs 
containing visible red blood islands was extremely variable between mES cell clones 
(Table 3.1). In most replicates, either very low cell numbers (≤ 105 cells/dish) or no 
cells were recovered at the harvesting step (4/7 replicates), with high variability in 
the appearance of red blood islands (Table 3.1).  
A number of media additives are available to augment in vitro differentiation 
of hES cells. With the expectation that such additives might also augment in vitro 
differentiation of mES cells, erythropoietin (Epo) only and Epo in combination with 
either dexamethasone (Dex) or stem cell factor (SCF) was added to EB 
differentiation media and tested using the suspension method. These media 
supplements were tested in combination with EB differentiation media using normal 
foetal calf serum or serum that had been heat inactivated. Although red blood islands 
were recovered from all these conditions (Figure 3.4i-iv), there was no obvious 
difference in the intensity of the red blood islands observed in the harvested cell 
pellet between the different conditions (Figure 3.4C). However, the numbers of cells  
 





Figure 3.3 Schematic of in vitro differentiation using the suspension method.  
(i) An example of WTH3 mES cells at day -2 before harvesting and plating in ES-
IMDM media. The image was taken at 10x magnification. 
(ii) An example of WTH3 mES cells at day 0 before harvesting and resuspension in 
EB-differentiation medium. The image was taken at 20x magnification 
(iii) An example of two WTH3 EBs at day 7 containing red blood islands fused 
together. The image was taken at 10x magnification. 
All images were taken at using a Zeiss axiovert 25s inverted microscope. 
 
recovered at the harvesting step from treatments with heat-inactivated serum were 
consistently much higher than treatments with normal serum (Table 3.2).  
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Table 3.1 Cell numbers and blood island scoring of mES cell clones.  
Results from mES cell clones including WTH3, ΔHS-40_20 and 6 other clones 
generated from gene targeting experiments in Chapter 5 are shown. Cell numbers 
harvested from one single 10 cm dish of cells differentiated in vitro with the 
suspension method are shown. A scoring legend indicating the number of EBs that 
contained visible red blood islands per dish is also shown. 
Red Blood Island Scoring Legend 
- No red blood islands observed 
+/- ≤5 red blood islands observed 
+ 6-10 red blood islands observed 
++ >10 red blood islands observed 
 
Table 3.2 Cell numbers recovered from a 10 cm plate following in vitro 
differentiation of WTH3 mES cells using the suspension method with media 
additives. A greater number of cells were recovered at the harvesting step from in 






Clone& Passage&number&at&Day&26& Cell&count&x&105& Blood&islands&
WTH3& 13# 1# $#
ΔHS240_20&& 6# 60# ++#
A5& 19# 4# $#
B1& 19# 4# +/$#
EA1& 9# 4# +#
EB7& 9# 9# +#
EB12& 9# 12# ++#
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Figure 3.4 In vitro differentiation of WTH3 mES cells using the suspension 
method with media variants.  
(A) Normal vs (B) heat inactivated serum was used in combination with (i) original 
media and media with additives (ii) Erythropoietin, (iii) Erythropoietin + 
Dexamethasone and (iv) Erythropoietin + Stem Cell Factor. These images were 
taken with a Zeiss axiovert 25s inverted microscope at the magnification indicated in 
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3.2.2.2 Hanging drop method of in vitro differentiation 
Due to a lack of reproducibility using the suspension method for in vitro 
differentiation, a new protocol was tested, termed the “hanging drop method”. This 
protocol was developed through discussion with the L. Forrester lab (CRM, The 
University of Edinburgh). This method differed from the suspension method in that 
EBs were formed on Day -2 from a cell suspension in hanging drops of IMDM-ES 
media. Each EB was formed from 300 single cells in 10-20 µl media suspended in a 
droplet hanging from the lid of a sterile petri dish. These EBs were harvested and 
cultured in suspension in EB-Differentiation media for 24 hours before transfer to 
gelatinised tissue culture plates in which they were allowed to adhere to the plate 
surface before harvesting after approximately 7 days (Figure 3.5). The hanging drop 
method was tested using normal EB-Differentiation media and supplemented media, 
using both normal and heat inactivated foetal calf serum. Although the hanging drop 
method produced EBs of a consistent and reproducible size and shape (Figure 3.6, 
Day 0), none of the treatments tested were sufficient to yield any visible red blood 
cells (Figure 3.6i-iv). 
 
Figure 3.4 Figure legend continued:  
Images of eppendorf tubes containing harvested cell pellets are shown in (C). The 
heat inactivated serum appears to give a more vibrant red cell pellet but the media 
additives do not appear to improve red blood island formation beyond the red cell 
intensity observed in the cell pellet from heat inactivated serum in combination with 
(i) the original method.  
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Figure 3.5 Schematic comparing in vitro differentiation using the suspension vs. 
the hanging drop method.  
The suspension method (green) differs from the hanging drop method (red) in the 
way EBs are formed (day 0 in suspension method vs. day -2 in hanging drop method) 










































Figure 3.6 In vitro differentiation of WTH3 mES cells using the hanging drop 
method with media variants.  
(A) Normal vs. (B) heat inactivated serum was used in combination with (i) original 
media and media with additives (ii) Erythropoietin, (iii) Erythropoietin + 
Dexamethasone and (iv) Erythropoietin + Stem Cell Factor. No red blood islands 
were visible in adherent cells and no red blood pellets were observed in the pelleted 
cell media (data not shown). Two independent biological replicates of in vitro 
differentiation using the hanging drop method with heat inactivated serum and 
original media were completed and gave similar results (data not shown). The images 
were taken with a Zeiss axiovert 25s inverted microscope at the magnification 





























Chapter Three: Validation of mES Cell Lines and Optimisation of In Vitro      
Differentiation 92 
3.2.2.3 Combined method of in vitro differentiation  
Although the hanging drop method did not produce any visible red blood 
cells, the reproducibility of EB formation was very promising. This suggested an 
adaptation of the suspension method, which had occasionally produced red blood 
cells, would lend reproducibility between replicates. As such, a modified protocol, 
here termed the “combined method”, was developed (Figure 3.7). This protocol was 
the same as that of the suspension method up until Day 0 when EBs were formed 
from a cell suspension in hanging drops of EB-Differentiation media. These EBs 
were harvested at Day 2 and plated in suspension in fresh EB-Differentiation media. 
The EBs were harvested at approximately Day 7 for downstream analysis. The 
combined method generated EBs of a reasonably consistent size and shape. Red 
blood islands were clearly visible in EBs produced using the combined method 
(Figure 3.8Aii).  
Importantly, the combined method produced greater numbers of red blood 
cells compared with the suspension method, as determined by flow cytometry after 
staining cells for Ter-119 (Figure 3.8B), an erythroid cell surface marker (Kina et al., 
2000). With the suspension method, a single 10cm3 dish of differentiated WTH3 
cells produced only 0.07 x 105 Ter119 positive cells (from a starting number of 
40,000 cells at Day 0), whereas 1.9 x 105 Ter119 positive cells were produced using 
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Figure 3.7 Schematic showing in vitro differentiation using the suspension vs. 
the hanging drop method. The combined method (orange) differs from the 
suspension method (green) and the hanging drop method (red) in the way EBs are 
formed (day 0 in suspension method and combined methods vs. day -2 in hanging 
drop method) and allowed to grow in suspension vs. adherence.  
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Figure 3.8 Comparison of in vitro differentiation using the suspension method 
and combined method.  
A. Microscope images of EBs containing blood islands at Day 7 in vitro 
differentiation using the (i) suspension and the (ii) combined method. These images 
were taken with a Zeiss axiovert 25s inverted microscope at the magnification 
indicated in the figure. 
B. Graph showing the number of Ter119 positive cells estimated by flow cytometry 
analysis at day 7 in vitro differentiation using the suspension method and varying 
numbers of hanging drop EBs (25-200 EBs HD per plate) used in the combined 
method.  
Two independent biological replicates of in vitro differentiation using the combined 
method on WTH3 and other cell clones were performed, both with similarly high 
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3.2.3 Molecular analysis of WTH3 mES Cells and in vitro 
differentiated cells 
RNA was extracted from mouse E14 ES cells, human H9 ES cells (received 
as a gift from D. Hay’s lab, The University of Edinburgh), humanised mouse WTH3 
ES cells and humanised mouse WTH3 ES cells which had been differentiated in vitro 
towards the erythroid lineage. These RNA samples were reverse transcribed and 
cDNA was generated and analysed by qPCR (SYBR Green). In agreement with 
previously published data (De Gobbi et al., 2011), no α- or β-globin transcripts were 
detected in E14 mES cells, however, human α-globin was detected in human ES cells 
and WTH3 humanised mES cells (Figure 3.9A). No signal from mouse α- or β-
globin was observed in human, humanised or mES cells (Figure 3.9B). As expected, 
human α-, mouse α- and mouse β- globin transcripts were all detected in WTH3 
humanised mouse cells differentiated in vitro towards the erythroid lineage (Figure 
3.9A and B). The observed expression data from these cell lines is summarised in 
Table 3.3. 
Table 3.3 Summary of expression data from cells from ES cells and in vitro 
differentiated WTH3 cells. The expression of human α-globin is detected in 






!! Human!α! Mouse!α! Mouse!β!
Mouse!ES!cell!(E14)! No# No# No#
Human!ES!cell!(H9)! Yes# No# No#
Humanised!mouse!ES!cell!(WTH3)! Yes# No# No#
In#vitro#differen=ated!WTH3! Yes# Yes# Yes#
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Figure 3.9 RT-qPCR amplification curves showing expression of human and 
mouse α-globin and mouse β-globin in WTH3 mES cells, H9 hES cells and in 
vitro differentiated WTH3 cells.  
(A) Human α-globin (Hum HBA) is expressed in WTH3 humanised ES cells and H9 
human ES cells. Expression of Hum HBA is detected at higher levels in WTH3 in 
vitro differentiated cells. Hum HBA expression is not detected in E14 mES cells. The 
reference house-keeping gene Ubiquitin C (UBC) is expressed in all samples.  
(B) Mouse α-globin (Mouse HBA) and mouse β-globin (Mouse HBB) is detected in 
WTH3 in vitro differentiated cells but not in WTH3 mES cells, H9 hES cells or E14 
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3.3 Discussion 
In this chapter, the WTH and ΔHS-40 mES cell lines were subcloned and two 
suitable subclones, WTH3 and ΔHS-40_20, were isolated. These mES cell subclones 
contain a high percentage of euploid cells (>80% for WTH3 and >50% for ΔHS-
40_20) and so should be appropriate for gene targeting experiments. The ability of 
these cells to differentiate in vitro was also confirmed which suggests they are 
suitable lines for generating mouse chimeras and performing in vitro differentiation 
assays.  
A robust in vitro differentiation protocol (combined method) for generating 
erythroid cells was optimised for use with the WTH3 mES cell line. Reproducibility 
issues observed here using the suspension method for generating EBs have been 
previously documented (Kurosawa, 2007). The use of heat inactivated serum in cell 
culture protocols has been traditionally used as a means of inactivating heat labile 
complement proteins which can negatively affect cell growth (Soltis et al., 1979). 
However, more recent comparisons have shown that heat inactivation often has no or 
a negative effect on the growth of different cell lines (Hauptman 2009). The use of 
heat-inactivated serum during in vitro differentiation had a positive effect on cell 
recovery at the point of harvesting and so was used in further optimisation of these 
protocols. The hanging drop method was able to produce reproducible EBs but did 
not generate any erythroid cells with visible haemoglobin expression.  
The media supplements tested with the suspension method and hanging drop 
method (Epo, Dex, SCF) are often used, in combination with others, in re-plating 
two-step approaches for generating erythroid cells. The supplements did not appear 
to have any effect on the qualitative appearance of red blood cells in the methods 
tested here, although this was not quantitatively assessed and so a more subtle effect 
may have been achieved from the addition of these supplements. As these 
supplements are quite expensive and did not qualitatively appear to have an effect on 
the appearance of red blood cells, I decided to instead test a combined method of in 
vitro differentiation, integrating steps from both the suspension and the hanging drop 
methods. This combined method was capable of consistently producing higher 
numbers of erythroid cells than previously tested methods.  
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Finally, the expression of human and mouse α-globin and mouse β-globin was 
tested by RT-qPCR in WTH3 humanised mES cells, H9 hES cells, E14 mES cells 
and WTH3 cells in vitro differentiated to the erythroid lineage. Human α-globin was 
detected in both WTH3 humanised mES cells and H9 hES cells whereas mouse α- 
and β-globin transcripts are not detected in these cell types, nor in E14 mES cells 
(Figure 3.9). The humanised mES cell line is capable of reproducing expression 
patterns observed in the H9 hES cells and is thus a suitable model for studying 
human α-globin transcriptional regulation. The detection of human and mouse α-
globin and mouse β-globin in the in vitro differentiated humanised WTH3 cells 
suggested that definitive erythroid cells were capable of being produced by the in 
vitro differentiation protocols used in this study.  
The isolation and validation of the WTH3 and ΔHS-40_20 mES cell lines 
provide essential tools that the experiments in the following chapters rely on. An 
important aim of this thesis is the study of epigenetic regulation at the α-globin locus 
during development. The successful optimisation of an in vitro differentiation 
protocol to produce definitive erythroid cells was an essential precursor to future 
analysis of erythropoiesis.  
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Chapter 4 Construct Preparation for Gene 
Targeting  
4.1 Introduction 
 In this chapter, I aimed to prepare a fluorescent reporter that would mark cells 
associated with α-globin gene activity in wild type and ∆HS-40 enhancer humanised 
mES cell backgrounds. Either the HBA1 or HBA2 genes could be fused with the 
coding region of a fluorescent reporter. However, as the humanised mice with a HS-
40 deletion express <2% of normal α-globin mRNA levels in erythroid cells 
(Vernimmen et al., 2009), it was necessary to consider strategies to maximise the 
detection of a tagged α-globin gene. Given that the HBA2 gene expression is 2-3 
times higher than HBA1 from approximately 8 weeks in utero (Albitar et al., 1992; 
Liebhaber et al., 1986), I focused on introducing a 2A-mCherry knock-in at the 3` end 
of HBA2 in humanised mES cells. Here, I describe the generation of a number of 
gene-editing tools that were used to generate knock-in mES cell lines. 
 Fusing genes with coding sequences that produce fluorescent proteins 
facilitates the visualisation of transcription in individual cells. Fluorescent reporters 
have been developed that have a range of excitation and emission profiles as well as 
varying levels of photostability. Monomeric Cherry (mCherry) was developed as a 
variant of the first red fluorescent protein isolated from Discosoma sp., DsRed 
(Shaner et al., 2004). The mCherry reporter has an excitation maximum of 587 nm, is 
highly photostable, and is more tolerant of 5` protein fusions than its predecessor 
(Shaner et al., 2004). This reporter has been successfully used for a range of different 
applications in many cell types, including erythroid cells (van Dijk et al., 2010; 
Ghamari et al., 2013). For example, a mCherry knock-in mouse was used to visualise 
the expression of the CDK9 transcription factor by live cell imaging of a number of 
different tissues, including foetal liver erythroid cells (Ghamari et al., 2013). 
Furthermore, live imaging of β-globin transcription has been achieved using mCherry 
(Martins et al., 2011). The knock-in gene I aim to generate includes a 2A peptide 
sequence between the HBA2 and mCherry genes. The 2A peptide sequence causes 
interrupted translation through a ribosomal skip mechanism, without affecting the rate 
of translation (Szymczak et al., 2004). This allows for stoichiometric expression from 
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2A-linked genes and will facilitate the quantification of α-globin expression in 
individual cells via mCherry detection.  
 
Gene targeting via recombineering technology 
Gene targeting techniques allow site-specific manipulation of a target locus to 
generate a deletion, mutation or insertion of a defined sequence. Two of these 
techniques include recombineering and CRISPR/Cas9, as previously described in 
detail (Chapter 1, pp. 32 and pp. 38, respectively). Recombineering techniques 
involve the use of bacteriophage recombineering proteins which are expressed in E. 
Coli cells and homology directed repair (HDR) mechanisms in mammalian cells. 
Briefly, a gene is first manipulated in vitro, for example in a BAC, HDR donor 
vectors and gene targeting vectors are generated, and then multiple gene targeting 
steps in ES cells are performed and chimeras are generated. This system uses 
recombination proteins Redα, Redβ and Gam from the λ phage which have been 
inserted into the bacterial genome of E. Coli strains (Muyrers et al., 2000). The 
recombinase mediated cassette exchange (RMCE), which is conducted in ES cells, 
relies on the use of site-specific recombinases that mediate the directed exchange of 
counter selective cassettes (Liu, 2013). Fragments of >100 kb have been successfully 
knocked-in using recombineering techniques (Wallace et al., 2007). 
 
Gene targeting via CRISPR/Cas9 technology 
CRISPR/Cas9 technology is used to induce double stranded breaks at a 
specific target sites. In the presence of an appropriately designed HDR donor vector, 
an insert can be introduced into a specific locus (Ran et al., 2013a). In order to 
prevent the digestion of the HDR donor vector, or the inserted DNA fragment after 
HDR, by the Cas9 nuclease, it is necessary to modify the sequence that the guide 
RNA targets. In many cases the modification of the donor DNA is trivial, as the guide 
RNA target sequences are not important for gene function or silent mutations can 
simply be introduced. Notably, the 3`UTR of the α-globin genes are required for their 
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stability (Weiss and Liebhaber, 1995). It is therefore undesirable for a random indel 
to be introduced after the 2A-mCherry insertion, as this is likely to reduce the 
expression of the fusion gene. For this reason, I designed a strategy to introduce a 
previously tested 4 bp mutation into the 3`UTR of the donor plasmid at the target site 
of the designed guide RNA. This 3`UTR mutation does not affect the stability of 
HBA2 mRNA (Weiss and Liebhaber, 1995) but does result in mismatches between 
the target site and the seed region of the designed guide RNA. These mismatches are 
likely to dramatically reduce the efficiency with which Cas9-mediated cleavage will 
occur (Wu et al., 2014).  
 
Vectors to facilitate CRISPR/Cas9 mediated HDR and counter-selection of gene 
cassettes 
The HDR vectors used in the CRISPR/Cas9 gene targeting strategy described in this 
chapter (Figure 4.2) were generated using Gibson assembly, an efficient PCR based 
cloning method (Gibson et al., 2009).  Briefly, a short ~20 bp overlap is introduced 
into two DNA fragments by high fidelity PCR. T5 exonuclease is then used to digest 
the 5` end of each strand and this is counteracted by Q5 High Fidelity polymerase 
activity, which simultaneously replaces digested DNA. T4 DNA ligase is then used 
to ligate the two fragments of DNA.  
CRISPR/Cas9 gene editing efficiency is extremely dependent on the genomic 
locus and guide RNA sequence, and also on the cell type and stage used. Although 
NHEJ efficiency can range from 1-90% (Bassett et al., 2013; Mandal et al., 2014; 
Ran et al., 2013a; Wang et al., 2013), the range of HDR efficiency is generally much 
lower at 0.5-30% (Ran et al., 2013a; Yang et al., 2013). The integration of a selection 
cassette into a HDR donor vector increases mES cell targeting screening efficiency 
(reviewed in Gonzalez 2016). Antibiotic selection cassettes were traditionally 
integrated and excised using Cre/loxP or FLP/FRT recombination technologies. A 
single loxP or FRT site remains after excision, which has the potential to recombine 
with other site-specific recombination target sites in the genome. For example, the 
WTH3 mES cell line used in this study contains an FRT and a lox511 site within the 
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human α-globin locus which remain from previous targeting events (Wallace et al., 
2007). The use of piggyBac transposase technology overcomes this problem. A 
counter selective cassette can be flanked by piggyBac inverted repeats which can be 
seamlessly excised in the presence of the piggyBac transposase without leaving a 
‘scar’ (Yusa et al., 2011). In this chapter, I generated two HDR donor vectors, one 
without a selection cassette and one containing a PGK-puromycinΔthymidine-kinase 
counter-selection cassette flanked with piggyBac inverted repeats (PB:PuroΔTK). 
The use of the counter-selection cassette allows for the positive selection of correctly 
targeted mES cells based on puromycin resistance. Following confirmation of correct 
integration, the piggyBac transposase can be transiently expressed to facilitate the 
seamless removal of the PB:PuroΔTK counter-selection cassette. Clones in which the 
counter-selection cassette is excised can be selected by a resistance to fialuridine 
(FIAU) and susceptibility to puromycin.   
This chapter describes the recombineering strategies designed to generate 
humanised mES cells with a knock-in fluorescent reporter tag, which culminated in 
the generation of a BAC containing a 2A-mCherry fusion. A number of 
CRISPR/Cas9 genome editing strategies to target this locus are also described. A 
guide RNA that targets the HBA2 3`UTR was generated and validated while HDR 
donor vectors (with and without selection cassettes) were produced by successive 
rounds of Gibson assembly. A mutation in the HBA2 3`UTR to disrupt the binding 
site of the guide RNA was included in the HDR donor vectors and the effects of this 
mutation on HBA2 and mCherry protein and RNA expression were tested.    
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4.2 Results 
4.2.1 Recombineering and RMCE strategy for gene targeting 
at HBA2 
In this section I describe the strategy and work done to prepare HDR donor 
and targeting vectors for generating a fluorescent reporter knock-in in mES cells by 
recombineering and RMCE. I successfully completed two rounds of recombineering 
to generate a BAC containing HBA2-2A-mCherry. However, due to the time 
consuming nature of recombineering, it was then decided to instead investigate 
CRISPR/Cas9 technology as a means of gene targeting.  
The humanised mES cell line used in this project was generated using site-
specific recombinase technology in combination with recombineering strategies. A 
BAC (BAC344L6) that was generated as part of the Human Genome Project and 
contained >190 kb of the human α-globin locus (Al-Hasani et al., 2004; Osoegawa 
et al., 2001) was used for the gene targeting strategies. As described in Chapter 1 
(pp. 28) BAC344L6 was triple targeted and 117 kb of the human α-globin locus was 
exchanged with 85 kb of the mouse α-globin locus in mouse ES cells to generate the 
WTH cell line (Wallace et al., 2007). A similar gene targeting approach using a 
recombineering strategy was designed to knock-in a 2A-mCherry fluorescent 
reporter into the subcloned WTH3 and ΔHS-40_20 mES cells at the HBA2 gene. 
However, the humanised locus within these two cell lines contain FRT, F3 and 
lox511 sites that remain from previous gene targeting strategies (Wallace et al., 
2007). The RMCE entry donor and targeting vectors, received as a gift from Dr. 
Andrew Smith (CRM, University of Edinburgh) also contain the site-specific 
recombination target sites, loxP and FRT. These sites need to be replaced with rox 
and F5 sites, where appropriate, in order to prevent spurious recombination events 
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Figure 4.1 Recombineering/RMCE strategy for generating a 2A-mCherry 
knock-in humanised mES cells with a wild type α-globin locus and with a 
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The gene recombineering/RMCE strategy outlined in Figure 4.1 involves the 
generation of a donor vector (Figure 4.1A). Four cloning steps in BACs are required 
to generate this donor vector, including three recombineering steps in BACs. In the 
first recombineering steps, a rpsL-Gentamycin (rpsL-Gent) cassette is to be fused to 
the 3` end of HBA2 in a BAC containing the human α-globin locus, BAC344L6, to 
generate BAC Gent. The second recombineering step involves the exchange of the 
rpsL-Gent cassette in BAC Gent with a 2A-mCherry fluorescent reporter cassette to 
generate BAC-2A-mCherry. The entry donor vector, pRMCE-donor, requires the 
replacement of site-specific recombination loxP sites with rox sites to generate 
pRMCE-donor-rox. The final donor vector (pHBA2_HA-2A-mCherry-HprtΔ5`) 
contains 10 kb of homology to the human HBA2-2A-mCherry locus and includes the 
3` end of the HPRT minigene, upstream of the HBA2 gene. To generate the final 
donor vector, the HBA2-2A-mCherry cassette can be retrieved from BAC-2A-
mCherry into the modified entry donor vector, pRMCE-donor-rox.  
A number of recombineering steps are also required in this strategy to 
generate the gene-targeting vector (Figure 4.1B). First, a cloning step is required to 
replace the site-specific recombination sites in the gene targeting entry vector, 
pRMCE-targeting, with lox511 and rox sites to generate pRMCE-targeting-  
 
Figure 4.1 Legend continued: 
The original strategy for recombineering involves 9 cloning steps, many of which 
require intense screening, and 6 RMCE cell targeting steps. In this gene targeting 
strategy a donor vector (pHBA2_HA-2A-mCherry-HprtΔ5`) and a gene-targeting 
vector (pRMCE-HprtΔ3`-Neo-5&3`HA) are to be generated (A and B, respectively). 
RMCE must then be performed using these two vectors in the mES cell lines, WTH3 
and ΔHS-40_20, to generate humanised mES cell lines with a fluorescent reporter 
knock-in (C). The recombineering and cloning steps to be performed on BACs or 
plasmids are shown as blue arrows. Green arrows indicate gene-targeting steps to be 
performed in the mES cell lines, which are shown in green text. Steps that were 
completed are shown in bold text. The gene targeting strategy was designed to 
generate two knock-in mES cell lines (orange boxes with green text), which would 
then be used to generate mouse lines by blastocyst injection. Primary erythroblasts 
generated from mouse lines and erythroblasts generated by in vitro differentiation 
from mES cells would then be analysed. 
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lox511/rox. A 5` and a 3` homology arm targeting the HBA2 locus are retrieved from 
BAC344L6 by recombineering and two subcloning vectors are thus generated 
(pHBA2_5` and 3`HA-KanR). These two homology arms are sequentially subcloned 
into the modified gene targeting entry vector to generate the final gene targeting 
vector, pRMCE-HprtΔ3`-Neo-5&3`HA. This final gene-targeting vector includes the 
5` end of the HPRT minigene upstream of the HBA2 gene. 
Once the gene targeting and donor vectors are completed, three RMCE steps 
are undertaken in the WTH3 and ΔHS-40_20 mES cell lines (Figure 4.1C). 
Transfection of humanised mES cells with (1) the final gene-targeting vector confers 
neomycin resistance when integrated into the mES cell genome. Co-transfection of 
(2) the final donor vector with a plasmid expressing Dre recombinase into correctly 
targeted mES cells generates correctly targeted mES cells that are both HAT resistant 
and neomycin susceptible and contain a 2A-mCherry reporter cassette at HBA2. A 
final transfection with (3) a plasmid expressing the Flp recombinase gene mediates 
the removal of the Hprt minigene and yields the final two humanised cell lines with a 
fluorescent reporter knock-in. These mES cell lines can then be used to produce 
erythroid cells via the generation of mice and the use of in vitro differentiation 
techniques. 
 
4.2.1.1 Recombineering strategy to generate a BAC with a HBA2-2A-
mCherry fusion. 
As briefly described above (section 4.2.1), an in vitro recombineering strategy 
was designed to fuse 2A-mCherry to the 3`UTR of HBA2 in BAC344L6 (Figure 4.2). 
This BAC344L6-2A-mCherry (BACmCh) could then be used to generate a donor 
vector for RMCE in mES cells (Figure 4.1C) or potentially be used as a tool to 
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Figure 4.2 Recombineering strategy to generate a BAC with a HBA2-2A-
mCherry fusion.  
A. Strategy for the site-specific insertion of an rpsL/Gent selection cassette at the 
3`end of HBA2 in BAC344L6. Briefly, the rpsL/Gent DNA fragment was generated 
by PCR from a plasmid and introduced into E. coli containing BAC344L6 by 
electroporation. E. coli cells were induced to express recombination proteins and 
these cells were selected by gentamycin resistance and screened by PCR.  
B. Strategy for exchange of an rpsL/Gent selection cassette with a 2A-mCherry 
cassette in BAC344L6/GentR. The 2A-mCherry (2A-mCh) DNA fragment was 
generated by restriction digestion from a plasmid and introduced by electroporation 
into E. coli containing BAC344L6/GentR by electroporation. E. Coli cells were 
induced to express recombination proteins and these cells were selected by 
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In vitro recombineering strategies are based on differential antibiotic 
selection. Here, an rpsL/Gent counter-selectable cassette was inserted at the 3`UTR 
of HBA2 in BAC344L6, which was exchanged with the 2A-mCherry cassette (Figure 
4.2). Initial selection of BAC clones containing the rpsL/Gent cassette (BAC Gent 
clones) was achieved by screening for clones resistant to gentamycin and sensitive to 
streptomycin (Figure 4.2A). Subsequently, clones containing the 2A-mCherry 
cassette were identified based on their resistance to streptomycin and sensitivity to 
gentamycin (Figure 4.2B). 
 
4.2.1.2 Generation of BAC Gent 
The rpsL/Gent fragment was generated by PCR from a plasmid pR6K-photo-
rpsL-Gent. The PCR product included a 5` 50 bp homology arm to the last 50 bp of 
HBA2 exon 3, and a 3` 50 bp homology arm to the first 50 bp of the HBA2 3`UTR 
(excluding the stop codon). The PCR product was introduced by electroporation to 
DY380 cells containing BAC344L6 that were induced to express recombination 
proteins. Electroporated cells were expanded on LB/Agar with 3-4 µg/ml gentamycin 
selection. Approximately 270 surviving colonies were re-plated on fresh LB/Agar 
plates with 3 µg/ml gentamycin selection. Of these, 24 clones were randomly selected 
and expanded in liquid LB with 3 µg/ml gentamycin selection and BAC mini preps 
were performed on these cultures.  
Screening of selected clones for correct integration of the rpsL/Gent cassette 
was performed by PCR with the orange primers depicted in Figure 4.3A. Five PCR 
positive clones (BAC Gent A-E) and a PCR negative clone (BAC Gent F) were 
identified (Figure 4.3B). These clone were then screened by Southern blot for correct 
integration of rpsL/Gent using a Gent probe (Figure 4.3C). Correct insertion of 
rpsL/Gent was confirmed in BAC Gent A-D by Southern blot analysis, however BAC 
Gent E and F appeared to have doublets suggesting either incomplete restriction 
enzyme digestion (this would give bands of 4.4 kb for HindIII and 1.5 kb for HpaI) or 
additional random integration events. DY380 cells containing BAC Gent A-F were 
also plated on LB/Agar containing 75 µg/ml streptomycin to screen for susceptibility   
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Figure 4.3 Correct fusion of rpsL/Gent to the last codon of HBA2 in BAC344L6.  
A. Schematic of primers, probes and restriction sites used in screening correct 
integration of rpsL/Gent. HpaI and HindIII restriction sites using in Southern blot 
screening are indicated in magenta and green, respectively.  
B. Composite gel image showing PCR screening of BAC Gent clones A-F. Orange 
arrows in (A) indicate primer pair used, which produce a product of 1.1 kb following 
correct insertion of the rpsL/Gent cassette and no product without insertion. Clones 
BAC Gent A–E (lanes 1-5) all contained the correct 1.1 kb product. BAC344L6 (lane 
7) gave no product, as expected.  
C. Southern blot screening of BAC Gent clones A-F using a probe for gentamycin 
(magenta box in A). Digestion with HindIII gave a single expected band size of 4.1 
kb (observed in lanes 1-5) and digestion with HpaI gave an expected band size of 1.3 
kb (observed in lanes 8-11 and lane 13). Apparent doublets are expected to be a 
result of incomplete digestion of the BAC DNA (lanes 6 and 12). BAC344L6 gave 
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to this antibiotic conferred by a functional rpsL gene. BAC Gent C and E were the 
only two clones that showed no growth on LB/Agar plates or LB liquid cultures 
supplemented with 75 µg/ml streptomycin. As a result of this streptomycin screen it 
was decided to pursue further cloning steps with BAC Gent C and E.  
 
4.2.1.3 Generation of BAC-2A-mCherry 
The donor plasmid used to insert the 2A-mCherry cassette directly in between 
the final codon and the stop codon of HBA2 was designed to contain 50 bp homology 
arms to HBA2, the ‘self-cleaving’ 2A peptide and the mCherry fluorescent reporter 
gene (5`-exon 3 HBA2 - 2A-mCherry - 3`UTR of HBA2 -3`). This cassette was 
synthesized and cloned into a pUC19 vector by GenScript (pUC_ex3HBA2_2A-
mCherry-3`UTR). The 2A-mCherry fragment was generated by restriction digestion 
with AscI. This fragment was introduced by electroporation to DY380 cells 
containing BAC Gent C and E that were induced to express recombination proteins. 
Electroporated cells were expanded on LB/Agar with 100 µg/ml streptomycin 
selection.  
Approximately 400 clones survived from the BAC Gent C electroporation and 
130 clones survived from the BAC Gent E electroporation. A random selection of 50 
individual clones from each of these plates were duplicate plated on LB/Agar 
containing either 100 µg/ml streptomycin or 3 µg/ml gentamycin selection. BACs 
were isolated from 24 clones that grew on streptomycin plates but not on gentamycin 
plates. These clones were screened by PCR for correct integration of the 2A-mCherry 
cassette using the orange primers in Figure 4.4A. BACmCh5 (a derivative of BAC 
Gent C) was the only positive clone identified by PCR screen (Figure 4.4B). The 
correct replacement of the rpsL/Gent cassette with the 2A-mCherry cassette was 
confirmed in BACmCh5 by Southern blot using a mCherry probe (Figure 4.4C).  
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Figure 4.4 Exchange of 2A-mCherry with rpsL/Gent in BAC Gent-C.  
A. Schematic of primers, probes and restriction sites used in screening for correct 
integration of the 2A-mCherry (2A-mCh) cassette. The HpaI and HindIII restriction 
sites used in Southern blot screening are indicated in magenta and green, 
respectively.  
B. Representative gel image showing PCR screening of BAC-mCh clones. The 
orange arrows in A indicate the primers used in screening that were expected to give 
a PCR product of 1.1 kb following exchange of rpsL/Gent with 2A-mCherry. Only 
the mCh5 clone appeared to be the correct size (lane 3). Bands of 1.4 kb (observed in 
lanes 2, 4-7) suggested the rpsL/Gent cassette was still present at HBA2. The 
negative control BAC344L6 (lane 8) showed no amplification. 
C. Southern blot screening of BAC-mCh clones using a probe for 2A-mCherry (red 
box labeled ‘mCh’ in A). Digestion with HindIII gave an expected band size of 4.9 
kb (observed for clone mCh5, lane 1) and digestion with HpaI gave an expected band 
size of 5.4 kb (observed for mCh5, lane 5). The negative controls BAC Gent C and 
BAC344L6 lanes showed no apparent bands (lanes 3, 4, 7 and 8), as expected. Bands 
of lower sizes for clone mCh20 (lanes 2 and 6) indicated 2A-mCherry may have 
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4.2.2 CRISPR/Cas9 strategy for gene targeting at HBA2 
A second gene targeting strategy was designed to knock-in the 2A-mCherry 
reporter cassette in humanised mES cell lines at the HBA2 gene using CRISPR/Cas9 
technology. This strategy required the generation of a homology directed repair 
(HDR) donor vector and CRISPR/Cas9 targeting vector (Figure 4.5A and B). Donor 
vectors were generated with relatively shorter homology arms (0.8-1.3 kb) than those 
required in the previously described recombineering strategy (2-5 kb). Donor vectors 
used in this strategy were generated by Gibson assembly. Briefly, an 800 bp 3` and a 
5` homology arm to the HBA2 locus were sequentially added from the BACmCh5 
template to the donor vector pUC-ex3HBA2-2A-mCh-3`UTR that was used to 
generate BACmCh5. A further 500 bp was added to the 3` homology arm to generate 
the final HDR donor vector without a selection cassette, pAB017. 
The next HDR donor vector that was generated by Gibson assembly 
(pAB018) contained a PB:PuroΔTK selection cassette. The 3` homology arm 
extension in pAB017 was designed such that when PB:PuroΔTK was inserted at an 
appropriate TTAA site downstream of the HBA2 stop codon, an 800 bp homology 
arm to the HBA2 locus would be present downstream of the counter-selection 
cassette. The final HDR donor vector (pAB027) was generated by modifying 
pAB018 to include a mutated HBA2 3`UTR.  
To generate the targeting plasmid a single guide RNA, sgRNA-A, was designed to 
target the 3`UTR of HBA2. The sgRNA-A sequence was then cloned into a plasmid 
expressing Cas9 to generate the final targeting vector, pCas9-sgRNA-A. A cut at the 
endogenous HBA2 locus, mediated by pCas9-sgRNA-A transfection, was validated 
by T7 Endonuclease I assay (Figure 4.5B). It was also important to confirm that the 
3`UTR mutation included in HDR vector pAB027 did not negatively effect the 
expression of HBA2-2A-mCherry in vitro. To this end, two expression vectors were 
cloned which included the HBA2-2A-mCherry cassette and either a wild type or 
mutated 3`UTR.  The expression of these two constructs was compared by Western 
blot and RT-qPCR (Figure 4.5C).    
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Figure 4.5 CRISPR/Cas9 strategy for generating a 2A-mCherry knock-in 
humanised mES cells with a wild type α-globin locus and with a deleted HS-40 
enhancer. The generation of HDR donor vectors for use in the CRISPR/Cas9 
targeting strategy involved 5 cloning steps, many of which involved Gibson 
assembly, a highly efficient method of cloning, and 2-5 cell targeting steps, 
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Once the HDR donor and targeting vectors were completed, a number of 
different gene targeting strategies could be employed in the WTH3 and ΔHS-40 mES 
cell lines (Figure 4.5D). In a gene targeting strategy using a HDR donor vector 
without selection cassettes (Figure 4.5Di), WTH3 or ΔHS-40_20 mES cells are co-
transfected with the targeting vector pCas9-sgRNA-A and the HDR donor vector 
pAB017. This would generate two humanised mES cell lines with a HBA2-2A-
mCherry fusion that are ready for downstream analysis. Using a HDR donor vector 
with a selection cassette (Figure 4.5Dii) would instead yield two puromycin resistant 
mES cell lines, with less screening. These would need to be transfected again with a 
plasmid expressing a PiggyBac transposase to remove the selection cassette from the 
final FIAU resistant and puromycin sensitive mES cell lines. An alternative strategy 
for generating a humanised mES cell line with a deleted HS-40 enhancer was also 
designed (Figure 4.5Div). A pair of guide RNAs flanking the HS-40 enhancer were 
designed, cloned and validated by T7 Endonuclease I assay (data not shown). These 
could potentially be used to remove the HS-40 enhancer from the WTH3-2A-
mCherry knock-in line. The final knock-in mES cell lines would then be ready for in 
vitro differentiation assays and the generation of mice. 
 
Figure 4.5 Legend continued: 
A number of donor vectors were cloned (A), as was a primary CRISPR/Cas9 
targeting vector (B). Two expression vectors were also cloned to determine the effect 
of the 3`UTR mutation on HBA2-2A-mCherry expression (C). A number of different 
gene targeting strategies were designed (D). Cloning steps performed on plasmids 
are shown as blue arrows. Green arrows indicate the gene-targeting steps performed 
in mES cell lines, which are shown in green text. The steps that were completed are 
shown in bold text. Dashed green arrows indicate a cell-targeting route, which was 
attempted but was unsuccessful in generating PCR positive clones. Purple arrows 
indicate an alternative route for generating the ΔHS-40-2A-mCherry knock-in cell 
line.  The gene-targeting strategy was designed to generate two knock-in mES cell 
lines (orange boxes with green text) that would then be used to generate mouse lines 
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4.2.2.1 Generation of a HDR vector without selection (pAB017) 
A HDR donor vector (pAB017) was designed to knock-in a 2A-mCherry 
cassette at the HBA2 gene without the use of a selection cassette. This HDR vector 
was generated by sequential Gibson assembly cloning steps. Briefly, an 800 bp 5` 
homology arm and a 1300 bp 3` homology arm were sequentially cloned by Gibson 
assembly into a vector (pUC-ex3HBA2-2A-mCh-3`UTR) which contained the 2A-
mCherry reporter cassette flanked by a 50 bp 5` and 3` homology arm.  
First, the 800 bp 3` homology arm was amplified by PCR from BACmCh5. 
Primers were designed to amplify an insert (3` arm) including the entire HBA2 
3`UTR. The insert primers also included a ~20 bp 5` overhang homologous to the 
last 20 bp of mCherry, including the stop codon, and a ~20 bp 3` overhang 
homologous to the plasmid backbone in pUC-ex3HBA2-2A-mCh-3`UTR (Figure 
4.6A; synthesised by GenScript) following the HBA2 3`UTR. A second set of 
primers were designed to amplify the entire vector, pUC-ex3HBA2-2A-mCh-3`UTR, 
excluding the HBA2 3`UTR segment. The vector and insert fragments were cloned 
into one plasmid (pAB001, Figure 4.6B) using Gibson assembly. A random selection 
of 10 plasmid clones were screened by restriction digestion with AscI and 6 clones 
were determined to be have the correct restriction digestion pattern (Figure 4.6D). 
These clones were Sanger sequenced (data not shown) and clone pAB001.1 showed 
seamless integration of the 800 bp 3` homology arm.  
Next, the 800 bp 5` homology arm was amplified by PCR from BACmCh5. 
Insert primers were designed to amplify an insert (5` arm) including the entire HBA2 
coding sequence and promoter. The insert primers also included a ~20 bp 5` 
overhang homologous to the plasmid backbone in pAB001 preceding the third HBA2 
exon and a 3` overhang homologous to the first 20 bp of 2A-mCherry. The vector 
primers were designed to amplify the entire vector pAB001 excluding the HBA2 
exon 3 segment. The vector and insert fragments were cloned into one plasmid 
(pAB007, Figure 4.6C) using Gibson assembly. A selection of 5 plasmid clones were 
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Figure 4.6 Insertion of homology arms into HDR subcloning targeting vector by 
Gibson assembly. 
A. Plasmid map of pUC-ex3HBA2-2A-mCherry-3`UTR. 
B. Plasmid map of pAB001 (pUC-ex3HBA2-2A-mCherry-3`UTR with additional 
3`homology arm).  
C. Plasmid map of pAB007 (pAB001 with additional 5`homology arm). 
D. Representative gel image from restriction digest screen of pAB001 Gibson 
assembly clones. AscI sites flank the entire 2A-mCherry insert in pUC-ex3HBA2-
2A-mCherry-3`UTR. Digesting with AscI gives fragments of 2727 bp + 883 bp 
without the insert and 2727 bp +1633 bp with the addition of an 800 bp 3` homology 
arm. Lanes 2, 4, 6, 10, 12 and 14 contained positive clones and were sent for Sanger 
sequence confirmation. Clone 3.3 (not shown) was confirmed by Sanger sequencing 
and used in further cloning experiments.  
E. Representative gel image from restriction digest screen of pAB007 Gibson 
assembly clones. Digestion with AscI gives fragments of 2727 bp + 1633 bp without 
the insert (3`arm only) and 2727 bp +2433 bp with the addition of an 800 bp 5` 
homology arm. Clones 7.2 and 7.3 were positive and sent for sequence confirmation. 
The negative control, pAB-003.3 from which 5`arm clones were derived, showed the 
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screened by restriction digestion with AscI and 3 clones were determined to have the 
correct restriction digestion pattern (Figure 4.6E). These clones were analysed by 
Sanger sequencing (data not shown), which indicated the seamless integration of the 
5` homology arm in clone pAB007.2. 
Finally, a 500 bp 3` extension to the 3` homology arm was amplified by PCR 
from BACmCh5. The insert primers were designed to include a ~20 bp 5` overhang 
homologous to the last 20 bp of the 3`arm in pAB007 and a 3` overhang homologous 
to 20 bp of the backbone in pAB007 following the 3`arm. The vector primers were 
designed to amplify the entire vector pAB007. The vector and insert fragments were 
cloned into one plasmid (pAB017, Figure 4.8A) using Gibson assembly. A selection 
of 13 plasmid clones were screened by PCR and 7 clones were deemed as positive 
(data not shown). One of these PCR positive clones, pAB017.2 was screened by 
restriction digestion with multiple restriction enzymes and was determined to be 
correct (Figure 4.8B). This clone was analysed by Sanger sequencing (data not 
shown) and showed seamless integration of the 3` homology arm extension. 
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Figure 4.7 Generation of HDR vector pAB017 by Gibson assembly. 
A. Plasmid map of pAB17 (pAB007+3`arm extension)  
B. The clone pAB17.2 was identified as a positive clone following Gibson assembly 
mediated insertion of a 3`arm extension. The plasmid identity was confirmed by 
restriction digestion with HindIII (lanes 4 and 11), ScaI (lanes 5 and 12), BsaI (lanes 
6 and 13) and HpaI (lanes 7 and 10). Restriction digestion reactions of pAB17.2 (i) 
and the template for pAB17.2 cloning, pAB7.2 (ii), were run alongside uncut 
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4.2.2.2 Generation of a HDR vector with selection (pAB027) 
To generate a HDR donor vector, which included a counter-selective cassette, 
the PB:PGK:PuroΔTK selection cassette was cloned into HDR vector pAB017 by 
Gibson assembly to generate pAB018 (Figure 4.8A). Firstly, the 3236 bp 
PB:PGK:PuroΔTK selection cassette was amplified by PCR from the vector pMCS-
AAT-PB:PGKpuro-delta-tk, received from the Sanger Institute (Yusa et al., 2011). 
The insert primers were designed to amplify the selection cassette and to include a 
~20 bp 5` and a 3` overhang with homology to a site within the 3` homology arm of 
pAB017. These primers were designed to clone the selection cassette directly 
downstream of a point in the 3`arm where a native TTAA site is present. The primers 
were also designed to introduce a novel TTAA site directly downstream of the 
selection cassette. Following transposase mediated removal of the selection cassette 
only one TTAA site would remain at the locus ensuring seamless excision. Vector 
primers were designed to amplify the entire vector pAB017. The vector and insert 
fragments were cloned into one plasmid (pAB018, Figure 4.8A) using Gibson 
Assembly. A selection of 23 plasmid clones were screened by PCR and 7 clones 
were determined to be correctly cloned. All of these correct plasmid clones were 
screened by restriction digestion with the enzyme HindIII and all of these clones 
were determined to be correct (Figure 4.8B). These clones were analysed by Sanger 
sequencing (data not shown) and clone pAB018.11 showed seamless integration of 
the PB:PGK:PuroΔTK selection cassette. 
Finally, a ~720 bp dsDNA fragment was generated (GeneBlock, IDT) to 
include a 4 nt mutation in the HBA2 3`UTR at the sgRNA-A target site (see section 
4.2.2.4, pp. 123 for details). The GeneBlock insert and vector pAB018 were digested 
with SbfI and cloned using Gibson Assembly to generate pAB027. Correct cloning 
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Figure 4.8 Generation of HDR vector with a selection cassette by Gibson 
assembly. 
A. Plasmid map of pAB018 (pAB017 + PB:PGK:PuroΔTK selection cassette). 
B. Screen of pAB18 cloning. Clones were screened by PCR initially and 7 plasmid 
clones, which were positive from PCR screens (data not shown), were digested with 
HindIII. All clones screened gave correct digestion pattern (lanes 1-7). The negative 
control pAB7.2 (lane 8) does not contain the selection cassette. The expected band 
sizes following digestion with HindIII are shown in the figure. Clone pAB018.11 
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4.2.2.3 Generation and validation of CRISPR/Cas9 vector targeting 
HBA2 
To fuse a 2A-mCherry cassette at the final translated codon of HBA2 using 
CRISPR/Cas9, a guide RNA was required to target the final exon or the 3`UTR of 
HBA2. In humanised mES cells the two adult α-globin genes, HBA2 and the 
downstream HBA1 are present. The coding and 3`UTR sequences of HBA2 and 
HBA1 were compared using Clustal Omega (McWilliam et al., 2013). The entire 
coding sequences of the HBA2 and HBA1 genes are identical (data not shown) 
however the sequences of the two genes diverge at the 3`UTR (Figure 4.9A). Using 
an online tool for designing guide RNAs (crispr.mit.edu) a suitable PAM and guide 
RNA seed sequence was identified 36 nt away from the last coding nucleotide of 
HBA2, in a region where the HBA2 and HBA1 sequences have diverged (shown in 
purple in Figure 4.9A). A single guide RNA (sgRNA-A) containing the 20 bp 
sequence preceding the identified PAM was cloned into an expression vector 
containing human codon optimised SpCas9 and a GFP fluorescent cassette 
(pSpCas9-2A-EGFP (PX458), (Ran et al., 2013a), received as a gift from Dr. P. 
Hohenstein, University of Edinburgh, Figure 4.9B). SgRNA-A targeted the HBA2 
3`UTR specifically and contained 5 mismatches for the HBA1 3`UTR and 4 
mismatches for the HBA2 3`UTR mutation included in HDR donor vector pAB027 
(Figure 4.9A).  
The plasmid pCas9-sgRNA-A and a vehicle control were transfected into 
WTH3 mES cells and positively transfected cells were isolated by FACS. GDNA 
was isolated from positively transfected cells and a T7 Endonuclease I assay was 
performed on the DNA. A band corresponding to the expected digestion pattern was 
observed in T7 digested cells transfected with pCas9-sgRNA-A (black arrowhead, 
Figure 4.9D). The indel efficiency of sgRNA-A was estimated to be 22%.  
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Figure 4.9 Validation of sgRNA targeting HBA2 3`UTR. 
A. The coding and 3` UTR nucleotide sequence of human HBA1 and HBA2 were 
compared using the webtool Clustal Omega (McWilliam et al., 2013). The TAA stop 
codon for both genes are shown in red and the 3`UTR is shown in blue. Identical 
nucleotides are indicated “*” underneath the nucleotide sequence. A guide RNA, 
sgRNA-A shown in purple, was designed to target the HBA2 3`UTR at the point 
where the HBA2 and HBA1 UTR sequences begin to diverge. The PAM sequence is 
underlined. 
B. Plasmid map of pCas9-sgRNA-A. The human U6 promoter drives sgRNA-A 
expression and the Chicken beta actin short promoter and CMV enhancer (CBP) 
drives the expression of hSpCas9-2A-GFP. A nuclear locatisation signal (NLS) is 
present at the 5` and 3` end of hSpCas9.  
C.  T7 Endonuclease Assay. WTH3 mES cells were transfected with pCas9-sgRNA-
A and a vehicle control. The primers used amplify an expected band size of 284 bp 
and digestion of the sgRNA-A sample with T7 Endonuclease (“+” below the gel 
image) gives bands of approximately 164 and 120 bp (black arrow indicates digested 
product). The images were analysed using ImageJ software and indel frequency was 




HBA2      ACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAATACCGTTAAGCTGGAGCCT 
HBA1      ACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAATACCGTTAAGCTGGAGCCT 
          ************************************************************ 
  
HBA2      CGGTAGCCGTTCCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCCTCCTTGCA-C 
HBA1      CGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTTCCTGCACC 
          **** *** * * ** *****  **********  * * ************ * **** * 
  
HBA2      CGGCCCTTCCTGGTCTTTGAATAAAGTCTGAGTGGGCAGCAGCCTGTGTGTGCCTGGGTT 
HBA1      CGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGCAGCCTGTGTGTGCCTGAGTT 
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4.2.2.4 Mutagenesis of HBA2 3`UTR does not affect expression 
To test the effects of the HBA2 3`UTR mutation included in the pAB027 
HDR donor vector (Figure 4.10A), two expression vectors were generated. Each 
vector contained a ~2 kb HBA2-2A-mCherry cassette under the control of a CMV 
promoter (Figure 4.10B) and included (1) a wild type HBA2 3`UTR or (2) a HBA2 
3`UTR with the mutated sequence used in HDR donor vector pAB027 (Figure 
4.10A). The expression levels of these cassettes was then assayed by western blot 
and reverse transcription qPCR (RT-qPCR).  
Briefly, a ~2 kb fragment containing the HBA2-2A-mCherry fusion gene and 
the entire 5`UTR and mutated 3`UTR of HBA2 was gel purified following sequential 
restriction digestion of pAB027.4 with HpaI and EagI. The 5` overhang generated by 
EagI digestion was blunted by treatment with Klenow enzyme. The pCDNA3.1(-) 
expression vector (received as a gift from Prof. Paul Digard, University of 
Edinburgh) was linearised by digestion with EcoRV and dephosphorylated to prevent 
re-ligation by treatment with rSAP. The two fragments were ligated overnight and 20 
colonies were screened by PCR. Of the colonies screened, 5 appeared positive and 
were expanded and plasmid DNA was isolated. These 5 plasmid clones were 
screened by restriction digestion with SmaI. Two of these pCMV-HBA2-2A-
mCherry-3`UTRmutation clones were found to have the insertion in the correct 
orientation and were confirmed by Sanger sequencing. A wild type pCMV-HBA2-
2A-mCherry-WT3`UTR expression vector was then generated by repairing the 
3`UTR sgRNA-A target site mutation in pCMV-HBA2-2A-mCherry-3`UTR 
mutation using site directed mutagenesis. Correct repair was confirmed by Sanger 
sequencing (data not shown).  
The pCMV-HBA2-2A-mCherry expression vectors (Figure 4.10B) with a 
3`UTR mutation and WT 3`UTR were transfected into WTH3 mES cells, alongside a 
vehicle control (containing only Lipofectamine reagent, OptiMEM and TE). Whole 
cell lysates were extracted and western blots were performed using antibodies 
specific to HBA and mCherry (expected band size; 15 and 27kDa, respectively), and 
β-actin as a loading control (expected band size; 40kDa). The HBA protein was only  
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Figure 4.10 Expression validation by western blot following HBA2 3` UTR 
mutation. 
A. The first 55 nucleotides of wild type HBA2 3`UTR following the HBA2 stop 
codon are shown. The binding site for sgRNA-A is shown in purple with the PAM 
underlined. The 3`UTR mutation included in pAB027 is shown underneath in red.  
B. Plasmid map of expression vector pCMV-HBA2-2A-mCherry.  
(C-D) WTH3 cells were lipofected with constructs containing the CMV-HBA2-2A-
mCherry cassette with a 3`UTR mutation (3`UTR), a WT 3`UTR (WT) or a vehicle 
control (UT). Western blotting was performed using antibodies for HBA (C) and 
mCherry (D). HBA was not detected in any sample apart from the positive control 
for HBA, 0.1 µg primary erythroblasts cell lysate (lane 8) which gave the expected 
band size of ~15 kDa. mCherry expression was detected in all transfected cells (D) 
and confirmed equal expression and correct translation of mCherry, not fused to 
HBA2. A positive control of a lysate from HEK293 cells expressing mCherry (27 
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detected in the positive control of primary erythroblasts lysate (lane 8, Figure 4.10B). 
A western blot probing for mCherry was performed on the same samples and a band 
of approximately 27 kDa is observed in all western blot lanes containing lysates from 
transfected cells with expression vectors (lane 1-4, Figure 4.10C). Of note, the 27 
kDa band observed in the pCMV-HBA2-2A-mCherry transfected cells is the same 
molecular weight as the band observed in the positive control sample (received as a 
gift from Prof. Paul Digard, University of Edinburgh), HEK293 cells transfected 
with pCMV-mCherry only (lane 7, Figure 4.10C).  
WTH3 mES cells were lipofected again with pCMV-HBA2-2A-mCherry 
expression vectors with a 3`UTR mutation and WT 3`UTR and a vehicle control. 
RNA extractions were performed on mCherry positive cells isolated by FACS. RT-
qPCRs (Taqman) were performed on cDNA generated from two independent 
biological replicates (transfections performed on different days) and one technical 
replicate (transfections performed on same day in different tissue culture wells). The 
expression levels of mCherry and HBA were normalised to the expression the 
housekeeping gene, GAPDH.  The mCherry and HBA expression levels varied 
between the transfection replicates but, importantly, no statistically significant 
difference was detected between mCherry or HBA expression in the 3`UTR mutation 
vs. the WT 3`UTR transfected samples (Figure 4.11). As expected, mCherry 
expression was not detected in the vehicle control samples but no statistical 
difference was detected in HBA expression between the transfected samples and the 
vehicle control sample (Figure 4.11).  
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Figure 4.11 Expression validation by RT-qPCR following HBA2 3` UTR 
mutation. 
WTH3 cells were transfected with constructs containing a CMV-HBA2-2A-mCherry 
expression cassette with a 3`UTR mutation, a WT 3`UTR or a vehicle control. RT-
qPCR was performed on mCherry positive cells isolated by FACS. Paired data points 
from two independent biological replicates (transfections on independent days) and 
from one technical replicate for the 3`UTR mut and WT samples (transfection on 
same day in independent wells) are shown. Paired data points from two independent 
biological replicates for the vehicle control are also shown. A one-way ANOVA 
analysis showed no significant difference between HBA expression in the three 
conditions. The expression of mCherry and HBA in cells transfected with a WT 
3`UTR vs. 3`UTR mutation construct cannot be distinguished by statistical analysis 
using a paired two-tailed t-test. The expression of mCherry and HBA is shown 
relative to Gapdh expression. The error bars represent the standard deviation from 
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4.3 Discussion 
In this chapter, a number of gene targeting strategies using recombineering and 
CRISPR/Cas9 technologies were designed. Recombineering was successfully 
employed to fuse a 2A-mCherry cassette to HBA2 in a BAC containing the human α-
globin locus. A number of CRISPR/Cas9 gene targeting tools were also generated. A 
CRISPR sgRNA targeting the 3`UTR of HBA2 was designed, cloned and validated. 
Gibson assembly was used to generate a HDR donor vector with and without a 
piggyBac flanked counter-selective cassette. Finally, a 3`UTR mutation included in 
the HDR donor vectors was confirmed to preserve the expression of HBA2-2A-
mCherry.  
 
Recombineering/RMCE vs. CRISPR/Cas9 
The recombineering steps undertaken to generate BACmCh5, although successful, 
were laborious and time consuming. The concentration of antibiotics used to isolate 
DY380 E. coli cells containing positively targeted BACs required extensive 
optimisation (data not shown) and 6 months had elapsed before the generation and 
confirmation of BACmCh5. A further 7 cloning steps would then have been required 
to generate the gene targeting and donor vectors required for RMCE in mammalian 
cells (Figure 4.2). A number of these cloning steps would involve additional E. coli 
recombineering steps with at least 6 gene-targeting steps in the mES cells. As this 
was a time-sensitive project, alternative gene targeting strategies, which had the 
potential to progress more rapidly, were prioritised. Nevertheless, the targeted 
BACmCh5 proved to be an extremely useful tool. It was used as a template for 
generating the CRISPR/Cas9 HDR donor vectors in this chapter and also used as a 
positive control for PCR screening during gene targeting in Chapter 5 (pp. 132).  
Of interest, two recent publications have successfully knocked-in large 
genomic regions (200 kb and 42 kb, respectively) with the combined use of the Cas9 
nuclease and a BAC (Baker et al., 2017; Yoshimi et al., 2016). In the first case, a 
ligation based method was used in which two sgRNAs, targeting either the gDNA or 
the BAC, two single-stranded donor oligonucleotides with homology to the gDNA, 
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Cas9 mRNA and a BAC with no homology to the gDNA were co-injected into rat 
embryos. Approximately 10% of the born pups showed correct integration of 200 kb 
of sequence unique to the BAC by PCR (Yoshimi et al., 2016). A more recent study 
from Francis Stewart’s lab used lipofection to introduce (1) Cas9 expressing 
plasmids with sgRNAs targeting both the BAC and the gDNA and (2) an engineered 
BAC with long homology arms to the gDNA (4-50 kb), to mES cells (Baker et al., 
2017). Although only a low number of correctly targeted clones were recovered (1-8 
clones, depending on the length of homology arm used), these represented up to 14% 
of the antibiotic resistant clones recovered, indicating the importance of antibiotic 
selection cassettes in targeting screens (Baker et al., 2017). These two methods 
suggest another potential use for the BACmCh5 generated here, in combination with 
CRISPR/Cas9 technology, in future gene targeting strategies.  
The use of CRISPR/Cas9 technology for gene editing became widespread 
from 2013 onwards following the publication of a number of high impact protocols 
claiming extremely accurate and fast editing efficiencies (Mali et al., 2013b; Ran et 
al., 2013a; Wang et al., 2013; Yang et al., 2013). Indeed, a study comparing knock-in 
efficiency in Zebrafish embryos using CRISPR/Cas9 or BAC technology showed 
that the CRISPR/Cas9 technology was 15% more efficient than the latter (Kimura et 
al., 2014). A number of research groups in the Roslin Institute and the University of 
Edinburgh have become proficient users and instructors of this technology, hence 
CRISPR/Cas9 technology was investigated as an alternative means of targeting the 
α-globin locus. The multiple CRISPR/Cas9 gene editing strategies that were 
designed included just 5 cloning steps to generate the HDR donor vectors and almost 
all of these steps involved Gibson assembly, an extremely efficient PCR based 
cloning technique. The number of gene targeting steps required in mES cells was 
between 2 and 6, depending on the strategy employed. This suggested that the 
CRISPR/Cas9 would provide a faster route than recombineering to successful gene 
editing in mES cells and so I focused on generating the tools to pursue this strategy.  
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Generation of CRISPR/Cas9 gene targeting tools 
First, sgRNA-A was designed to specifically target the 3`UTR of HBA2. This guide 
spanned a region of the 3`UTR that has diverged between HBA2 and HBA1 including 
7 mismatches between the two genes. It was expected that this guide would therefore 
be unable to anneal to, and generate indels at, HBA1. The guide RNA sequence was 
cloned into an expression plasmid containing human optimised Cas9 and a GFP 
reporter to generate the targeting vector, pCas9-sgRNA-A, and was validated by T7 
Endonuclease I assay.  
Next, two HDR donor vectors for use with the CRISPR/Cas9 strategy were 
generated by Gibson assembly. The first vector, pAB017, included a 5` homology 
arm of 800 bp and a 3` homology arm of 1300 bp to the HBA2 locus, but did not 
contain a selection cassette. I also decided to generate a second HDR donor vector, 
pAB027, which included a 5` and 3` homology arm of 800 bp to HBA2 and also 
included a piggyBac flanked counter-selective cassette. Although many reports have 
lauded the efficiency of Cas9 in producing indels (Mali et al., 2013b; Mandal et al., 
2014; Wang et al., 2013), the efficiency of HDR targeting using traditional 
CRISPR/Cas9 techniques is quite low at ~0.5-30% (Ran et al., 2013a; Yang et al., 
2013). The inclusion of a counter selective cassette could potentially increase the 
efficiency of gene targeting screening but also increases the number of gene targeting 
events required to generate a final locus with the removed selection cassette (Yusa et 
al., 2011).  
Although CRISPR/Cas9 gene targeting can be used to knock-in sequences via 
HDR, there is a risk that the CRISPR/Cas9 complex will generate an indel mutation 
via NHEJ if the guide RNA PAM sequence or the guide seed sequence is not 
destroyed by integration of the donor sequence. It has been shown that the HBA2 
3`UTR is sensitive to mutations which can easily disrupt its expression. As such, a 
known mutation (Weiss and Liebhaber, 1995) was incorporated at the HBA2 3`UTR 
in the HDR vector pAB027 where the sgRNA-A guide RNA was designed to anneal 
to. To confirm that this mutation did not negatively affect the expression of the 
HBA2-2A-mCherry transcript, two expression vectors were generated containing a 
CMV-HBA2-2A-mCherry expression cassette with a WT or mutated 3`UTR.  
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The WT and 3`UTR mutated expression vectors were transfected into WTH3 
mES cells and western blots on whole cell lysates confirmed that mCherry was 
expressed at similar levels from both the wild type and 3`UTR mutation constructs 
(Figure 4.10D). Interestingly, a western blot using an antibody against HBA on the 
same cell lysate samples did not detect HBA in any of the samples of transfected 
cells, but HBA was detected in a positive control sample using primary erythroblasts 
cells (Figure 4.10C). The Alpha Haemoglobin Stabilising Protein (AHSP) is abundant 
in erythroid cells and has been shown to be important for stabilising higher order 
HBA complexes but has not been shown to be necessary for HBA monomer 
stabilisation in vitro (Kihm et al., 2002). Therefore, the absence of AHSP in mES 
cells should not affect the stability of HBA protein in mES cells.  
The HBA2 gene is located 5` to the mCherry gene in the expression construct 
and the two genes are separated by a 2A peptide sequence which mediates separate 
translation of the two mRNA sequences via a ribosomal skip mechanism (Szymczak 
et al., 2004). No ‘uncleaved’ HBA2-2A-mCherry protein could be detected in any of 
the transfected samples (expected size; 42 kDa) suggesting that 2A peptide mediated 
‘cleavage’ efficiency is high. As the mCherry protein and transcripts are detected, it 
would suggest that the HBA2 gene is also transcribed and translated but may not 
accumulate to detectable levels in the transfected mES cells. Although HBA mRNA 
or protein has been detected (Biagioli et al., 2009) or ectopically expressed (Ji et al., 
2011; Weiss and Liebhaber, 1994) in non-erythroid cell lines, a literature search has 
not identified any reports in which HBA protein was successfully transiently 
expressed in mES cells. It remains unclear why transient expression of HBA could 
not be detected but mCherry could in the experiments described here.   
RT-qPCR data showed that both mCherry and HBA transcripts were detected 
in transfected cells and, importantly, there was no significant difference detected by 
RT-qPCR between the levels of transcripts detected in the WT vs. 3`UTR mutation 
samples (Figure 4.11). It is also important to note, however, that no statistically 
significant differences were detected between the HBA expression in transfected and 
vehicle control cells. It is known that an RNA-protein complex called αCP is required 
to enhance HBA mRNA stability specifically in erythroid cells but HBA mRNA and 
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protein expression can still be readily detected in non-erythroid cell types that are 
transiently transfected with globin expression constructs (Weiss & Liebhaber 1994; Ji 
et al. 2007; Biagioli et al. 2009; Ji et al. 2011).  
The gene targeting strategies and large number of new, validated tools 
generated in this chapter complete an essential step in the progress of a major goal of 
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Chapter 5 Gene Targeting at the α-Globin 
Locus 
5.1 Introduction 
A number of gene targeting attempts using CRISPR/Cas9 technology targeting 
the α-globin locus in humanised mES cells are described in this chapter. All the 
targeting strategies employed attempted to fuse a 2A-mCherry cassette to the last 
codon of HBA2 in the humanised WTH3 mES cell line. The targeting vector, pCas9-
sgRNA-A, was used in all targeting attempts in conjunction with either a HDR donor 
vector without (pAB-017) or with a selection cassette (pAB-027). A number of 
different transfection methods were used to introduce the constructs into mES cells 
and the recovered clones were screened by PCR and Southern blotting.  
The optimisation of transfection efficiency is essential to ensure the availability 
of a large pool of transfected cells for screening during gene-targeting experiments. 
A number of transfection methods have been developed to introduce plasmids into 
mammalian cells. A traditional method used to transfect mES cells is electroporation, 
in which a small electric charge is passed through the cells to increase the 
permeability of their membranes (reviewed in Kim & Eberwine 2010). Since 2002, 
over 2,500 papers have been published using a modernised electroporation system 
called nucleofection (Lonza, http://bio.lonza.com/citations.html). Nucleofector kits 
have been optimised with different buffers and electroporation settings for a variety 
of cell types. Another transfection method, here termed lipofection, is based on the 
formation of cationic liposome/DNA complexes which fuse with the cell membrane 
and enter the cell via the endocytic pathway (reviewed in Maurisse et al. 2010). The 
varying efficiencies of these transfection techniques for use with mES cell lines has 
been tested and several studies show that nucleofection and lipofection techniques 
outperform traditional electroporation (Lakshmipathy et al., 2004; Li et al., 2014; 
Maurisse et al., 2010). Nucleofection, however, can result in extremely high 
percentages of cell death depending on the cell type used (Lakshmipathy et al., 
2004).  
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The choice of an appropriate screening method to analyse clones isolated after 
transfections in gene targeting is also extremely important. Restriction fragment 
length polymorphism assays and PCR screening are simple methods often used in 
HDR screening strategies in combination with Sanger sequencing (Ran et al., 2013a; 
Yang et al., 2013). The more laborious Southern blotting methods developed by 
Edwin Southern in the University of Edinburgh (Southern, 1975) are seen as the 
‘gold standard’ of genotyping and are still used to give a more complete view of the 
location and context of a genomic insertion. Other genotyping methods include 
qPCR and next-generation sequencing (Bell et al., 2014; Gómez-Rodríguez et al., 
2008) but these are less frequently used due to their higher cost. The use of a 
selection cassette facilitates the efficient removal of clones lacking the appropriate 
antibiotic resistant gene before screening, thus increasing targeting screening 
efficiency (reviewed in Gonzalez 2016).  
In this chapter, three transfection methods were used to introduce a 
CRISPR/Cas9 targeting vector and HDR donor vector, with and without a selection 
cassette, to WTH3 mES cells. The gene targeting attempts and screening 
strategies/results are summarised in Figure 5.1. In total over 650 clones were 
isolated, expanded and screened by a combination of PCR assays. A number of 
clones were taken forward for further Sanger sequencing, Southern blot and qPCR 
screening. Clones were identified that contained a single insertion of the 2A-mCherry 
at the HBA2 locus.   
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Figure 5.1 Summary of targeting strategies and results. 
Timeline showing the various targeting strategies and transfection methods used with 
the aim of inserting the 2A-mCherry reporter cassette into the HBA2 locus in WTH3 
humanised mES cells. Turquoise boxes indicate when positive selection was used (as 
determined by the HDR donor vector used). Orange boxes indicate the transfection 
methods used and numbers indicate which targeting strategy was used. The number 
of colonies screened, the outcome of screening and the screening method used are 
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5.2 Results 
5.2.1 Knock-in strategy using Cas9 and sgRNA-A in 
combination with pAB-017  
Initially, a gene targeting strategy was designed using the validated targeting 
vector (see Chapter 4, pp. 122), pCas9_sgRNA-A, and the HDR donor vector pAB-
017. The HDR donor vector pAB-017 included two HBA2 homology arms and a 2A-
mCherry cassette fused to the 3` end of HBA2 without a selection cassette. Briefly, 2 
million WTH3 mES cells were co-nucleofected with 1.5 µg pCas9_sgRNA-A and 
1.5 µg pAB-017.2. One day after cells were transfected, positively transfected cells 
(79% of total population) were isolated by FACS for GFP expression. GFP positive 
cells were seeded in fresh 10 cm dishes at low density (200-1000 cells/dish) and 
single cells were left to expand into colonies for 8 days. Approximately 350 mES cell 
colonies were picked into 96 well plates. Picked colonies were expanded and cells 
were harvested for screening by PCR.   
Following gDNA extraction, screening PCRs were performed on all ~350 
clones using the primers shown in orange in Figure 5.2A. These primers should give 
a WT band of 325 bp or a larger band of 1.1 kb following integration of 2A-mCherry. 
No clones appeared to show the correct 1.1 kb integration band, however, some 
clones appeared to have bands of slightly greater or less than the expected 325 bp 
WT band (lane 10 vs. lane 11, Figure 5.2B). This suggested that an indel event 
occurred in these clones, which is consistent with CRISPR/Cas9 activity. PCRs were 
repeated on selected clones with a high fidelity Q5 polymerase and sent for Sanger 
sequencing. Sanger sequencing confirmed the presence of indels in the region of the 
sgRNA-A target site in clones 4B11 and 2B8 (Figure 5.2C).  
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Figure 5.2 Knock-in strategy using sgRNA-A in combination with pAB-017.  
A. Schematic showing knock-in strategy using HDR donor vector pAB-017, a vector 
without a selection cassette, in combination with sgRNA-A (blue arrow) and Cas9. 
The orange arrows show a primer pair used in PCR screening in B. These were 
designed to generate a WT band at 325 bp and a band indicating a positive insertion 
at 1.1 kb. The occurrence of both bands would suggest a random integration of the 
donor vector has occurred. 
B. Representative gel image from PCR screening. Approximately 350 clones were 
screened and no integration events were detected. Certain clones gave slightly larger 
(lane 11) or smaller bands (not shown) compared to the WT band (lane 5). The 
gDNA control WTH3 gave a WT band of 325bp (lane 5). As a positive control for 
the 1.1 kb band, pAB17.2 was mixed with WTH3 gDNA at equimolar concentrations 
(lane 7). Negative controls gDNA from E14 cells and H2O (lane 3 and 9, 
respectively) only gave no apparent bands. All lanes that are unlabeled above the gel 
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5.2.2 Knock-in strategy using Cas9 and sgRNA-A in 
combination with pAB-027  
5.2.2.1 Targeting strategy using pAB-027 
As co-transfection of a HDR vector without a selection cassette (pAB-017) 
and pCas9_NucA did not yield clones with an integration of the 2A-mCherry 
cassette, the targeting was repeated with a new HDR vector containing a selection 
cassette (pAB-027) in order to improve screening efficiency (Figure 5.3). The 
selection cassette included in pAB-027 is a piggyBac inverted repeat flanked PGK 
driven puromycin-Δthymidine kinase cassette (PB:PGK-PuroΔTK). This cassette 
allows for positive selection of clones with correct integration using puromycin 
selection. Following transient piggyBac transposase transfection clones with the 
selection cassette seamlessly removed can be isolated by negative selection with 
fialuridine (FIAU). A large array of PCR screening primer sets and probes for 
Southern blot screening were developed to ensure correct integration of the 2A-
mCherry and selection cassette at the HBA2 locus.  
 
Figure 5.2 Legend continued: 
C. PCR products from two clones with unexpected PCR product sizes (4B11 and 
2B8-not shown in gel) were sent for sequencing. Results indicated that small 
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Figure 5.3 Knock-in strategy using sgRNA-A in combination with pAB-027.  
Targeting strategy using HDR vector pAB-027 in combination with sg-RNA-A (blue 
arrow). The plasmid pAB-027 is a HDR donor vector including the PB:PGK-
PuroΔTK cassette and a 5` and two 3` homology arms (HA). Transfected cells are 
selected by resistance to puromycin and screened by PCR and Southern blot to 
ensure correct integration of the 2A-mCherry and selection cassette. Correctly 
targeted cells are transfected with a PiggyBac transposase. Cells are selected by 
resistance to FIAU and sensitivity to puromycin and screened by PCR and Southern 
blot to ensure correct integration of the 2A-mCherry and selection cassette. 
  
Primary Targeted Locus 
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5.2.2.2 Screening of potential 2A-mCherry knock-in clones following 
nucleofection/electroporation using HDR vector pAB-027  
Briefly, 10 nucleofections of 2 million WTH3 mES cells with 1.5 µg 
pCas9_sgRNA-A and 1.5 µg pAB-027 were performed. One day later, cells were 
seeded in fresh 10 cm dishes initially at low density (200-1000 cells/dish), but later 
experiments at high density (1,000,000 cells/dish) when it became clear that the 
targeting efficiency (and thus the numbers of puromycin resistant clones) was low. 
Cells were plated in mES cell media supplemented with 1 µg/ml puromycin and 
single cells were left to expand into mES cell colonies for 8-14 days. A total of 16 
puromycin resistant mES cell colonies were recovered into 96 well plates and 
expanded for freezing down cell stocks and for PCR genotyping.  
In order to recover a higher number of PCR positive puromycin resisitant 
clones, two electroporations were performed. Briefly, 10 million WTH3 mES cells 
were co-electroporated with 5 µg pCas9_sgRNA-A and 5 µg pAB-027. One day later 
cells were seeded in fresh 10 cm dishes (1 million cells/dish) in mES cell media 
supplemented with 1 µg/ml puromycin and single cells were left to expand into mES 
cell colonies for 8-14 days. A total of 61 puromycin resistant mES cell colonies were 
recovered into 96 well plates and expanded for freezing down cell stocks and for 
PCR genotyping.  
Following gDNA extraction, screening PCRs were performed on all 77 
puromycin resistant clones recovered from nucleofections and electroporations using 
primer set 1 (mCherry PCR) shown in orange in Figure 5.4A. These primers were 
expected to give a WT band of 325 bp or a larger band of ~1.1 kb following 
integration of 2A-mCherry. Of the 77 puromycin resistant clones tested, 8 clones 
were positive for a band at ~1.1 kb, indicating integration of 2A-mCherry (lane 2, 
Figure 5.4Bi). Of these, 6 clones survived cell expansion and were brought forward 
for further screening (clones NA5 and NB1 from nucleofections and clones EA1, 
EB7, EB12 and ED9 from electroporations). Clone EA2 from electroporations was 
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Figure 5.4 PCR screening of potential 2A-mCherry knock-in clones following 
nucleofection/electroporation with pCas9-sgRNA-A and pAB-027. 
A. PCR screening strategy for testing the puromycin resistant clones. Primer set 1 
(orange arrows) is the only primer set that amplifies a band in the wild type HBA2 
locus. Primer set 2 and 3 (red and blue arrows) are designed to specifically amplify 
bands in the primary targeted locus.  
B. Composite gel images showing examples of PCR screening results from 
puromycin resistant clones. (i) mCherry insertion PCR screening was performed 
using primer pair 1. Clone NA2 appears to contain an insertion whereas NA3 appears 
to have both a wild type and insertion band. Clone NA2 did not survive cell 
expansion and so was not tested in future screens. BACmCh5 was used as a control 
for insertion (1.1 kb band, lane 4) and WTH3 gDNA was used as a control for non-
insertion (325 bp band, lane 5). Negative controls E14 gDNA (lane 6) and H2O (lane 
7) did not yield a PCR product or produced a background signal. (ii) A 5` arm PCR 
screen was performed using primer pair 2. Positive control DNA (BACmCh5 only; 
lane 9) mixed at equimolar concentrations to 100 ng WTH3 gDNA (lane 10) gave 
expected insertion band size of 1.5 kb. Negative controls WTH3 and E14 gDNA and 
H2O (lanes 11-13) and all clones screened (lanes 2-8) did not yield a PCR product or 
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A 5`arm screening PCR was designed using primer set 2 (red arrows) 
indicated in Figure 5.4. This screen was designed to amplify a PCR product of ~1.5 
kb following site-specific correct integration of 2A-mCherry using a forward primer 
that was located outwith the region included in the HDR vector and a reverse primer 
specific to the 2A-mCherry insertion. These primers were optimized using a template 
of BACmCh5 DNA mixed at equimolar concentration to 100 ng of WTH3 gDNA 
(lane 12, Figure 5.4Bii). A 3`arm screening PCR was designed using primer set 3 
(blue arrows) in Figure 5.4A. This screen was designed to amplify a PCR product of 
~1.4 kb following site specific correct integration of PB:PGK-puroΔtk using a 
forward primer that was specific to the selection cassette and a reverse primer located 
outwith the region included in the HDR vector. These primers were optimised on a 
GeneBlock (IDT) containing primer target sites mixed at equimolar concentration to 
100 ng of WTH3 gDNA (lane 12, Figure 5.4Biii). Both the 5` and 3` arm PCR 
screens indicated that none of the 6 mCherry PCR positive clones contained the 
correct insertion (Figure 5.4Bii and iii).  
DNA probes for Southern blotting were designed to hybridise to a region 
within the HBA2-2A-mCherry locus either specific to the 2A-mCherry inserted 
cassette (mCherry probe) or beyond the homology arms included in the HDR vectors 
used in this thesis (5` probe, Figure 5.5A). The probes were designed such that 
Southern blots would reveal the specific location of the 2A-mCherry cassette as well 
as the integrity of the surrounding HBA2 locus following homology directed repair. 
The probes were generated by either restriction digestion of pUC_ex3HBA2_2A-
mCherry-3`UTR (mCherry probe) or by PCR from a DNA template of BACmch5 
(5`probe). Due to the repetitive nature of the alpha globin locus, the 284 bp 5` probe 
had the potential to bind both a site 3.3 kb 5` of HBA2 (5` Probe, Figure 5.5A) and a  
Figure 5.4 Legend continued: 
B iii. A 3` arm PCR screen was performed using primer pair 3. Positive control DNA 
(lane 9; synthesised 1.6 kb GeneBlock from IDT containing sequence from 
puromycin cassette and extending beyond the 3` homology arm) mixed at equimolar 
concentrations to 100 ng WTH3 gDNA (lane 10) yielded a PCR product consistent 
with the expected insertion band size of 1.4 kb. Negative controls WTH3 and E14 
gDNA and H2O (lanes 11-13) did not yield a PCR product. All clones screened 
(lanes 2-8) appeared negative.  
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second site 0.7 kb 3` of HBA2 (5` Probe*, Figure 5.5A) which is 98% homologous  
to the first site. Southern blots were performed on the mCherry PCR positive clones 
using the mCherry and 5` probes. A single band of approximately 9 kb was present 
when gDNA from clones EB12 and ED9 was tested with the mCherry probe (Figure 
5.5B). Two bands of approximately 9 kb and 5.5 kb were present on the Southern 
blot with the 5` probe of DNA from clone NB1, EA1 and ED9. A single wild type 
band of ~14 kb was present on the Southern blot with the 5` probe of DNA from 
clone EB12 (Figure 5.5C). According to the PCR and Southern blot data, more 
clones screened from the nucleofections and electroporations contained the correct 
integration of the 2A-mCherry cassette. These results are summarised in Table 5.1.  
 
Table 5.1 Summary of screening results of puromycin resistant clones recovered 
after nucleofection/electroporation. The results from each PCR and Southern blot 
screen are listed as “Yes” for a positive result and “No” for a negative result (no 
band detected or incorrect banding pattern detected). A total of 8 puromycin resistant 
clones were recovered that were positive for PCR 1 and 6 of these survived cell 




Clone,ID NA2 NA4 NA5 NB1 EA1 EA2 EB7 EB12 ED9
PCR,(1),mCherry Yes Yes Yes Yes Yes No Yes Yes Yes
PCR,(2),5`,arm & & No No No No No No No
PCR,(3),3`,arm & & No No No No No No No
Southern,mCherry,Probe & & No No No No No Yes Yes
Southern,5`,Probe, & & No No No No No No No
Nucleofection Electroporation
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Figure 5.5 Southern blot screening of potential 2A-mCherry knock-in clones 
following nucleofection/electroporation with pCas9-sgRNA-A and pAB-027. 
A. A schematic of the primary targeted locus indicating BamHI restriction sites and 
the locations of two Southern blot probes (purple boxes).  
B. Results of Southern blot using the mCherry probe. No signal was detected for 
negative controls E14 and WTH3, as expected. Correct knock-in clones are expected 
to have one band at 8.9 kb. EB12 and ED9 have approximately the correct band size 
and EB7 appears as a doublet. A second mCherry Southern blot was performed and 
gave similar results (data not shown).  
C. Results of Southern blot using 5` probe. WTH3 showed correct expected band 
size of 14.1 kb. No signal was detected for negative control E14, as expected. 
Correct knock-in clones are expected to have two bands at 8.9 and 7.9 kb, due to 
BamHI restriction sites in the Puro gene. None of the DNA screened resulted in 
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5.2.2.3 PCR screening of potential 2A-mCherry knock-in clones 
following lipofection 
As nucleofection and electroporation of WTH3 cells with pAB-027 and 
pCas9_sgRNA-A continued to yield very low numbers of puromycin resistant 
clones, which did not contain the correct insertion, lipofection was tested as a method 
to transfect the cells. Briefly, 5.6 million WTH3 mES cells were lipofected in 
suspension with 15 µg pCas9_sgRNA-A and 15 µg pAB-027.4. Cells were harvested 
and seeded in fresh 10 cm dishes initially at high density (1 million cells/dish) 24 h 
after transfection. Harvested cells were plated in mES cell media supplemented with 
1 µg/ml puromycin and single cells were expanded into mES cell colonies for 9 days. 
A total of ~280 puromycin resistant mES cell colonies were recovered into 96 well 
plates and expanded for freezing down cell stocks and for PCR genotyping.  
The mCherry PCR using primer set 1 in Figure 5.6. A previously identified 
clones which were found to be negative after further interrogation (Table 5.1). 
Therefore it was decided to perform initial screening PCRs using primer set 2  (5` 
arm) and primer set 3 (3` arm) shown in Figure 5.6A.  Following gDNA extraction, 
initial screening PCRs were performed on all ~280 puromycin resistant clones 
recovered from lipofections. The 5` and 3` screening primers were expected to yield 
bands of 1.5 and 1.4 kb, respectively, following integration of 2A-mCherry, without 
the presence of a WT band. The expected band size was amplified from 158 clones 
with the 5` arm PCR, 223 clones with the 3` arm PCR and 145 of these clones were 
positive for both 5` and 3` PCRs (double positive).  Four double positive clones 
(L1B7, L1C5, L1C6, L1C10), one 5` only positive clone (L1B2), one 3` only 
positive clone (L1A10) and one puromycin resistant clone, which was negative for 
both PCR screens (L1A11) (Figure 5.6Bii and iii), were expanded and interrogated 
by further screening. Given the previous difficulty in isolating a positive clone, two 
additional PCR screens were developed. The four double positive PCR clones were 
positive for two PCR screens spanning the 2A-mCherry cassette and the region 
between mCherry and PB:PGK-PuroΔTK cassette (Figure 5.6Biv and v). A final 
PCR screen spanning the PB:PGK-PuroΔTK cassette was designed to amplify a wild 
type region of 1.9 kb and 5.1 kb across the insertion (Figure 5.6A). Although the 
positive control insert band was not detected (possibly due to difficultly of PCR  
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Figure 5.6: PCR screening of potential 2A-mCherry knock-in clones following 
lipofection of WTH3 with pCas9-sgRNA-A and pAB-027. 
A. PCR screening strategy for the Puromycin resistant clones. Primer set 1 and 5 
(orange and green arrows) are the only primer sets that amplify a band in the wild 
type HBA2 locus. Primer set 2, 3 and 4 (red, blue and black arrows) should only 
amplify bands in the primary targeted locus.  
B. Gel images showing PCR screening results using primer sets (i) mCherry PCR (ii) 
5` arm PCR; (iii) 3` arm PCR; (iv) mCherry-PB Puro PCR and (v) PB-Puro PCR. 
Clones L1B7, L1C5, L1C6 and L1C10 are positive for primer screens (i-iv). Of 
these, only clones L1C5 and L1C6 do not show amplification of WT PCR product in 
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amplification across piggybac repeats), a wild type band was detected in clones 
L1B7 and L1C10 suggesting that these could be mixed clones (Figure 5.6Bv). The 
PCR screening data (summarised in Table 5.2) suggested that clones L1B7, L1C5, 
L1C6 and L1C10 contain a 2A-mCherry and selection cassette at the correct position 
in the HBA2 locus and that L1C5 and L1C6 are pure clonal populations.  
 
5.2.2.4 Southern blot screening of candidate 2A-mCherry knock-in 
clones following lipofection 
The candidate knock-in clones L1B7, L1C5, L1C6, L1C10, and three 
negative clones, including the 5` arm only positive clone (L1B2), 3` arm only 
positive clone (L1A10) and one puromycin resistant clone that was negative for both 
PCR screens (L1A11), were screened by Southern blot using the mCherry and 5` 
probes (Figure 5.7A). A single band at approximately 9 kb was detected in all four 
potential knock-in clones with the mCherry probe (Figure 5.7B) suggesting the 2A-
mCherry and selection cassette integrated at the correct genomic locus. Using the 5` 
probe doublets of the correct expected size were detected in clones L1C5, L1C6 and 
L1C10 (Figure 5.7C). A triplet was detected in clone L1B7 which indicated a large 
scale genomic rearrangement had occurred. A single WT band at approximately 14 
kb was detected in the WTH3 sample using the 5` probe and no band was detected in 
the E14 negative control sample, which suggested that the probe was annealing to the 
correct genomic locus. The detection of correctly sized doublets in the potential 
knock-in clones suggested that a correct integration of the 2A-mCherry and selection 
cassette had occurred. The mCherry and 5` probe Southern blots were performed two 
and three times, respectively, with each blot showing the same banding pattern. The 
results of PCR and Southern blot screening are summarised in Table 5.2. 
Figure 5.6B Legend continued: 
The contrast was increased in B (iii) in lanes 2-12. A positive control was run for 
each PCR in lane 12. The positive control DNA consisted of 100 ng WTH3 gDNA 
with equimolar concentrations of (i, iv, v) pAB-027, (ii) BACmCh5 and (iii) a 
synthesised 1.6 kb GeneBlock from IDT containing sequence from the PB:PGK-
PuroΔTK cassette to outside the 3` homology arm. The positive control failed in 
screen (i) and (ii) but PCR products of the expected size were successfully amplified 
using this screen.  
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Figure 5.7 Southern blot screening of potential 2A-mCherry knock-in clones 
following lipofection of WTH3 with pCas9-sgRNA-A and pAB-027. 
A. A schematic of the wild type and primary targeted HBA2 locus showing BamHI 
restriction sites and the locations of two Southern probes (purple boxes).  
B. Results of Southern blot using mCherry probe. WTH3 and E14 negative controls 
showed no signal, as expected. A single band at the expected size was observed in 
clones L1B7, L1C5, L1C6, L1C10 and L1B2 suggesting the mCherry-PB:PGK-
PuroΔTK cassette was inserted once in the correct genomic position. The negative 
clone L1A11 contains a single band at an incorrect size suggesting a single insertion 
occurred at an incorrect genomic location. A second mCherry Southern blot was 
performed and gave similar results (data not shown). Figure legend is continued on 













Chapter Five: Gene Targeting at the α-Globin Locus 148 
Table 5.2 Summary of screening results of puromycin resistant clones recovered 
after lipofection. The results from each PCR and Southern blot screen are listed as 
“Yes” for a positive result and “No” for a negative result (no band detected or 
incorrect banding pattern detected). A total of 7 puromycin resistant clones were 
screened. Clones L1C5 and L1C6 were positive for all screening methods. 
 
 
Figure 5.7 Legend continued: 
C. Results of Southern blot using the 5` probe. The WTH3 positive control gave the 
correct band size of ~14 kb indicating the probe successfully annealed to the target 
with no background signal. E14 negative control gave no signal. A triplet was 
observed in clone L1B7 and negative clone L1B2. Two bands of the correct expected 
sizes (8.9 and 7.9 kb) were observed for clones L1C5, L1C6 and L1C10. Incorrect 
sized doublets were observed in the negative clones L1A10 and L1A11. This data 
suggests that the correct insertions had occurred in clones L1C5, L1C6 and L1C10. 




Clone+ID+ L1B7+ L1C5+ L1C6+ L1C10+ L1B2+ L1A10+ L1A11+
PCR+(1)+mCherry+ Yes$ Yes$ Yes$ Yes$ Yes$ Yes$ No$
PCR+(2)+5`+arm+ Yes$ Yes$ Yes$ Yes$ Yes$ No$ No$
PCR+(3)+3`+arm+ Yes$ Yes$ Yes$ Yes$ No$ No$ No$
PCR+(4)+mCherryHPB:Puro+Yes$ Yes$ Yes$ Yes$ Yes$ No$ No$
PCR+(5)+PB:+Puro+ No$ $$ $$ No$ No$ $$ No$
Southern+mCherry+Probe++Yes$ Yes$ Yes$ Yes$ Yes$ No$ No$
Southern+5`+Probe+ No$ Yes$ Yes$ Yes$ No$ No$ No$
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5.2.2.5 A qPCR screening strategy of candidate 2A-mCherry knock-in 
clones 
A qPCR screening strategy was developed to confirm no duplications had 
occurred in the α-globin locus following correct integration of the 2A-mCherry 
cassette. Taqman primer sets and probes were designed to target the region included 
in the Southern blot 5` probe, a region downstream of that included in the HDR 
vectors (3` probe) and at the HS-40 enhancer ~60 kb upstream of the HBA2 gene 
(Figure 5.8A). No increase was detectable by qPCR in the copy number variation of 
the 5` probe region in the clones L1C5, L1C6 and L1C10 (Figure 5.8B). As 
expected, the only clone that potentially showed an increase in copy number by 
qPCR at the HS-40, 5` and 3` probe region was L1B7 (Figure 5.8B), the clone in 
which a triplet was detected by Southern blot using the 5` probe.  
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Figure 5.8 QPCR Screening of candidate knock-in clones following lipofection 
of WTH3 mES cells with pCas9-sgRNA-A and pAB-027. 
A. Map showing the locations of Taqman qPCR probes to assess copy number 
variation of 5` and 3` probe regions. The HS-40 probe (not shown) is located ~60 kb 
upstream of the HBA2 gene.  
B. Results from qPCR screening of copy number variation in the HS-40, 5` probe 
and 3`probe regions, normalised to the geometric mean of mouse α-globin (ex2) and 
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5.2.2.6 Phenotypic analysis of candidate 2A-mCherry knock-in clones 
following lipofection 
The potential knock-in clones L1B7, L1C5, L1C6, L1C10 did not express 
detectable levels of mCherry at the mES cell stage, as expected (data not shown). In 
vitro differentiation of these clones was performed using the combined method 
(Chapter 3, pp. 94) and all clones were found to express levels of mCherry detectable 
by fluorescent microscopy by Day 7 of in vitro differentiation (Figure 5.9). In vitro 
differentiated EBs were harvested and mCherry levels were quantified by flow 
cytometry. Three clones showed mCherry expression in over 10% of the EB cell 
population (L1B7, L1C5, L1C10) while L1C6 showed mCherry expression in only 
2.4% of EB cells (Table 5.3). The WTH3 mES cell line showed no expression of 
mCherry after in vitro differentiation (Table 5.3, Figure 5.9). 
 
Table 5.3 Results of flow cytometry using candidate knock-in clones. Clones 
were differentiated in vitro towards the erythroid lineage using the combined method 
and flow cytometry was performed on harvested EBs. All knock-in clones showed 
mCherry expression following differentiation whereas the negative control parental 
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Figure 5.9 Phenotypic analysis of candidate knock-in clones by in vitro 
differentiation and fluorescent microscopy. Clones were differentiated in vitro 
towards the erythroid lineage using the combined method and imaged on Day 7 of 
differentiation. All clones expressed mCherry following differentiation unlike the 
negative control parental clone, WTH3. The mES cell images (mESC) were taken 
using a Zeiss axiovert 25s inverted microscope at 20x magnification. The EB images 
were taken using a Zeiss axiovert 100 inverted microscope at 10x magnification. The 
fluorescent mCherry EB images were taken using a TRITC/dsRED filter and merged 
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5.3 Discussion 
In this chapter, I made multiple attempts to fuse a 2A-mCherry cassette to the 
HBA2 gene in humanised mES cells using CRISPR/Cas9 technology. A guide RNA, 
sgRNA-A was used in combination with two HDR donor targeting vectors, with and 
without a selection cassette, and three different methods of transfection were tested. 
An extensive array of screening methods were employed to analyse the recovered 
mES cell clones and of the approximately 650 clones analysed, three clones (L1C5, 
L1C6 and L1C10) were recovered that had an insertion event without the occurrence 
of apparent chromosomal rearrangement events within the locus. The methods used 
and the results obtained for gene targeting are summarised in Table 5.4. 
 
Table 5.4 Summary of gene targeting methods and results. Three methods of 
transfection were used in gene targeting; nucleofection (nuc), electroporation (elec) 
and lipofection (lipo). Positively transfected cells were isolated by FACS for strategy 
1 and by puromycin resistance (Puro) for strategy 2-4. For strategy 1-3, PCR screen 
1 was first used to isolate positive clones. For strategy 4, PCR screen 2 and 3 were 
first used to identify 145 clones positive for both PCR screens. Out of 7 of these 
double PCR positive clones, 5 were positive for PCR screen 1. Three clones were 




Gene targeting and screening 
The first gene targeting strategy used the HDR donor vector without a 
selection cassette, pAB-017, in combination with sgRNA-A. Of the 350 clones 
recovered, no clones were identified that had a correct insertion event, as assessed by 
PCR screen 1. However, a number of clones were isolated with indels at the HBA2 
3`UTR, suggesting that sgRNA-A was successfully guiding Cas9 to its target to 





Vector( Cell(Number( clones(isolated(1.(mCherry(2.(5'(arm( 3.(3'(arm( Southern(blot(
1( pAB017' 2'x'106' Nuc' FACS' ~350' 0' 4' 4' 4''
2( pAB027' 20'x'106' Nuc' Puro' 16' 3' 0' 0' 0'
3( pAB027' 20'x'106' Elec' Puro' 61' 5' 0' 0' 0'
4( pAB027' 2.6'x'106' Lipo' Puro' ~280' '(5)' 158' 223' 3'
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pathway. This confirmed that sgRNA-A was appropriate to use in targeting the 
HBA2 3`UTR, however a new targeting strategy to increase the efficiency of 
selection following HDR was required.  
The second targeting strategy I employed used nucleofection of pCas9-
sgRNA-A in combination with a HDR donor vector that contained a piggyBac 
flanked counter selective cassette, pAB-027. The incorporation of a selection cassette 
was expected to increase selection efficiency and decrease the number of clones 
required for screening (Gonzalez, 2016; Yusa et al., 2011). Another apparent benefit 
of the incorporation of a selection cassette was that positively transfected cells did 
not require sorting by FACS, a costly and time consuming technique. Instead, 
transfected cells could be transferred after 24 h to media supplemented with 1 µg/ml 
puromycin to directly select for the integration of the selection cassette. 
Unfortunately, extremely low numbers of puromycin resistant clones were recovered 
using this strategy on multiple occasions (16 clones isolated from 10 nucleofections 
transfecting 20 x 106 mES cells). It has been reported that adult stem cells also have 
extremely high cell death rates following nucleofection but that the use of 
electroporation results in higher rates of cell recovery (Lakshmipathy et al., 2004). 
Therefore, electroporation was tested as a means of transfection (strategy 3, Table 
5.4). Indeed, a higher number of puromycin resistant clones were recovered when 
cells were electroporated vs. nucleofected (61 clones from 2 electroporations 
transfecting 20 x 106 mES cells). Although 8/77 puromycin resistant clones isolated 
using strategy 2 and 3 were positive for PCR screen 1 using primers flanking the 2A-
mCherry insertion site, none of these clones were positive for additional PCR screens 
or Southern blot screens.  
Finally, a fourth gene targeting strategy was implemented and lipofection was 
used as method of transfection in an attempt to increase the number of recovered 
clones. Surprisingly, a large increase in the proportion of recovered clones to 
transfected cells was observed using lipofectamine as a method of transfection (280 
clones from 7 lipofections transfecting 5.6 x 106 cells). Previous reports suggested 
that there was not much difference in transfection efficiency or toxicity between 
lipofection and nucleofection in HEK293 or mES cells, however only feeder-
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dependent J1 mES cells were tested in that report (Li et al., 2014; Maurisse et al., 
2010).  
Isolation of correctly targeted knock-in clones 
Of the 280 puromycin resistant clones recovered using strategy 4, 145 were 
positive for PCR screens 2 and 3. Four clones that were positive for two independent 
PCR screens were expanded and further interrogated. This analysis revealed that two 
of these clones (L1B7, L1C10) were positive for two additional PCR screens and two 
(L1C5, L1C6) were positive for three additional PCR screens across the entire 
insertion cassette (Figure 5.6). The four initial clones (L1B7, L1C5, L1C6, L1C10) 
were screened further by Southern blot (Figure 5.7). Southern blot screening using a 
mCherry and 5` probe indicated that a single correct insertion of the 2A-mCherry 
cassette in the correct position occurred in three of the clones analysed (L1C5, L1C6, 
L1C10), and this result was reproducible using freshly isolated DNA.  
A triplet band was detected in one of the candidate knock-in clones (L1B7) 
using the 5` probe which suggested large scale chromosomal rearrangements may 
have occurred in this clone. Given that the Southern blotting experiments indicated 
that a duplication event had occurred in this clone during gene targeting, I developed 
a third screening method to clarify the genotype of the isolated clones. QPCR has 
often been used to measure copy number variation and genotype for genomic 
duplication events (Gómez-Rodríguez et al., 2008; Grimholt et al., 2014; Tai et al., 
2016). Furthermore, qPCR has successfully been used to detect duplications in the α-
globin locus of α-thalassemia patients (Grimholt et al., 2014). I developed a qPCR 
(Taqman) screening strategy to identify clones without duplication events. I tested 
the strategy on the candidate 2A-mCherry clones using a Taqman probe within the 5` 
probe region that was used in Southern blotting, and two additional probes at the HS-
40 enhancer and a region 3` of HBA2. According to the Southern blot data, a 
duplication of the 5` probe region occurred in clone L1B7, while the copy number of 
this region in clones L1C5, L1C6 and L1C10 should be the same as that of WTH3. 
As expected, qPCR screening only detected a 1.4-1.7 fold increase in copy number in 
clone L1B7 with no real difference in copy number between the remaining clones 
and WTH3. Importantly, qPCR screening detected a 1.7 fold increase in copy 
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number at the HS-40 probe, located approximately 60 kb upstream of the guide RNA 
target site, and the 3` probe regions in clone L1B7. This suggested that a 
chromosomal rearrangement of at least 60 kb had occurred in this clone that resulted 
in the duplication of the HBA2 coding sequence and the HS-40 regulatory region. 
This additional screening by qPCR confirmed that no duplications of the α-globin 
locus had occurred during gene targeting in the correctly targeted clones L1C5, L1C6 
and L1C10.  
Phenotypic analysis of 2A-mCherry clones 
In vitro differentiation of the candidate 2A-mCherry knock-in mES clones 
was performed using the combined method developed in Chapter 3 (pp. 94). Day 7 
EBs were analysed by fluorescent microscopy and flow cytometry and all 2A-
mCherry knock-in clones analysed (L1B7, L1C5, L1C6 and L1C10) showed 
expression of mCherry, although lower levels were detected in clone L1C6 (Figure 
5.9; Table 5.3). The activation of mCherry expression in the erythroid lineage 
validated the PCR and Southern blot screening data which showed a single insertion 
of the 2A-mCherry cassette at the HBA2 locus in these clones (Figure 5.6; Figure 
5.7).  
Conclusions 
In this chapter mES cell clones were isolated that contained a single insertion of 
the 2A-mCherry cassette. This was a significant step forward in the generation of a 
fluorescent reporter system for α-globin in a ΔHS-40 background. As only 8 months 
remained in this project at the time these cell lines were isolated, it would not have 
been possible to complete all the remaining gene targeting steps (the removal of the 
piggyBac selection cassette and the deletion of the HS-40 enhancer) and generate 
mouse colonies from the resulting mES cells for analysis studies. Future work would 
involve the completion of the remaining gene targeting steps, generation of mouse 
colonies, isolation of primary red blood cells and ChIP and expression analysis 
following FACS of the HBA2-2A-mCherry expressing and non-expressing 
populations. 
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Chapter 6 Epigenetic Editing to Manipulate 
Bivalent Histone Modifications 
6.1 Introduction 
Previous chapters in this thesis focused on the generation of a knock-in of a 
fluorescent reporter in order to efficiently track the transcription of HBA2 on a single 
cell level. As previously discussed, HBA2 transcription is largely controlled by the 
activity of a distal enhancer. In the absence of this enhancer, erythroid cells express 
α-globin in a heterogeneous manner, which is correlated with the maintenance of 
both activating and repressing histone marks in these cell populations (De Gobbi et 
al., 2017; Vernimmen et al., 2011). The fluorescent knock-in cell line would 
facilitate the isolation of cells expressing HBA2 and cells that lack HBA2 expression, 
which would then be used to characterise the histone status at the α-globin locus. In 
this way, the nature of bivalency at the α-globin locus would be assessed, however, 
these experiments would not be informative as to the function of this bivalency. One 
way to understand how bivalency influences gene expression would be to analyse 
gene expression changes during differentiation after depleting or accumulating 
histone marks at a specific gene. In this manner, a causal relationship between 
bivalency resolution, gene expression and development can be established. 
In this chapter, I describe the development of a strategy aimed towards 
modifying the presence of chemical groups on the tails of histones, which are 
associated with gene expression behaviours. Initially, I developed a high-throughput 
and efficient cloning system that facilitates the construction of gene fusions 
containing a combination of promoters, DNA binding domains and enzymatic 
domains. Vectors containing these gene fusions were transfected into cells in order to 
assess their effects on a model locus (Figure 6.1). Before presenting the results of 
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Figure 6.1 Using TALE fusion protein activity to modify histone status.   
A TALE array can be designed to interact with any chosen DNA sequence. If the 
TALE array is fused to an epigenetic editing enzymatic domain, modifications of the 
histone state in the vicinity of the binding event may occur. In the example shown 
here, JMJD3, a H3K27me3 demethylase, is targeted to a promoter marked with 
H3K27me3 and H3K4me3. The removal of H3K27me3 at the bivalent gene 
promoter by JMJD3 may be sufficient to increase the expression of the gene. This 
figure is adapted from Vernimmen (2014). 
 
Golden Gate cloning to generate TALE fusion proteins 
Both the catalytically inactive Cas9 (dCas9) coding region and TALEs can be 
fused to the enzymatic domains of other proteins (Hilton et al., 2015). Here, I used 
TALE fusions to direct site-specific epigenetic changes, as at the time these 
experiments were designed, these artificial DNA-binding domains had already been 
validated for this purpose (Konermann et al., 2013; Maeder et al., 2013a; Mendenhall 
et al., 2013). A modified version of the Golden Gate assembly protocols used in 
Cermak et al. (2011) was used to construct the TALE fusions in this chapter because 
of the flexibility and efficiency this technique offers. Golden Gate assembly is a 
cloning method based on the use of type IIS restriction enzymes, which cut DNA 
close to, but outside, their continuous, asymmetric recognition sites (Figure 6.2A). 
These enzymes were first used in cloning schemes in 1996 (Lee et al., 1996; Padgett 
and Sorge, 1996) where they were employed to generate multimers of individual 
cloned fragments of DNA. When cloning schemes are appropriately designed, type 
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Figure 6.2 Golden Gate assembly of TALE constructs.  
A. The recognition site of the type IIS restriction enzyme BsmBI (and its 
isochizomer, Esp3I) is shown in blue. This enzyme cleaves its recognition site at the 
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complementary cohesive ends on different DNA modules, which can then be ligated 
together in a particular order (Figure 6.2B). This method of using type IIS restriction 
sites to assemble at least nine DNA modules together was termed ‘Golden Gate’ 
cloning (Engler et al., 2008, 2009). Later methods based on Golden Gate cloning, 
including MoClo (Modular Cloning) and GoldenBraid, developed libraries of 
plasmids containing DNA modules which could be shuffled to assemble a vast 
number of final constructs with minimal effort (Sarrion-Perdigones et al., 2011; 
Weber et al., 2011). For example, a library of Golden Gate compatible plasmids 
containing different promoters, gene coding regions and terminators can be shuffled 
to produce a large number of combinations in the final expression vector.  
 
Figure 6.2 Legend continued: 
(B-C). Golden Gate cloning strategy for fusing five DNA modules from plasmids 
into the destination vector, TALE Fusion Expression Vector (pTFE). Before 
initiating the Golden Gate assembly protocol to generate the Promoter-TALE-
enzymatic domain cassette, several entry plasmids were prepared. Two separate 
plasmids that contain the 5` and 3` (Array 1 and Array 2) section of the complete 
TALE array were cloned while the plasmid containing the last half repeat (LR) is 
available as part of the TALE assembly kit (Cermak et al., 2011). In addition, two 
other plasmids harbouring the promoter and enzymatic domains, respectively, were 
cloned. Each of these regions of interest are flanked by Type IIS restriction sites, 
which were designed to re-ligate in a specific order upon addition of the restriction 
enzyme and ligase. The TALE array (Array 1, Array 2 and LR) was designed to 
insert between the TAL N- and C- terminal domain coding regions. The promoter 
and enzymatic domain DNA sequences were designed to insert up- and downstream, 
respectively, of the TAL N- and C- terminal sequences. Digestion with BsmBI 
releases the insert modules, each flanked with a unique 4 nt overhang (colored boxes 
A-H). These overhangs anneal to their complementary cohesive ends (colored boxes 
A*-H*) and are ligated to one another in a specific order in the presence of T4 
Ligase. The selection of colonies was based on ampicillin resistance of pTFE while 
blue-white selection was also employed, as the LacZ cassette is lost once the TALE 
array has been inserted into pTFE. TAL N` and C`, TAL N- and C-terminal domains; 
BFP, CMV-mTagBFP-polyA cassette; LacZ, a LacZ cassette; AmpR, an ampicillin 
resistant cassette; Prom, promoter of choice; GOI, gene of interest; 3xFLAG, three 
times FLAG tag; Array 1, RVD 1-10; Array 2, RVD 11-(n-1); LR, the last half 
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The protocols described in Cermak et al. (2011) use Golden Gate cloning to 
sequentially assemble TALE DNA binding arrays into a destination vector. A TALE 
array can be reliably designed to target a specific genomic locus using online tools 
(Doyle et al., 2012). Once a TALE array containing ~12 – 30 RVDs has been 
designed it is then assembled in two steps (Cermak et al., 2011). First, the RVD 
modules 1-10 and 11-(n-1) (Array 1 and 2) are assembled into two spectinomycin 
resistant plasmids, respectively, using Golden Gate assembly, where n is the number 
of RVDs in the final TALE array. Arrays 1, 2 and the last half repeat are then 
inserted into a destination vector in between the N- and C-terminal coding TALE 
domains using Golden Gate Assembly. I modified the pTal2 destination vector 
(Cermak et al., 2011), to generate a TALE Fusion Expression vector, pTFE, by 
introducing additional Golden Gate restriction sites, a CMV-mTagBFP-polyA 
cassette (BFP) and a poly-A signal  (Figure 6.2B). The cloning scheme was designed 
such that each of the sequences encoding enzymatic domains are separated from the 
coding regions of the TALEs by a sequence encoding a short Glycine-Glycine-
Glycine-Serine linker in the final fusion constructs (previously used in TALE fusions 
in (Maeder et al., 2013a)). The inclusion of this linker region was intended to prevent 
potentially inhibitory interactions between the enzymatic domains and the TALE 
proteins. The subcloning vectors were designed such that each of the genes would be 
fused to sequences encoding a 3xFLAG tag at the 3` end, which is a commonly used 
epitope tag (3xFLAG has previously used in epigenetic editing fusion constructs in 
(Hilton et al., 2015; Kearns et al., 2015; Maeder et al., 2013a; Mendenhall et al., 
2013)). The addition of these linker and epitope sequences was designed to preserve 
the reading frames of the final fusion genes. 
 
Using Nrp1 as a model target to test epigenetic editing tools 
NRP1 is a transmembrane receptor that binds vascular endothelial growth 
factor (VEGF) (Fantin et al., 2013; Kawasaki et al., 1999). NRP1 is expressed in 
developing neurons and is important during axon guidance, vascular sprouting and 
brain angiogenesis (Aspalter et al., 2015; Fantin et al., 2013; Kawasaki et al., 1999). 
The Nrp1 promoter contains a CpG island, is bivalent (Figure 6.3A) and does not   
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Figure 6.3 Nrp1 characteristics in mES cells.  
A. Enrichment tracks for H3K4me3 and H3K27me3 in “Bruce4” mES cells at Nrp1 
are shown from ChIP sequencing data of histone modifications from 
ENCODE/LICR data set release 3 (August 2012) and mapped on the mouse July 
2007 (NCBI37/mm9) genome assembly (http://genome.ucsc.edu/; Kent et al. 2002). 
The locations of four primer pairs used in ChIP-qPCR in this chapter are shown as 
orange arrows.  
B. RT-qPCR data for Nrp1 in mES cells transfected with the TALE vector tNrp1-
VP64 and the negative control TALE tNrp1-Δ. The expression shown is relative to 
GAPDH expression and to eGFP transfection. Expression changes are also shown for 
mES cells that have differentiated into epiblast stem cells (EpiSCs; by addition of 
growth factors activin A and Fgf2) or NPCs (by retinoic acid mediated 
differentiation). The mean log2 expression data from three biological replicates is 
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bear DNA methylation in mES cells (Sabo et al., 2004, 2006). Nrp1 expression can 
be detected at low levels in mES cells and increases as cells differentiate towards the 
neural lineage (Mikkelsen et al., 2007; Therizols et al., 2014). Therizols et al. (2014) 
from the Bickmore lab at the University of Edinburgh designed a TALE that targeted 
the Nrp1 promoter and was fused to the strong acidic transactivation domain, VP64 
(tNrp1-VP64; Therizols et al. 2014). This TALE fusion promoted efficient and 
robust activation of Nrp1 in mES cells transiently transfected with tNrp1-VP64 to 
levels comparable with the endogenous expression of Nrp1 in neural precursor cells 
(NPCs; Figure 6.3B). Because the Nrp1 locus bears similarities to the HBA2 locus 
(bivalent, CpG island-containing and methylation-free DNA) and because of the 
availability of validated tools (tNrp1 and tNrp1-VP64), Nrp1 was selected as a model 
target site for the epigenetic editing tools generated in this chapter. The validated 
TALE sequence targeting the Nrp1 promoter was used to generate the TALE fusion 
constructs while plasmids from the Bickmore lab containing the tNrp1-VP64 coding 
regions and the tNrp1 coding region alone (tNrp1-Δ, TALE-Only-B) were used as 
positive and negative controls, respectively (Therizols et al. 2014).  
Using enzymatic domains to manipulate histone modifications 
The relationship between histone status and gene expression is unclear. 
H3K4me3 and H3K27me3 are commonly described as an “activator” and a 
“repressor” of gene transcription, respectively. As described in Chapter 1 (pp. 2), a 
number of studies have shown that a dramatic global reduction in H3K4me3 does not 
result in major changes in global gene expression levels (Clouaire et al., 2012; 
Hormanseder et al., 2017; Lenstra et al., 2011; Muramoto et al., 2010). Also, 
H3K27me3 deposition has been shown to occur only after transcription has been 
silenced (Hosogane et al., 2013; Yuan et al., 2012). The instructive role of these two 
histone marks in gene transcription is in doubt, as indeed is the importance of 
colocalisation of these two marks for appropriate gene expression during 
differentiation (Hu et al., 2013). These marks may, however, play an important role 
in terms of epigenetic memory of transcriptional states (Coleman and Struhl, 2017; 
Hormanseder et al., 2017; Howe et al., 2017; Muramoto et al., 2010). To improve our 
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understanding of these histone marks, I aimed to promote methylation of H3K4 and 
H3K27, respectively, and demethylation of H3K27. 
A number of proteins are involved in catalysing H3K4me3 deposition (see 
Chapter 1, pp. 2). The RBBP5 protein is a core member of the SET1-like MLL1 
complex and, along with the other two subcomponents, WDR5 and ASH2L, it is 
essential for the assembly and H3K4me3 methyltransferase activity of the SET1-like 
MLL complex (Avdic et al., 2011; Cao et al., 2010; Dou et al., 2006). The catalytic 
components of the SET1 and SET1-like complexes are often extremely large, 
ranging from ~5-17 kb in gene length and ~200-600 kDa in protein size. These large 
DNA regions may be difficult to clone and the large protein domains may interfere 
with TALE binding activity. Therefore, the small Rbbp5 coding region (~1.6 kb) was 
cloned and tested. Localising the RBBP5 protein to a particular locus may stimulate 
the recruitment of the entire MLL complex, thus stimulating H3K4me3 deposition 
and, perhaps, transcription. This hypothesis is supported by the observation that 
targeted high levels of H3K4me3 deposition by the meiotic methlytransferase 
PRDM9 is sufficient to induce small changes in transcription at silent loci in a 
context dependent manner (Cano-Rodriguez et al., 2016).  
EZH2 is a core member of the H3K27me3 histone methyltransferase 
complex, PRC2 (O’ Carroll et al., 2001). Although EZH2 is the catalytically active 
component of the PRC2 complex, the presence of both SUZ12 and EED are required 
to stimulate this activity (Margueron et al., 2009; Pasini et al., 2004). Previous 
reports suggest that inducing H3K27me3 at specific promoters significantly reduces 
gene expression (Konermann et al., 2013). As discussed in detail in the Introduction 
(pp. 42), a recent report using three sgRNAs targeting dCas9-EZH2 to a gene 
promoter was able to induce a 9-fold enrichment of H3K27me3 at the gene promoter, 
however, the effect of this localisation on transcription was unclear (O’Geen et al., 
2017). It is possible that the localisation of the EZH2 protein to a particular locus can 
stimulate the recruitment of the entire PRC2 complex and thus stimulate H3K27me3 
deposition and perhaps suppress transcription. 
JMJD3 is a H3K27me3 demethylase important in transcriptional regulation 
and development (Agger et al., 2007; Burgold et al., 2008; Hong et al., 2007). A C-
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terminal segment of JMJD3, including the conserved JmjC domain, is sufficient for 
its demethylase activity in vitro (Kruidenier et al., 2012). The demethylase activity of 
JMJD3 at some bivalent loci is important for PolII release, which allows for 
complete transcription elongation (Chen et al., 2012). Targeting the JMJD3 protein 
to a particular locus may be sufficient to remove H3K27me3 marks and promote 
transcription. 
A tNrp1-VP64 fusion protein was used as a positive control to confirm the 
induction of Nrp1 expression in vitro by TALE targeting. As discussed in Chapter 1 
(pp. 40), the level of induction of gene expression by different strategies using VP64 
constructs can vary substantially. Notably, a 100,000 fold induction in target gene 
expression only causes a 5-20 fold enrichment of H3K4me3 (Black et al., 2016). 
However, an ~20x induction of target gene expression is not sufficient to induce 
H3K4me3 enrichment at the gene promoter (Cano-Rodriguez et al., 2016). In this 
chapter, I test the effects of a tNrp1-VP64 fusion on Nrp1 gene expression and 
H3K4me3 enrichment. 
Here, I will describe the generation of a number of Golden Gate subcloning 
vectors containing a variety of DNA modules. Nrp1 was used as a model target gene 
with which to test this system, however, the intention was to translate the validated 
methodology to target the human α-globin locus in humanised mES cells. Therefore, 
this system was optimised in the humanised mES cell line, WTH3, which is used in 
all the transfection experiments described. Vectors were produced containing DNA 
modules whose protein products are designed to modify the presence of methyl 
groups on different histone tails associated with the Nrp1. I will describe the effects 
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6.2 Results 
6.2.1 Generation of a TALE fusion expression vector cloning 
system  
In this section I describe the design and generation of a TALE fusion 
expression vector cloning system (Figure 6.4). The system was based on the Golden 
Gate assembly protocols and plasmids used to generate TALE array constructs in 
Cermak et al. (2011). To generate an expression vector into which a promoter, a 
TALE array and a gene of interest (GOI) could be cloned, I first modified the pTal2 
vector (Cermak et al., 2011). I cloned additional BsmBI Golden Gate restriction sites 
into pTal2 to facilitate the addition of a promoter and GOI into this vector by the 
Golden Gate methodology. I also inserted a CMV-mTagBFP-polyA cassette, to 
allow for the identification of transfected cells by fluorescent microscopy, and a 
poly-A signal downstream of the entry site for the GOI. The final ampicillin resistant 
expression vector, pTALE-Fusion-Expression vector (pTFE) was used in Golden 
Gate restriction reactions (Figure 6.2B, Figure 6.4A).  
I then generated kanamycin resistant subcloning vectors that were used in 
Golden Gate reactions that contained the GOI tagged with 3xFLAG, and the 
promoter of choice. The epigenetic editing genes used in these TALE fusions were 
first cloned into pUC19 vectors (Figure 6.4B). Two kanamycin resistant cloning 
vectors, pKanR-MCS (pStb205 and pGreen) were then equipped as GOI entry vectors 
(pKanR-MCS-3xFLAG-GG) by the cloning of additional restriction sites and a 
3xFLAG sequence (Figure 6.4C). The sequences encoding the epigenetic editing 
enzymes were then subcloned into one of the pKanR-MCS-3xFLAG-GG vectors to 
generate kanamycin resistant vectors appropriate for Golden Gate assembly (Figure 
6.4D). A phosphoglycerate kinase (PGK) promoter was also inserted into the 
kanamycin resistant vector, pGreen, with the addition of appropriate Golden Gate 
restriction sites (Figure 6.4E). The TALE array plasmids were then assembled 
(Figure 6.4F) as described previously (Cermak et al., 2011). 
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Figure 6.4 Schematic showing cloning steps for generating expression plasmids 
for fusing epigenetic editing genes of interest (GOI) to site-specific TALE 
arrays. Plasmid construct groups shown in blue text were cloned in this study. Green 
boxes indicate the constructs used in the final Golden Gate assembly reactions to 
generate the TALE fusion expression vectors (orange box) used in transfections later 
in this chapter. The details of the cloning scheme (A-G) are described in the text 
(section 6.2.1). The pTal2 plasmid and the TALE Assembly plasmid kit (Cermak et 
al., 2011) were received as a gift from Dr. Peter Hohenstein (University of 
Edinburgh). The pKanR-MCS plasmids pStb205 and pGreen were received as a gift 
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Finally, the completed fusion expression vectors were assembled (Figure 
6.4G). This was achieved by the ligation of BsmBI digested Golden Gate subcloning 
vectors (green boxes in Figure 6.4). These vectors contained a TALE array designed 
to target the Nrp1 promoter fused to a GOI-3xFLAG under the control of a promoter 
of choice. 
 
6.2.1.1 Cloning epigenetic editing genes from cDNA into pUC19 vectors  
Three genes were cloned from WTH mES cell cDNA libraries using the scheme 
outlined in Figure 6.5. Primers were designed to amplify the full-length mouse 
coding region of Rbbp5 (1,617 bp) and Ezh2 (2,241 bp). Primers were also designed 
to amplify the C-terminal coding region of mouse Jmjd3 (1,467 bp), including the 
sequences that encode the amino acid regions (1130-1641) required for catalytic 
activity (Kruidenier et al., 2012). The fragments of interest were isolated after 
separation on an agarose gel and phosphorylated using T4 PNK. The pUC19 vector 
was linearised by digestion with the blunt end restriction enzyme SmaI and 
dephosphorylated with CIP. The purified insert fragments were then ligated into a 
purified vector fragment. Ligated products were transformed into chemically 
competent E. coli and successful cloning of resulting plasmids (Figure 6.6A) was 
confirmed by restriction enzyme pattern analysis with EcoRI and HindIII (Figure 
6.6B). The entire cloned fragment was sequenced using Sanger technology and 
although a number of SNPs were identified in the cloned Rbbp5 and Jmjd3 fragments 
no non-synonymous SNPs were identified in any of the cloned genes (Table 6.1). 
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Table 6.1 SNPs identified within cloned genes. SNPs were identified in the Rbbp5 
and Jmjd3 genes cloned from WTH3 mES cells by comparison of Sanger sequencing 
data from cloned vectors to the published reference sequence for mouse on NCBI. 
All SNPs identified were previously annotated in dbSNP (NCBI) and are 
synonymous mutations that do not change the identity of the amino acid residue. No 
SNPs were detected in the cloned Ezh2 sequence.  
 
  
Gene$$ SNP$ refSNP$ NCBI$ref$seq$WTH$cDNA$seq$ Residue$change$
RBBP5$$ 1" rs31916079" A" G" Gly"."Gly"
$ 2" rs6350018" G"" C" Ser"."Ser"
$ 3" rs3700112" A" G" Lys"."Lys"
$ 4" rs32724155" T" C" His"."His"
JMJD3$ 1" rs13467325" A" G" Val"."Val"
 







































Figure 6.5 Schematic showing steps for cloning epigenetic editing genes.  
A. Genes of interest (GOI; Rbbp5, Ezh2 and Jmjd3) were amplified by PCR from 
cDNA libraries prepared using WTH mES cell RNA as a template. Gene fragments 
were isolated and purified on agarose gels and then phosphorylated with T4 PNK. 
B. The pUC19 cloning vector was linearised by digestion with SmaI. The vector was 
then isolated and purified on an agarose gel and dephosphorylated with CIP.  
C. The GOI and vector fragments were purified, quantified, ligated and then 
transformed into E. coli. Plasmids were isolated from E. coli colonies and screened 
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Figure 6.6 Cloning epigenetic editing genes from cDNA into pUC19. 
A. Plasmid maps of (i) pUC19-RBBP5, (ii) pUC19-JMJD3 and (iii) pUC19-EZH2. 
B. Agarose gel images showing restriction digestion with EcoRI/HindIII of three 
plasmids confirming cDNA from epigenetic editing genes has been successfully 
cloned into the pUC19 vector. The expected restriction digestion patterns are shown.   
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6.2.1.2 Generation of FLAG-tagged subcloning vectors 
TALE fusion constructs were generated using a modified protocol from 
Cermak et al. (2011), which employs Golden Gate cloning using plasmids with 
counter selective antibiotic resistant cassettes to increase screening efficiency. Here, 
I modified two available plasmids to generate vectors that included 3xFLAG tags 
followed by a TAA stop codon and additional restriction enzyme sites (Figure 6.7A). 
These plasmids harbour cassettes that confer kanamycin resistance to bacteria, which 
can be counter-selected against the ampicillin-resistant phenotypes of pTal2-
containing bacteria. To generate these plasmids, complementary single-stranded 
oligonucleotides containing the 3xFLAG cassette were synthesised (Sigma), 
annealed and digested with the restriction enzymes XbaI and NotI. The digested 
fragment was ligated with the pStb205 and pGreen vectors, which were also digested 
with XbaI and NotI and dephosphorylated with the enzyme rSAP (Figure 6.7A). 
These ligation reactions were transformed into chemically competent E. coli and 
plated on LB/agar supplemented with kanamycin. The successful cloning of the 
resulting plasmids, pStb205_3xFLAG and pGreen_3xFLAG (Figure 6.7B ii and iv) 
was confirmed by digestion with restriction enzyme BsmBI (Figure 6.7C) and Sanger 
sequencing (data not shown).  
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Figure 6.7 Cloning 3x FLAG into KanR vectors to generate KanR Golden Gate 
subcloning vectors for epitope tagging genes of interest. 
A. Cloning strategy to generate KanR subcloning vectors including a 3xFLAG tag 
and additional restriction sites. A synthesised oligonucleotide containing restriction 
sites and a 3xFLAG tag was cloned into two KanR vectors; pStb205 and pGreen.  
B. Plasmid maps of (i) pStb205, (ii) pStb205_3xFLAG, (iii) pGreen and (iv) 
pGreen_3xFLAG.  
C. Gel image showing restriction digestion with BsmBI of plasmids in B confirming 
the expected digestion patterns of the 3xFLAG-containing plasmids was observed. 
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6.2.1.3 Generation of a subcloning vector containing the PGK promoter 
The PGK constitutive promoter was also cloned into the kanamycin resistant 
vector, pGreen, using a similar strategy to that shown in (Figure 6.7A). Briefly, 
primers were designed to amplify the PGK promoter from pAAT:PGK:PB:Puro-
delta-TK (Yusa et al., 2011) and include additional restriction sites. The PCR product 
was purified and phosphorylated with the enzyme T4 PNK. The pGreen vector was 
digested with NotI and XbaI and the resulting linearised vector was dephosphorylated 
with the enzyme rSAP. The concentrations of the purified vector and insert 
fragments were quantified on an agarose gel and ligated overnight. Ligated products 
were transformed into chemically competent E. coli and plated on LB/agar 
supplemented with kanamycin. Resulting colonies were screened by colony PCR 
(data not shown) and correct cloning of the pGreen-PGK vector (Figure 6.8A) was 
confirmed by restriction digestion with BsmBI (Figure 6.8B) and Sanger sequencing 
(data not shown). Although a BsmBI site is located within the PGK promoter this site 
generates overhangs that are not compatible with any of the overhangs designed for 
Golden Gate cloning in this cloning strategy (see Appendix, pp. 249). As such, the 
PGK promoter will be digested by BsmBI but this site should reconstitute itself 
following ligation.  
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Figure 6.8 Cloning the PGK promoter into KanR vectors to generate a KanR 
Golden Gate subcloning vector. 
A. Plasmid map of pGreen-PGK. 
B. Gel image showing restriction digestion of pGreen-PGK with BsmBI confirming 
the PGK promoter was successfully cloned. The expected restriction digestion 
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6.2.1.4 Cloning epigenetic editing genes and promoter into Golden 
Gate subcloning vectors  
In order to generate GOI subcloning vectors that could be used in Golden 
Gate restriction reactions, the GOIs were cloned into the KanR-3xFLAG vectors in a 
manner that generated additional Golden Gate restriction sites. The epigenetic editing 
genes Rbbp5, Ezh2 and Jmjd3 were cloned from pUC19 vectors (Figure 6.6A) into 
kanamycin resistant subcloning vectors, pStb205_3xFlag or pGreen_3xFlag (Figure 
6.7Bii and iv, respectively) using the strategy outlined in Figure 6.9. Briefly, primers 
were designed that included additional restriction digest sites to amplify the genes of 
interest. Following amplification, the PCR products were digested with the 
restriction enzymes EcoRI and XbaI. The digested products were isolated from an 
agarose gel and phosphorylated with the enzyme T4 PNK. The pStb205_3xFlag 
vector was also digested with EcoRI and XbaI and was dephosphorylated using the 
enzyme rSAP. The insert and vector fragments were purified and ligated overnight. 
The ligation reactions were transformed into chemically competent E. coli and plated 
on LB/agar supplemented with kanamycin. The resulting colonies were screened by 
PCR (data not shown) and the successful cloning was confirmed by restriction 
digestion with BsmBI (Figure 6.10B) and Sanger sequencing (data not shown).  
This strategy proved successful in cloning the plasmids 
pStb205_RBBP5_3xFlag and pStb205_EZH2_3xFlag (Figure 6.10Ai and iii). 
However, no clones were isolated containing the complete, correctly orientated 
Jmjd3 sequence from pUC19-JMJD3. The same cloning strategy (Figure 6.9) was 
used to clone Jmjd3 into the pGreen_3xFlag vector, which did not contain Gateway 
recombination sites. This generated the plasmid pGreen_JMJD3_3xFlag (Figure 
6.10Aii), which was confirmed to be correct by restriction digestion with BsmBI 
(Figure 6.10B) and Sanger sequencing (data not shown).  
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Figure 6.9 Cloning strategy to generate KanR subcloning vectors including a 
gene of interest (GOI) fused to 3xFLAG tag.  
The genes of interest were amplified by PCR from plasmids using primers that 
contained additional restriction sites. The resulting PCR products were cloned into a 
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Figure 6.10 Cloning epigenetic editing genes into pKanR-3xFLAG. 
A. Plasmid maps showing KanR subcloning vectors including a gene of interest, (i) 
Rbbp5, (ii) Jmjd3 or (iii) Ezh2, a 3xFLAG tag and additional restriction sites.  
B. Gel image showing restriction digestion with BsmBI of KanR subcloning vectors 
pStb205-RBBP5-3xFLAG, pGreen-JMJD3-3xFLAG and pStb205-EZH2-3xFLAG 
(lane 2, 3 and 4, respectively), confirming the gene cassette was successfully cloned. 
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6.2.1.5 Generation of Nrp1 TALE fusion vectors 
TALE fusions constructs were generated by Golden Gate cloning using a 
modified protocol and plasmids from the Voytas Lab (Cermak et al., 2011). The 
pTAL2 vector (Cermak et al., 2011) contained one single set of BsmBI Golden Gate 
restriction sites flanking a LacZ gene and flanked by the TAL N- and C- terminal 
domains. This vector was designed to fuse TALE arrays and contains Gateway 
cloning sites flanking the TAL N- and C- terminal domains to allow subcloning of 
the TALE array into an expression vector.  
To circumvent this final subcloning step, pTAL2 was modified to generate a 
TALE fusion expression vector, pTFE (Figure 6.11A) which would serve as a 
Golden Gate entry vector for inserts containing a promoter, TALE array and fusion 
domain of any design. The destination vector, pTFE, also contained a CMV-
mTagBFP (BFP) expression cassette and ampicillin resistance gene. The sequences 
adjacent to the BsmBI restriction sites for each insertion-destination site were 
designed to generate unique overhangs (coloured boxes in Figure 6.11A). These 
unique overhangs in the pTFE destination vector were only compatible with the 
BsmBI overhangs in the appropriate subcloning vector (Appendix B, pp. 249). This 
allows for the orderly assembly of a promoter, TALE array and tagged gene of 
interest in an expression vector in a single ligation reaction.  
To test the TALE fusion system, a panel of fusion constructs including a 
TALE array targeting the bivalent promoter of Nrp1 (tNrp1) were generated. In these 
constructs, tNrp1 was designed to fuse with a 3x FLAG tagged Rbbp5, Jmjd3 and 
Ezh2, or a TALE-Only-A negative control (Figure 6.11B). The Nrp1-TALE arrays 
were designed to target the same Nrp1 promoter sequence as a previously published 
set of TALEs, which were shown to efficiently target the Nrp1 promoter (Therizols 
et al., 2014).  
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Figure 6.11 Generation of TALE fusions.  
A. Cloning strategy for fusing promoter, TALE array and gene of interest (GOI) 
tagged with 3xFLAG into modified TALE Fusion Expression Vector, pTFE. All 
plasmids are digested with an excess of BsmBI and then ligated at equimolar 
concentrations before transforming into chemically competent E-coli and expanding 
on ampicillin LB/agarose plates. The use of counterselective antibiotic resistant 
cassettes decreases the number of background colonies during cloning. 
B. Schematic showing the TALE Array fusions generated in this study. TALE arrays, 
which were designed to target the Nrp1 promoter, were fused to full-length cDNA of 
Rbbp5 (TALE-RBBP5_FL), the catalytic c-terminus of Jmjd3 cDNA (TALE-
JMJD3_ΔN) and the full-length cDNA of Ezh2 (TALE-EZH2_FL). All of these 
fusions, including a TALE-Only negative control (TALE-Only-A) were tagged with 
a 3xFLAG tag. TAL-N, TAL N-terminus; TAL-C, TAL-C terminus; NLS, nuclear 
localisation signal; 3xFLAG, three times FLAG epitope tag; βP, beta propeller 
region; Hinge, WI, WDR5 interaction motif; JmjC, Jumonji-C domain (catalytic 
domain); αH, alpha helical domain; GATAL, a DNA binding domain which interacts 
with a G-A-T-A DNA motif; SANT, SANT domain for protein-histone interactions; 
CXC, a DNA binding domain which interacts with a C-X-C DNA motif; SET; 
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Briefly, all the plasmids required in cloning the final TALE fusion constructs 
were digested with an excess of restriction enzyme BsmBI and ligated to achieve the 
desired final construct. Ligated products were transformed into chemically 
competent E. coli and plated on LB/agar supplemented with ampicillin. This ensured 
that none of the subcloning vectors, which were either kanamycin or spectinomycin 
resistant, would be able to expand under ampicillin selection. Resulting colonies 
were screened by PCR (data not shown) and confirmed by restriction digestion with 
BsmBI and Sanger sequencing. 
Firstly, Golden Gate reactions were performed as described above to insert 
either PGK or the Nrp1 TALE array (tNrp1) into pTFE to generate the plasmids 
pPGK-TFE and pTFE-tNrp1 (Figure 6.12). These three vectors could then be used in 
further Golden Gate reactions to generate the final fusion vectors (Figure 6.13), 
pPGK-tNrp1-GOI-3xFLAG with either Rbbp5, Jmjd3, Ezh2, or the TALE-Only-A  
negative control. The cloning efficiency of the 3xFlag tagged gene of interest was 
approximately 60%, however, the insertion efficiency of the PGK promoter was 
much lower at 1-6%, possibly due to the high GC content of the PGK promoter. The 
sequence of the final fusion constructs pPGK-tNrp1-RBBP5-3xFlag, pPGK-tNrp1-
JMJD3-3xFlag, pPGK-tNrp1-EZH2-3xFlag and pPGK-tNrp1-3xFlag was confirmed 
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Figure 6.12 TALE fusion expression plasmid and subcloning vectors. 
A. Plasmid maps showing (i) pTALE-Fusion-Expression (pTFE) and subcloning 
vectors (ii) pPGK-TFE and (iii) pTFE-tNrp1.  
B. Gel image showing restriction digestion with BsmBI of pTFE, pPGK-TFE and 
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Figure 6.13 Cloning final Nrp1 TALE fusion plasmids 
A. Plasmid maps showing final TALE fusion plasmids including the PGK promoter, 
tNrp1 and a gene of interest tagged with 3xFLAG are shown (i-iii). A negative 
control TALE fusion containing the PGK promoter, tNrp1 tagged with 3xFLAG 
(also here called TALE-Only-A) is also shown (iv). 
B. Gel image showing restriction digestion with BsmBI of final TALE fusion 
plasmids confirming successful cloning. The expected restriction digestion pattern is 
shown. An unexpected band of >8 kb was detected in digestions of final fusion 
plasmids containing Jmjd3 and Ezh2, possibly due to incomplete plasmid digestion, 
but these clones were confirmed by Sanger sequencing and determined to be 
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6.2.2 Effects of tNrp1 TALE fusions on Nrp1 gene expression 
6.2.2.1 Transfection strategy and validation of construct expression 
In this section, I describe the strategy used to test the ability of tNrp1 TALE 
fusions to modify Nrp1 expression and histone methylation marks in vitro (Figure 
6.14A). Firstly, the fusion constructs were transfected into WTH3 mES cells and 
positively transfected cells were isolated 24 h after transfection by FACS. A time 
course experiment was performed during which positively transfected cells were 
harvested for analysis 24-96 h after transfection. The four tNrp1 fusion constructs 
generated in this thesis (Figure 6.13A) were tested using this strategy alongside two 
published control tNrp1 fusions (Therizols et al., 2014). The tNrp1 fusions included 
tNrp1-VP64 (a TALE targeting the Nrp1 promoter with VP64) as a positive control 
and tNrp1-Δ (also here called TALE-Only-B), as a negative control. These control 
fusions contain a 2A-eGFP cassette and also contain a 3xFLAG tag.  
To confirm the expression of TALE fusion proteins, WTH3 mES cells were 
lipofected with each of the TALE fusion contructs, together with a negative vehicle 
control (Lipofectamine reagent mixed with OptiMEM and TE only). The bulk, 
unsorted population was harvested 24 h later and lysed for protein analysis. A 
western blot was performed with the cell lysates using a FLAG antibody. A β-actin 
antibody was used as a loading control (Figure 6.14B). The western blot confirmed 
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Figure 6.14 Experimental strategy and TALE fusion construct expression. 
A. Experimental strategy for TALE fusion transfection experiments. WTH3 
humanised mES cells were transfected with TALE fusion plasmids (Time: 0 h). 
Approximately 24 h later, transfected cells were harvested. Positive cells were 
isolated by FACS and either processed for downstream analysis (RNA, ChIP) or 
maintained in culture until a later time point. Cells maintained in culture were 
harvested and processed for downstream analysis at approximately 24 h time points 
up to 96 h post-transfection.  
B. WTH3 cells transfected with TALE fusion vectors and a vehicle control were 
harvested (unsorted) 24 h after transfection. A western blot was performed on cell 
lysates using a FLAG antibody confirming construct expression. Expected protein 
sizes of TALE fusions are shown on the right. A β-actin loading control showed 











Lane %Sample % % % %3x%FLAG%(kDa)%
1.  """pPGK<tNrp1<RBBP5<3xFLAG " "175"
2.  """pPGK<tNrp1<EZH2<3xFLAG " "201"
3.  """pPGK<tNrp1<JMJD3<3xFLAG " "171"
4.  """pPGK<tNrp1<3xFLAG " " "116"
5.  """pCAG<3xFLAG<tNrp1<VP64 " "84"
6.  """pCAG<3xFLAG<tNrp1 " " "78"
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For RNA and chromatin analysis, 4-7 wells in 6 well plates were lipofected 
with each plasmid sample and only positively transfected cells (isolated by FACS) 
were analysed in an effort to amplify any detected change in signal due to expression 
of the TALE fusions. First, live cells were gated in P1 (Figure 6.15) and either BFP 
or GFP positive cells were isolated (Figure 6.15A and B) from the unstained cell 
populations (Figure 6.15C). Overall, transfection efficiencies of plasmids containing 
the BFP marker were lower (<20% of live cells) than those containing the GFP 
marker (20-70% of live cells) (Figure 6.16A). Notably, the cell death following 
FACS was extremely high (~65-95%) in all experiments (Figure 6.16B). Following 
FACS in independent biological replicates 1-3, the total number of positively 
transfected cells in each sample was split between a number of different wells for 
harvesting at different time points. In an attempt to reduce cell death, in replicate 4 
and 5 the same number of positively transfected cells for each sample was plated at a 
higher density in 96 or 24 well plates. However, cell recovery still remained low in 
replicate 4 and 5  (Figure 6.16B).  
Following FACS, only cells positive for fluorescence were re-plated for 
harvesting at later time points. Despite being positive for fluorescence at the time of 
FACS, mES cells in all samples began losing fluorescence even 24 h after FACS 
(Figure 6.17). At 96 h after FACS very few fluorescent mES cells can be detected by 
fluorescent microscopy in positively transfected samples (Figure 6.18). In a similar 
transfection experiment of Plat-E cells (a modified HEK293T cell line) using the 
same plasmids, expression of the fluorescent proteins was maintained at very high 
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Figure 6.15 Gating strategy in TALE fusion experiments. 
Representative examples of the gating strategy used during FACS are shown here. In 
all cases, live cells were gated excluding doublets and cell debris (P1). Cells 
positively expressing BFP (A) or GFP (B) were collected and used for downstream 
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Figure 6.16 Transfection efficiency and cell death in TALE fusion experiments 
A. Graph plotting transfection efficiencies of TALE fusion plasmids in independent 
biological replicates as determined by FACS data. TALE fusion plasmids containing 
a BFP marker transfected at lower efficiencies compared to those containing a GFP 
marker. However, there was a higher degree of variance between transfection 
efficiencies in biological replicates of plasmids containing a GFP marker vs. those 
containing a BFP marker.  
B. Graph plotting the average estimated cell recovery 24 h after FACS in each 
biological replicate of transfection experiments. Cell recovery was estimated based 
on the number of cells collected by FACS, the number of cells harvested at a time 
point at least ~24 h following FACS and the average time of mES cell duplication. 
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Figure 6.17 Fluorescent microscopy images of tNrp1 fusion plasmid transfected 
cells at 48 h post transfection. 
Representative images (A-C) from tNrp1 fusion plasmid transfection experiments 
showing transfected cells from replicate 5 in 96 well plates 24 h following FACS. 
Fluorescent images (B-C) show that only a proportion of cells maintain fluorescence 
after FACS. The images were taken using a Zeiss axiovert 25s inverted microscope 
at 10x magnification using a DAPI filter to detect BFP fluorescence and a FITC filter 
to detect GFP fluorescence. The merge images were generated using the ImageJ 
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Figure 6.18 Fluorescent microscopy images of tNrp1 fusion plasmid transfected 
cells at 96 h post transfection. 
Representative images (A-C) from tNrp1 fusion plasmid transfection experiments 
showing transfected cells from replicate 4 in 24 well plates 96 h following 
transfection. Fluorescent images (B-C) show that the majority of cells completely 
lose fluorescence 96 h after transfection. The images were taken using a Zeiss 
axiovert 25s inverted microscope at 10x magnification using a DAPI filter to detect 
BFP fluorescence and a FITC filter to detect GFP fluorescence. The merge images 
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6.2.2.2 Monitoring changes in Nrp1 expression following the 
transfection of vectors containing TALE fusions 
WTH3 mES cells lipofected with TALE fusion plasmids were harvested 
between 24 and 96 h after transfection. Although reporter expression was low at 96 h 
post transfection, the time course was extended to this point for certain vectors to see 
if there was a latent effect of TALE fusion expression on Nrp1 transcription. RNA 
was isolated from harvested samples and reverse transcribed to produce cDNA 
templates that were then analysed by qPCR (Taqman). The relative expression of 
Nrp1/Gapdh for each transfection was normalised to the mean of the vehicle control 
at each time point (Figure 6.19).  
Nrp1 expression was at least ten times higher in the tNrp1-VP64 fusion 
transfected samples relative to the TALE-only B control at both 24 and 48 h post-
transfection (Figure 6.19A, Figure 6.20A). However, Nrp1 expression was highly 
variable in samples transfected with tNrp1-VP64 at 72 and 96 h (Figure 6.19A).  
Interestingly, Nrp1 expression was moderately higher in cells transfected 
with the tNrp1-JMJD3 fusion relative to the negative TALE-Only-A control at 96 h 
post- transfection (Figure 6.19B, Figure 6.20B). Nrp1 expression was similar in cells 
transfected with the tNrp1-EZH2 and -RBBP5 fusions relative to the TALE-Only A 
control at every time point analysed (Figure 6.19B). 
  
 
Chapter Six: Epigenetic Editing to Manipulate Bivalent Histone Modifications  192 
 
 
Figure 6.19 RT-qPCR analysis of Nrp1 expression in transfected cells.  
Dot plots A and B depict the changes in relative enrichment of Nrp1/Gapdh at 24-96 
h post-transfection for each of the TALE fusion transfection samples. Each point 
represents expression changes from each of the 2-5 paired independent biological 
replicates performed for each transfection. A ‘*’ indicates a statistically significant 
difference (p > 0.05) was observed between two samples.  
A. The relative enrichment of Nrp1/Gapdh in the positive control tNrp1-VP64, 
negative control TALE-Only-B and vehicle control samples. The error bars represent 
standard deviation from the mean.  
B. The relative enrichment of Nrp1/Gapdh in samples tNrp1-RBBP5, -JMJD3 and –
EZH2, and the negative control TALE-Only-A and vehicle control samples. The 
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Figure 6.20 Nrp1 expression in cells transfected with JMJD3 and VP64 tNrp1 
fusions. 
A. Bar chart plotting RT-qPCR data showing Nrp1 expression relative to Gapdh at 
24 and 48 h post transfection. Error bars indicate standard deviation over three 
independent biological replicates. A ‘*’ indicates a statistically significant difference 
was observed between two samples using a paired two tailed students T-test. Nrp1 
expression is elevated in cells transfected with the VP64-tNrp1 fusion relative to the 
TALE-Only-B negative control. 
B. Bar chart plotting RT-qPCR data showing Nrp1 expression relative to Gapdh at 
96 h post transfection. Error bars indicate standard error of the mean over four 
independent biological replicates. Nrp1 expression is elevated in cells transfected 
with the JMJD3-tNrp1 fusion relative to the TALE-Only-A negative control. A ‘*’ 
indicates a statistically significant difference was observed between two samples 
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6.2.3 Effects of tNrp1 TALE fusions on bivalent histone 
modifications at Nrp1 promoter 
As statistically significant increases in Nrp1 gene expression were detected in 
samples transfected with tNrp1-VP64 at 24 h and tNrp1-JMJD3 at 96 h, ChIP-qPCR 
analysis was performed on these samples, and the appropriate TALE-Only negative 
controls, at these time points. Three independent biological replicates of lipofection, 
FACS and harvesting of the tNrp1-VP64 and tNrp1-JMJD3 constructs and the 
TALE-Only-A and -B controls were performed, each on 6 wells of WTH3 mES 
cells. The ChIP for each independent biological replicate was also performed on 
independent days. The ChIP was performed on all samples using antibodies against 
the histone modifications, H3K4me3 and H3K27me3. ChIP-qPCR (SYBR Green) 
amplicons were designed to target a number of positions along the Nrp1 genomic 
locus (shown as orange arrows in Figure 6.3A). The expected results, based on 
analysis of ChIP-seq data from the “Bruce-4” mES cell line on the UCSC genome 
browser (Figure 6.3A), are listed in Table 6.2.  
 
Table 6.2 Expected results from ChIP qPCRs using antibodies for bivalent 
histone modifications, H3K4me3 and H3K27me3. The locations of the Nrp1 
amplicons are indicated as numbered orange arrows in the UCSC ChIP seq data plot 
in Figure 6.3A. Primer set 1 is 4.8 kb upstream of the Nrp1 start codon and set 2 is 
98 bp upstream from the tNrp1 binding site at the Nrp1 promoter. Expected results 
are based on published ChIP-seq data (UCSC). Negative control amplicons (5` 
mouse α-globin, 3` mouse α-globin and Gapdh) for both antibodies were also used to 
estimate background signal.  
 
 
Modifica(on* 1.*Nrp1*UpA*2.*Nrp1*UpB* 3.*Nrp1*ex2*4.*Nrp1*ex4* β9Ac(n*CpG* Gata6*
H3K4me3* None% Medium% %None% None% High% Medium%
H3K27me3* Low% Medium% %Low% Low% None% Medium%
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Figure 6.21 ChIP-qPCR Data from tNrp1 fusion transfections. 
A. Graph plotting H3K4me3 enrichment as a percentage of input chromatin for 3 
independent biological replicates did not show any significant difference increase 
between H3K4me3 levels in JMJD3-tNrp1 vs. TALE-Only-A samples harvested at 
96 h post-transfection.  
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The TALE fusion tNrp1-JMJD3 was expected to reduce the levels of 
H3K27me3 at the Nrp1 promoter (Nrp1 UpB) and the increase in expression of Nrp1 
suggested that H3K4me3 levels may be increased at the promoter. However, no 
change in H3K4me3 at the Nrp1 promoter was detected in tNrp1-JMJD3 treated cells 
relative to the TALE-Only-A negative control (Figure 6.21A). ChIP-qPCR analysis 
was performed on all samples from the H3K27me3 ChIP on tNrp1-JMJD3 and 
TALE-Only-A control samples, however, qPCR amplification was only detected 
from the IP samples from one out of the three biological replicates although 
amplification from the input samples was comparable to other experiments. In this 
sample there is no detectable decrease in H3K27me3 at the Nrp1 promoter in the 
tNrp1-JMJD3 treated sample vs. the TALE-Only-A Control (Figure 6.21B). 
However, it is important to note that detected H3K27me3 levels in the tNrp1-JMJD3 
sample are higher at all the amplicons tested compared to the TALE-Only-A control 
(Figure 6.21B). No significant change was detected in H3K4me3 levels between the 
tNrp1-VP64 and TALE-Only-B samples (Figure 6.21C). 
 
Figure 6.21 Legend continued: 
B. Graph plotting H3K27me3 enrichment as a percentage of input chromatin for one 
biological replicate did not show any reduction of H3K27me3 levels in JMJD3-tNrp1 
vs. TALE-Only-A samples harvested at 96 h post-transfection. 
C. Graph plotting H3K4me3 enrichment as a percentage of input chromatin for 2 
independent biological replicates did not show any significant difference between 
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6.3 Discussion  
The aim of this chapter was to develop an experimental strategy aimed at 
directly inferring the effects of modifying the identity of the chemical groups 
associated with histone tails. This strategy was developed using a model gene prior 
to interrogating the gene of interest in this thesis, HBA2, in order to identify areas in 
which the experimental design could be improved. Several positive conclusions have 
been reached over the course of this study. Firstly, an efficient cloning system for 
generating TALE fusions was developed and validated. This cloning system 
facilitates the rapid cloning of several modules including TALE arrays, promoters 
and enzymatic domains of interest, among other components. This system, with 
some modifications, will form the backbone of further studies. Secondly, I confirmed 
several published results, such as the induction of Nrp1 by the Nrp1-VP64 fusion 
protein, and extended them by showing that the levels of H3K4me3 do not change 
after transfection of the plasmid harbouring this fusion gene. Thirdly, the expression 
of Nrp1 was elevated in cells transfected with the tNrp1-JMJD3 fusion construct, 
which provides motivation for further investigation using the strategy outlined. Due 
to the initial experimental design, which included numerous positive and negative 
controls, the results obtained have also highlighted areas in which in the 
experimental strategy could be improved. Below, I will discuss the outcomes of these 
experiments and consider ways in which to optimise future experiments. 
A cloning system for construction of TALE fusion expression constructs 
Here, I developed a cloning system for the modular assembly of TALE fusion 
expression constructs, similar to MoClo (Weber et al., 2011) and based on a freely 
available Golden Gate TALE assembly kit (Cermak et al., 2011). Using this strategy, 
promoters of choice and different GOIs may be cloned into separate kanamycin 
resistant vectors. The plasmids are designed such that once the GOIs are cloned into 
the appropriate vector, they are fused at their 3` ends to a 3xFLAG tag, which can be 
used to reliably detect their expression via immunoblotting with a commercially 
available antibody (Figure 6.14B). TALE array entry plasmids can be assembled 
using the protocols outlined in Cermak et al. (2011). These components can then be 
inserted in a predetermined manner into the destination vector, pTFE, by digesting 
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them with an excess of the type IIS restriction enzyme (Figure 6.2B). I demonstrated 
the efficiency and usefulness of this system, which represents a key development of 
this study and will form the basis of future experimental strategies. 
Transfection efficiency of tNrp1 fusions 
The fusion proteins generated in this study were designed to target the 
promoter of Nrp1, a bivalent gene in mES cells, using a validated TALE sequence 
(Therizols et al., 2014). The activator tNrp1-VP64 and negative control tNrp1-Δ 
(Therizols et al., 2014) were used as controls to show that transient transfection of 
the targeted transactivator into WTH3 mES cells could efficiently induce Nrp1 
expression. The expression of the tNrp1 fusion proteins in WTH3 mES cells 
following transfection was confirmed by western blot (Figure 6.14B).  
Unexpectedly, the transfection efficiency (as estimated by FACS) of the 
TALE fusion constructs generated in this chapter was much lower (~10%) than the 
transfection efficiency of the control TALE fusions from the Bickmore lab (~40%; 
Figure 6.16). The TALE fusion constructs from the Bickmore lab were marginally 
smaller (7.3-7.5 kb) than those generated in this chapter (8.1-10.4 kb) which may 
have had an effect on transfection efficiency. The fluorescent marker used in the 
constructs generated in the chapter, mTagBFP (Subach et al., 2008), is comparably 
bright relative to eGFP, the fluorescent marker used in the constructs from the 
Bickmore lab, so one would expect them both to be detected by FACS with the same 
efficiency (Kremers et al., 2011). However, mTagBFP is somewhat less photostable 
than eGFP (Kremers et al., 2011). It is also important to consider that the eGFP gene 
is driven by a CAG promoter in the Bickmore constructs while the mTagBFP gene in 
the constructs generated here is driven by a CMV promoter. The CAG promoter 
drives constitutive and consistently high expression in a number of cell types while 
CMV promoter driven expression can vary widely between different cell types (Qin 
et al., 2010). This may have led to a lower detection rate by FACS of transfection 
efficiency and the use of another promoter may drive higher reporter expression. 
Another method that could have been used to compare transfection efficiency of 
these plasmids independent of fluorescence would have been to normalise the gene 
expression to a region homologous to all the transfected plasmids, such as a region 
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within the TAL N- and C- termini, however this approach was not pursued in this 
study.  
After transfection, the cells that were actively expressing a fluorescent marker 
were sorted by FACS and returned to culture. Fluorescence in the transfected mES 
cells was extremely rare just four days after transfection (Figure 6.18). However, 
Plat-E cells that were transfected with the same constructs maintained fluorescence 
in a high proportion of cells up to 96 h after transfection (data not shown). The Plat-E 
cell line, a modified HEK293T cell line, expresses the Simian virus 40 (SV40) large 
T-antigen which allows for the replication and maintenance of plasmids containing a 
SV40 origin of replication (Dubridge et al., 1987; Morita et al., 2000). However, 
none of the plasmids used in this study contain a SV40 origin of replication. It is thus 
unclear why the expression from these plasmids was maintained in the Plat-E cells 
but completely disappeared in the WTH3 mES cells 96 h after transfection.  
Further improvements of the experimental strategy 
This study has formed the basis to improve and optimise this experimental 
strategy. Methods to improve the low transfection efficiency observed in these 
experiments are discussed in the above section. The high degree of variability 
observed in the expression of Nrp1 following transfection severely limited the ability 
to observe differences between different treatment conditions (Figure 6.19). A 
number of strategies could be attempted to limit this variability, including use of 2i 
media for mES cell culture, removal of the FACS step and generation of stably 
transfected cell lines.  
It is well known that 2i media can reduce the variability of expression of 
genes involved in differentiation in mES cell lines (Guo et al., 2016; Ying et al., 
2008). Two inhibitors, of the FGF receptor tyrosine kinases and the ERK cascade, 
are used in 2i media to enforce a ground state of pluripotency in ES cells (Ying et al., 
2008). Although it has been reported that mES cells cultured in 2i media are harder 
to transfect than those cultured in normal mouse ES media (Tamm et al., 2013), 
recently optimised methods allow highly efficient transfection efficiency of mES 
cells cultured in 2i media (Tamm et al., 2016). Furthermore, the use of 2i medium 
 
Chapter Six: Epigenetic Editing to Manipulate Bivalent Histone Modifications  200 
has been shown to reduce the number of bivalent genes observed in mES cell culture 
(Guo et al., 2016), possibly resolving any observed bivalency that is strictly due to a 
epigenetically heterogeneous cell population rather than true bivalency. The use of 2i 
medium could reduce the rate of heterogeneous Nrp1 expression or histone 
methylation, providing a cleaner background for the study of expression and histone 
methylation changes at Nrp1.  
The use of a different transfection method could also be investigated with the 
view to boost TALE fusion expression rates and duration. The current system I have 
tested in this chapter uses transient transfection to introduce the TALE fusion 
constructs to mES cells, but expression of the fluorescent reporter in these constructs 
is undetectable 96 h after transfection (Figure 6.18). A stable transfection would 
allow sustained expression of the TALE fusion which could be combined with an 
inducible system to control TALE fusion induction in a temporal manner (Cano-
Rodriguez et al., 2016; Kim and Eberwine, 2010). Similarly, the use of multiple 
TALE fusions to ‘tile’ the Nrp1 promoter could have also led to a higher probability 
of affecting the histone methylation status and Nrp1 expression rates (Maeder et al., 
2013b; Mali et al., 2013a; Perez-Pinera et al., 2013). Indeed, the CRISPR/Cas9 
system could be used as an alternative to quickly generate many sgRNAs that target 
a gene promoter to attract multiple copies of a dCas9 fusion protein (Hilton et al., 
2015).  
Extremely low rates of cell recovery were observed following FACS of 
transfected WTH3 mES cells in this chapter (Figure 6.16B) and similarly high rates 
of apoptosis following FACS of mES cells has been reported previously (Fukuda et 
al., 2006). High rates of cell apoptosis may have negative effects on the health of 
surviving cells and induce changes in gene expression or spontaneous differentiation. 
To avoid the necessity of FACS in expression studies following transfection, the 
expression values of the target gene could be normalised to a sequence homologous 
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Effects of tNrp1 fusion on gene expression and histone modifications 
The effects of expressing tNrp1 fused to the enzymatic domains of RBBP5, 
EZH2 and JMJD3 was tested by qRT-PCR and ChIP-qPCR. The expression of Nrp1 
alone was increased 96 h post-transfection, relative to negative controls, only with 
the vector containing tNrp1-JMJD3. Notably, Nrp1 expression was increased in 
samples transfected with TALE-Only-A (a TALE-Only construct generated in this 
chapter) and -B (a TALE-Only construct generated in Therizols et al. (2014)) relative 
to the vehicle control. This increase is explained by the presence of activation 
domains in the C-termini of naturally occurring and synthetic TALEs, which can 
induce expression of a gene when targeted to a promoter (Cermak et al., 2011; 
Streubel et al., 2017). Notably, the tNrp1-RBBP5 and -EZH2 fusions, which are 
larger than the tNrp1-JMJD3 fusion (Figure 6.14B) did not induce Nrp1 expression. 
Given that the C-terminal end of JMJD3 confers a demethylase activity (Kruidenier 
et al., 2012), this result suggested that the increased expression observed was due to 
reduced levels of H3K27me3 at the Nrp1 locus. 
To test this, I performed ChIP-qPCR using an antibody that recognizes 
H3K27me3. Unfortunately, only one biological replicate of the H3K27me3 was 
successful and indicated that there was no decrease in H3K27me3 upon expression 
of tNrp1-JMJD3 (Figure 6.21). It is possible that the ChIP-qPCR was not sensitive 
enough or was somehow compromised. Indeed, it is suspicious that only two of the 
three IP samples from the ChIP replicates produced a detectable signal. It is also 
concerning that large differences were observed in H3K27me3 enrichment at the 
control genes between the tNrp1-JMJD3 and TALE-Only-A samples. I also 
performed a ChIP using an antibody that recognizes H3K4me3 in order to correlate 
any putative changes in methylation status at this histone tail with increases in 
expression associated with tNrp1-JMJD3 activity. Although all three biological 
replicates were successfully performed using this antibody, no changes in H3K4me3 
status were observed. This is perhaps not a surprising result given that little or no 
effect on global gene expression levels are observed when global changes to 
H3K4me3 enrichment are induced (Clouaire et al., 2012; Hormanseder et al., 2017; 
Lenstra et al., 2011; Muramoto et al., 2010). 
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Certain reports have shown that removal of H3K27me3 by JMJD3 can 
facilitate the induction of transcriptional elongation (Chen et al., 2012; Estarás et al., 
2013) or the loss of a transcriptionally repressed state over time (Coleman and 
Struhl, 2017). This would suggest that a loss in the H3K27me3 mark would occur 
before an increase in gene expression. In order to more completely understand the 
observed changes in expression, it would be desirable to repeat the H3K27me3 ChIP 
over a time-course to test whether Nrp1 expression changes are correlated with 
changes in H3K27me3 enrichment. It is also possible that the increase observed in 
transcription of Nrp1 following tNrp1-JMJD3 treatment was caused by a 
demethylase-independent function of JMJD3. It has been shown that JMJD3 also 
plays a role in activating gene transcription through chromatin remodelling (Miller et 
al., 2010). To test if the increase in Nrp1 expression is independent of the 
demethylase capability of JMJD3, the effect of a tNrp1 fusion protein containing a 
catalytically inactive form of JMJD3 on Nrp1 expression could be examined.  
A central issue, which this study partly attempts to address, is whether 
histone status truly reflects or affects gene expression levels and vice versa. It has 
been reported that large increases in H3K4me3 at particular gene promoters only 
induce very small changes in gene expression (Cano-Rodriguez et al., 2016). These 
findings were reflected in this study by the lack of change in H3K4me3 status upon 
high levels of Nrp1 induction by tNrp1-VP64, (Figure 6.19A, Figure 6.21A). It has 
also been shown that just a 15-fold increase in H3K4me3 enrichment at the human α-
globin genes in hES cells vs. erythroid cells corresponds to a 30-40,000 times 
increase in α-globin gene expression (De Gobbi et al., 2011). However, as discussed 
in Chapter 1 (pp. 2), several lines of evidence have suggested that H3K4me3 may not 
be instructive of changes in gene expression, but may instead be more important in 
maintaining a memory of a transcriptional state (Clouaire et al., 2012; Hormanseder 
et al., 2017; Howe et al., 2017; Lenstra et al., 2011; Muramoto et al., 2010).  
Nrp1 expression was unchanged after the transfection of cells with TALE 
fusions to RBBP5 or EZH2, which were hypothesized to stimulate H3K4me3 and 
H3K27me3 deposition, respectively (see section 6.1). However, it is important to 
note that previous reports suggest the targeting of multiple fusions along a DNA 
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sequence can improve the effects of these fusions on gene expression (Maeder et al., 
2013b; Mali et al., 2013a; Perez-Pinera et al., 2013). It is possible that the tiling of 
the Nrp1 promoter with multiple tNrp1-RBBP5 and –EZH2 fusions is required for a 
detectable effect on Nrp1 gene expression. Indeed, a recent report showed that co-
expression of three sgRNAs tiling a promoter and a dCas9-EZH2 fusion is sufficient 
to induce a 9-fold enrichment of H3K27me3 at that promoter (O’Geen et al., 2017). 
To more completely understand the performance of the tNrp1-RBBP5/EZH2 vectors, 
tiling experiments of the Nrp1 promoter with these fusions should be performed. 
Both qPCR and ChIP-qPCRs should then be performed to assess the levels of Nrp1 
induction and H3K27me3 and H3K4me3 at the Nrp1 locus. Furthermore, ChIP-
qPCR should be performed to assay the presence or absence of other components 
associated with the activities of these enzymes, such as the MLL and PRC2 
components.  
Conclusions 
  I have successfully generated and validated an efficient cloning system that 
will facilitate future experiments where complex gene fusions must be created. I have 
also replicated experimental findings from the literature and added to that knowledge 
by showing that H3K4me3 levels are not elevated at the Nrp1 locus after artificially 
inducing Nrp1 expression. Furthermore, I have performed the first experiments 
aimed at interrogating the effects of modulating the presence of chemical groups on 
the tails of histones at the Nrp1 locus. These experiments have led to some 
interesting results, such as the observation that the tNrp1-JMJD3 fusion protein 
promoted Nrp1 expression at certain time-points, possibly by influencing H3K27me3 
levels. However, as discussed in the above sections, more complete analyses are 
required to fully understand these results. Nevertheless, the advances described here 
have informed an improved experimental design. Progress will be more rapid in the 
second round of experiments as the cloning system has been generated and validated. 
Future experiments will include testing these TALE fusions at additional bivalent 
loci in ES cells, including the human α-globin genes, and monitoring changes in gene 
expression and histone modifications during in vitro differentiation of these cells.
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Chapter 7 Discussion and Conclusions 
Cellular differentiation depends on the activation and repression of specific gene 
sets at particular times during development. This is partially directed by epigenetic 
states, which are correlated with gene expression and silencing. Over the last decade, 
a body of evidence has shown that apparently antagonistic epigenetic marks can co-
localise to the same locus (termed bivalent domains). Although the biological 
significance of this co-localisation for gene expression remains under investigation, 
the techniques used to assay these states often lack the sufficient spatial resolution to 
define these genes as bivalent. Using the human α-globin locus as a model for 
bivalency, I aimed to answer two questions during my thesis. The first was to 
understand the true nature of bivalency at this locus, as it was originally identified as 
a bivalent gene using techniques that cannot distinguish between bivalency and 
mixed cell populations. The second question aimed at understanding the function of 
bivalency during development, which has been proposed to support developmental 
phase transitions. 
 
7.1 Characterising the nature of bivalency 
A heterogeneous human α-globin expression pattern in humanised mouse 
erythroid cells was observed when the HS-40 enhancer was removed (ΔHS-40)(De 
Gobbi et al., 2017). Notably, bivalency did not resolve at the human α-globin genes 
in these ΔHS-40 mouse erythroid cells (Vernimmen et al., 2011). An epigenetically 
mixed population of cells may underlie the heterogeneous human α-globin 
expression pattern observed in the ΔHS-40 mouse erythroid cells. This would 
suggest that the PcG protein removal mediated by the HS-40 enhancer (Vernimmen 
et al., 2011) is important for the maintenance of an epigenetically homogenous 
population and for the resolution of bivalency at the human α-globin genes. To test 
this hypothesis, I aimed to generate an in-frame fusion of a 2A-mCherry reporter 
cassette with the HBA2 gene in the human α-globin locus in humanised mES cell 
lines. Erythroid cells could then be isolated from these mES cells by in vitro 
differentiation, or from primary cells in a mouse knock-in line. The mCherry 
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expressing and non-expressing populations could then be isolated by FACS and 
analysed separately by ChIP-qPCR.  
In Chapter 3, I subcloned the humanised WTH and ΔHS-40 mES cell lines. I 
identified two subclones, WTH3 and ΔHS-40_20, with a suitable karyotype to 
perform gene targeting experiments. I also tested numerous variations of an in vitro 
differentiation protocol to generate erythroid cells and optimised a robust and 
efficient method for use with the WTH3 subclone. Upon completion of these critical 
steps, I designed gene-targeting strategies and generated a number of gene targeting 
tools in Chapter 4. I tailored a CRISPR/Cas9 gene targeting strategy and generated 
two HDR donor vectors while I also designed and validated a sgRNA targeting the 
HBA2 3`UTR. These HDR donor vectors were designed to introduce a short 
mutation to the HBA2 3`UTR, which was designed to prevent the sgRNA from 
recognising its target site after the insertion of the desired cassette. I confirmed that 
this 3`UTR mutation does not reduce reporter gene expression. Once all of the tools 
had been generated and validated, I began gene-targeting experiments using WTH3 
mES cells in Chapter 5. The gene targeting experiments required multiple rounds of 
optimization before a number of correct knock-in clones with a single copy of a 2A-
mCherry insertion were obtained.   
The WTH3 cell line containing a 2A-mCherry insertion at HBA2 generated in 
this study will be further engineered to remove the PiggyBac flanked selection 
cassette and the HS-40 enhancer. Transfection of the cells with a hyperactive 
transposase will mediate the removal of the selection cassette. SgRNAs targeting the 
5` and 3` ends of the HS-40 enhancer have been designed and validated (data not 
shown). Transfection of the cells with a combination of these sgRNA constructs 
should mediate the deletion of the HS-40 enhancer region in the presence of Cas9. 
Erythroid cells could then be obtained from the WTH3-HBA2-2AmCherry and ΔHS-
40-HBA2-2AmCherry mES cell lines by in vitro differentiation, or from primary 
cells from mouse knock-in lines. The mCherry expressing and non-expressing 
populations of cells could be isolated by FACS and analysed by ChIP qPCR.   
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Three experimental outcomes appear possible from these ChIP qPCR analyses. 
Firstly, it seems possible that the expression status of HBA2 will be reflected by its 
epigenetic status in the ΔHS-40 mutant background. If so, the mCherry positive 
population of ΔHS-40 erythroid cells would be marked by H3K4me3, but not 
H3K27me3, at the HBA2 gene. This data would suggest that the primary α-globin 
enhancer, HS-40, increases the probability of resolution of bivalency at its target 
gene, HBA2. Indeed, this enhancer-mediated resolution of bivalency at HBA2 could 
be achieved via the recruitment of the histone demethylase JMJD3 by HS-40 
(Vernimmen et al., 2011). Furthermore, if the mCherry negative population of ΔHS-
40 erythroid cells were monovalently marked with H3K27me3 this would suggest 
that both histone marks are directly involved in controlling gene expression.  
A second possible outcome would be that the mCherry positive population in 
the ΔHS-40 erythroid cells are monovalently marked with H3K4me3 while the 
mCherry negative population are bivalently marked with both H3K4me3 and 
H3K27me3. This observation would also suggest that the HS-40 enhancer increases 
the probability of H3K27me3 removal. Interestingly, this result would imply that the 
removal of the H3K27me3 mark is required for the activation of HBA2 expression as 
no actively expressing cells contain this mark.   
It is also possible that both the mCherry positive and negative population in the 
ΔHS-40 erythroid cells are bivalently marked with H3K4me3 and H3K27me3 at 
HBA2. This data would suggest that the presence of the HS-40 enhancer is necessary 
for the removal of the H3K27me3 mark at HBA2 in any erythroid cell. However this 
would also show that the removal of the H3K27me3 mark is not required for the 
activation of HBA2 gene expression.  
Techniques that do not require the use of a fluorescent reporter knock-in cell 
line could also be used to characterise the nature of bivalency at the human α-globin 
genes in WTH and ΔHS-40 erythroid cells. As described in Chapter 1 (pp. 12), 
recent technical advancements have managed to map bivalency to genomic loci in a 
number of cell types (Shema et al., 2016; Weiner et al., 2016). Co-ChIP or single 
molecule imaging/sequencing could be used to determine if the H3K4me3 and 
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H3K27me3 marks co-localise to the same individual nucleosomes across the human 
α-globin genes in the ΔHS-40 erythroid cells. However, these techniques are limited 
as they would be unable to directly indicate whether each nucleosome (marked by 
H3K4me3 only, H3K27me3 only or both) originated from an α-globin expressing 
cell. Single-molecule imaging/sequencing would reveal the proportion of ΔHS-40 
erythroid cells that carry each of the histone marks at the human α-globin gene. Our 
hypothesis suggests that the histone modification status at the human α-globin genes 
underlies human α-globin expression level in these cells; i.e. α-globin genes marked 
with H3K4me3 would be active and α-globin genes marked with both H3K4me3 and 
H3K27me3 or H3K27me3 alone would be inactive. Quantitative assessment of the 
ΔHS-40 erythroid cells has already shown that ~50% express human α-globin (De 
Gobbi et al., 2017). If the histone modification status reflects the binary α-globin 
expression status in individual cells, single molecule-imaging/sequencing data would 
reveal that ~50% of ΔHS-40 erythroid cells would be marked with H3K4me3 and the 
rest would be marked with both H3K4me3 and H3K27me3 or H3K27me3 alone.  
Nano-flare technology, described in Chapter 1 (pp. 43), could also be adapted 
to facilitate the isolation of cells that express human α-globin without the use of gene 
editing. This technique relies on the uptake of a spherical nucleic acid probe bound to 
a gold nanoparticle (Seferos et al., 2007). These nanoparticles are taken into the cell 
via receptor-mediated endocytosis, the process by which important factors involved 
in appropriate differentiation are absorbed into developing erythroid cells (Iacopetta 
et al., 1983; Sawyer et al., 1987). Once the nano-flare is within the cell, the binding 
of the target RNA transcript releases a fluorophore, allowing the detection of cells 
that are transcribing a particular gene (Seferos et al., 2007). This technology could be 
optimised for use in mouse erythroblasts using a probe homologous to human α-
globin in order to separate ΔHS-40 expressing and non-expressing cells. These two 
populations could then be analysed by ChIP-qPCR. 
A human α-globin reporter system has not yet been published and would 
provide a very flexible tool for studying human α-globin transcription. The tools 
generated here and the candidate population of targeted cell lines lay a foundation for 
the generation of this reporter. The results of ChIP qPCR experiments on erythroid 
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cells generated from these reporter lines would provide a novel insight into how 
enhancers are involved in the resolution of epigenetic bivalency and further data on 
how histone marks are involved in controlling gene expression.  
 
7.2 Characterising the function of bivalency 
The significance of bivalency during development is currently unclear. As 
discussed in Chapter 1 (pp. 18), the global depletion of H3K4me2/3 at bivalent genes 
rarely leads to the disruption of gene regulation or differentiation capacity of these 
cells (Denissov et al., 2014; Hu et al., 2013; Rickels et al., 2016). Conversely, effects 
have been observed on gene regulation when the H3K27me3 mark is depleted from 
tissue-specific bivalent genes (Jadhav et al., 2016). It is important to understand if 
bivalency is a developmentally significant feature of the epigenetic landscape, and to 
understand the contribution of each of these marks to the function of bivalency. 
Modifying epigenetic statuses in a site-specific manner and analysing how this 
affects gene expression would help to answer these questions.  
In Chapter 6 I developed a cloning strategy to generate TALE fusions to 
epigenetic editing enzymes. I used a TALE sequence targeting the bivalent mouse 
promoter Nrp1 and fused this to RBBP5, EZH2 and the catalytic domain of JMJD3. 
Interestingly, the tNrp1-JMJD3 fusion, containing the catalytic domain of the 
H3K27me3 histone demethylase JMJD3, caused a mild increase in Nrp1 gene 
expression. However, changes in the H3K4me3/H3K27me3 mark enrichment were 
undetectable by ChIP-qPCR. Many previous reports have suggested that the targeting 
of multiple fusions along a DNA sequence can improve the effects of these fusions 
on gene expression and histone modifications (Maeder et al., 2013b; Mali et al., 
2013a; Perez-Pinera et al., 2013). It therefore seems likely that the use of additional 
tNrp1-JMJD3 fusions tiling the Nrp1 promoter may cause a greater effect on Nrp1 
gene expression and histone modification status. It is also possible that tiling of the 
Nrp1 promoter with the tNrp1-RBBP5 and –EZH2 fusions is required for a 
detectable effect on Nrp1 gene expression. Indeed, these preliminary experiments 
provided a solid basis for future work and a number of possible improvements to the 
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experimental strategy are discussed in Chapter 6. The use of epigenetic editing tools 
can help to elucidate the function of individual histone modifications during 
transcriptional regulation. Furthermore, the manipulation of H3K4me3 and 
H3K27me3 at human α-globin (and other genes) in WTH and ΔHS-40 mES cells, 
followed by the analysis of dynamic changes in gene expression during in vitro 
differentiation, will reveal information related to the function of bivalency during 
development. Several other questions relating to the function of specific epigenetic 
states can also be addressed using these epigenetic editing tools. For example, it is 
unknown how the addition of the H3K27me3 mark would affect gene transcription 
during differentiation at genes that are monovalently marked with H3K4me3 but not 
expressed (Vastenhouw et al., 2010). It would also be interesting to assess the effects 
of manipulating the H3K4me3 mark at bivalent genes and monovalent H3K27me3 
marked genes. The epigenetic editing tools generated in this thesis provide a solid 
basis with which to investigate a variety of questions in a site-specific manner. 
This thesis has generated a number of tools for genetic editing and epigenetic 
editing at bivalent genes. These tools and experiments provide an important 
foundation for future experiments investigating both the nature of bivalency at the 
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mCherry Rev 2 cttgctcaccatGCCTGATC
PB GBlock 3arm Fwd CTAGACCCAGCTTTCTTGTACAA
Gen Rev Screen 2 CTCTTCTGACTCTGCCCACA
mCherry Fwd 2 tcccacaacgaggactacac
puroTK Rev ACTCGGTCCCCATGGTTTAG
a2 3`UTR Fwd Screen GGCCCTTCCTGGTCTTTGAA
HBA2_5_Insert_Rev3 GAGGAGGTGAGACTTAAGGATATGT
5` Southern blot 5' Probe Fwd TTTGTAAGGTGCATTCAGAACTCA
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9.2 Compatibility of overhangs produced in Golden 
Gate cloning experiments 
Table 9.4 List of BsmBI sites and overhangs in Golden Gate cloning plasmids 
used in Chapter 6. Each BsmBI restriction site (red) and the overhangs that are 
generated (teal) are shown for all of the Golden Gate plasmids used in Chapter 6. No 
two overhangs are compatible with any site other than their intended fusion partner, 






3' GCAGAGNNNNN     NCTCTGC
SEGMENT SIDE OVERHANG OVERHANG
pTFE 5' 5' CAGC 5' CGTCTTGTCGACTCGTCTCTTACC 3'
Promoter 3' 5' TACC 3' GCAGAACAGCTGAGCAGAGAATGG 5'
PCR 5' 5' GTCG 5' GTCGTGAGACG…TACCAGAGACG 3'
PROMOTER 3' 5' ATGG 3' CAGCACTCTGC…ATGGTCTCTGC 5'
pTFE 5' 5' GGGA 5' CCCTGGAGACG…CGTCTCCAACG 3'
TALE Array 3' 5' AACG 3' GGGACCTCTGC…GCAGAGGTTGC 5'
pFusA 5' 5' CCCT 5' CCCT…TALE… 3'
3' 5' ACCG 3'     …TALE…ACCG 5'
pFusB 5' 5' TGGC 5' TGGC…TALE 3'
3' 5' GATA 3'     …TALE…GATA 5'
LR 5' 5' CTAT 5' CTAT…LR… 3'
3' 5' TTGC 3'     …LR…TTGC 5'
pTFE 5' 5' CCAC 5' GGTGGGAGACG…CGTCTCTTAAG 3'
GOI 3' 5' TAAG 3' CCACCCTCTGC…GCAGAGAATTG 5'
PCR 5' 5' GGTG 5' CGTCTCAGGTG…TAAGTGAGACG 3'
GOI 3' 5' ATTC 3' GCAGAGTCCAC…ATTCACTCTGC 5'
pTFE 5' 5' AGTG 5' TCACCGAGACG 3'
BFP 3' 5' TCAC 3' AGTGGCACTGC 5'
JMJD3 5' 5' TAGA 5' CGTCTCGATCTA 3'
3' 5' ATCT 3' GCAGAGCTAGAT 5'
EZH2 5' 5' TTCT 5' AAGATGAGACG 3'
3' 5' AAGA 3' TTCTACTCTGC 5'
PGK 5' 5' GATC 5' CGTCTCACTAG 3'
3' 5' CTAG 3' GCAGAGTGATC 5'
STB205 5' 5' GAGT 5' CGTCTCGCTCAG 3'
3' 5' CTCA 3' GCAGAGCGAGTC 5'
pGREEN 1 5' 5' CCCC 5' GGGGGGAGACG 3'
3' 5' GGGG 3' CCCCCCTCTGC 5'
pGREEN 2 5' 5' TGAG 5' TGAGCGAGACG 3'
3' 5' ACTC 3' ACTCGCTCTGC 5'
SEQUENCE
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9.3 Infrequently used abbreviations  
32P Phosphorus-32 
3C Chromatin conformation capture 
AHSP Alpha haemoglobin stabilising protein  
ANOVA One-way analysis of variance 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BFP Blue fluorescent protein 
bp Base pair 
BSA Bovine serum albumin 
Cas9n Cas9 nickase 
CBP Chicken beta actin short promoter and CMV enhancer  
Cfp1 CxxC finger protein 1 
Cre Causes recombination 
dbSNP Short genetic variations database 
Dcp1A Decapping messanger ribonucleic acid 1A 
DMF Dimethylformamide 
DOT1L Disruptor of telomeric silencing 1-like 
DsRed Discosoma sp. Red 
DTT Dithiothreitol 
eGFP Enhanced green fluorescent protein 
EpiSC Epiblast stem cells  
Epo Erythropoietin 
EtOH Ethanol 
EWAS Epigenome-wide association studies 
FAM 6-carboxyfluorescein 
FANTOM Functional annotation of the mammalian genome 
FIAU Fialuridine  
FISH Fluorescent in situ hybridisation 
FITC Fluorescein isothiocyanate 
FLP Flippase 
FRT Flippase recombination target site 
G9a G9a histone methyltransferase 
HA Homology arms 
HEK293T Human embryonic kidney 293T  
HeLa cells Henrietta Lacks cells 
hES cell Human embryonic stem cell 
Hox Homeotic 
HP1 Heterochromatin protein 1 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HR Homologous recombination 
HRP Horseradish peroxidase  
HSF1 Heat shock factor 1 
HXKYacZ Histone X lysine Y acetylated Z times 
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HXKYmeZ Histone X lysine Y methylated Z times 
iCpG Intragenic CpG 
IDT Integrated DNA technologies 
IMDM Iscove’s modified dulbecco’s medium 
IP Immunoprecipitation 
iPS cell Induced pluripotent stem cell 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
JARID Jumonji and AT-rich interaction domain containing protein 
KAP1 KRAB associated protein 1  
KDM Histone lysine demethylase 
KRAB Krüppel-associated box  
LB Lysogeny broth 
LIF Leukemia inhibitory factor  
loxP Locus of X-over P1 
LR Last half repeat 
LSD1 Lysine-specific histone demethylase 1A 
Mb Megabase 
MCR-R Multispecies conserved region 
MEM Minimum essential medium 
MLL Mixed lineage leukaemia 
MMEJ Microhomology-mediated end joining  
MoClo Modular cloning 
MOPS 3-(N-morpholino)propanesulfonic acid 
NCBI National Centre for Biotechnology Information 
NEB New England Biolabs Inc. 
Neo Neomycin 
NF-kB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NPC Neural precurser cell 
Nrp1 Neuropilin 1 
NuRD  Nuclease remodeling deacetylase 
NURF Nucleosome remodeling factor 
Oct4 Octamer-binding transcription factor 4 
PacBio Pacific Biosciences 
PAM Protospacer adjacent motif  
PB:PuroΔTK PGK-puromycinΔthymidine-kinase counter-selection cassette 
flanked with piggyBac inverted repeats  
PHD  Plant homeodomain 
Plat-E Platinum-E 
PolII RNA polymerase II complex 
PRC Polycomb repressive complex 
PRDM9 Proline rich domain zinc finger protein 9 
PRE Polycomb repressive element 
PVDF  Polyvinylidene difluoride  
rcf Relative centrifugal force 
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re-ChIP Sequential chromatin immunoprecipitation 
REST  RE1-silencing transcription factor 
RNA-seq Ribonucleic acid next generation sequencing 
RNAi Ribonucleic acid interference 
rpm Rotations per minute 
RT Recombination target site 
SANT Switching-defective protein 3, adaptor 2, nuclear receptor 
corepressor, transcription factor IIIB 
SCF Stem cell factor  
SDM Site directed mutagenesis 
SDS Sodium dodecyl sulfate 
SET Su(var)3-9, enhancer-of-zeste and trithorax 
sgRNA Short single guide ribonucleic acid  
SM Selection marker 
SMRT Single molecule- real time 
SOB Super optimal broth 
SOC SOB with catabolite repression 
Spec Spectinomycin 
SSC Saline-sodium citrate 
ssDNA Single stranded DNA 
SSR Site-specific recombinase 
Suz12 Suppressor of zeste 12 
SV40 Simian virus 40 
T4 PNK T4 Polynucleotide Kinase  
TAE Tris-acetate EDTA 
TAF TATA-box binding protein associated factor 1 
TALEN Transcription activator-like effector nuclease 
TAMRA Tetramethylrhodamine 
TBE Tris-borate EDTA 
TBST Tris-buffered saline supplemented with Tween 20 
TE Tris-EDTA 
TET Ten-eleven translocation methylcytosine dioxygenase 
TFIID Transcription factor II D  
TSS Transcription start site 
Ubc Ubiquitin C 
UCSC University of California, Santa Cruz 
Utf1 Undifferentiated embryonic cell transcrption factor 1 
UTX/Y Ubiquitously transcribed tetratricopeptide repeat, X/Y 
VP Viral protein 
Wdr5 WD repeat-containing protein 5 
WT Wild-type 
Xist X-inactive specific transcript 
ZFN Zinc-finger nuclease 
 
